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Abstract
Neoadjuvant chemotherapy (NAC) is being increasingly used in the treatment of 
primary breast cancer (PBC). With the primary tumour in situ, the neoadjuvant 
treatment setting allows an in vivo assessment of tumour chemo-responsiveness 
and permits an evaluation of the possible underlying biological mechanisms of 
response. Angiogenesis is critical for the growth and metastases of breast cancer 
and with the development of novel agents targeting this process, an 
understanding of the vascular effects of conventional chemotherapy will enable 
the rational design of future drug combinations.
Functional magnetic resonance imaging (MRI) provides a non-invasive method 
for assessing tumour microvasculature. Using this technique, pre-treatment 
tumour vascularity and changes following two cycles of anthracycline-based 
NAC were measured in a series of patients with PBC. This demonstrated a 
significant reduction in the permeability and perfusion-related MRI parameters 
in tumours responding to treatment. The degree of change in Ktrans was able to 
predict for pathological non-response with a positive predictive value of 84%. 
Further, an evaluation of the pathophysiological correlates of functional MRI 
demonstrated an association between the permability/perfusion-related 
parameters and aggressive tumour features.
An evaluation of the effect of anthracycline-based NAC on 
immunohistochemically-derived measures of tumour angiogenesis was 
performed on a series of patients treated for PBC. A quantitative and a 
qualitative measure of tumour angiogenesis was performed (microvessel density 
[MVD] and pericyte coverage index [PCI] respectively), together with an 
assessment of VEGF expression. This demonstrated no change in MVD 
following treatment but a significant increase in PCI reflecting a reduction in the 
proportion of immature proliferating blood vessels. This was accompanied by a 
reduction in VEGF expression, which may be mediating this effect.
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These observations may have clinical importance as they may help identify 
patients who could benefit from alternative therapies early in their treatment 
course and they may assist in the rational design of combination cytotoxic and 
antiangiogenic treatment regimens.
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CHAPTER 1: INTRODUCTION
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1.1 BREAST CANCER -  AN OVERVIEW
1.1.1 EPIDEMIOLOGY
Breast cancer is the most common cancer in women worldwide accounting for 
25% of all female malignancies. The incidence of breast cancer is high in 
western, developed countries and in England and Wales almost 36,000 new 
cases were diagnosed in the year 2000 with a mortality of 11,500 in 2002 [1]. In 
the United Kingdom, one in nine women will develop breast cancer at some 
point in their life. Despite an increasing incidence, mortality rates from breast 
cancer have fallen, with a reduction of 20% in 1999 compared with the mid- 
1980s (figure 1.1). Earlier detection through the National Health Service 
mammographic breast screening programme and increased breast awareness, 
together with advances in systemic therapy have all contributed to this overall 
improvement in disease specific survival.
1.1.2 TREATMENT
The treatment of breast cancer depends on the stage of disease at presentation. In 
general, the stages can be grouped into:
1. Early breast cancer
2. Locally advanced breast cancer (operable and inoperable, including 
inflammatory disease)
3. Metastatic breast cancer
1.1.2.1 Early breast cancer
Early breast cancer can be defined as operable disease confined to the breast, 
with or without involved mobile ipsilateral axillary lymph nodes. A 
multimodality approach to treatment is recommended with surgery, systemic 
therapy and radiation therapy according to both tumour and patient factors. The 
aim of treatment is to achieve a cure.
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In terms of locoregional treatment, it is now well established that wide local 
excision of the breast cancer followed by adjuvant breast irradiation gives the 
same outcome in terms of survival as mastectomy and, as such, breast 
conservation is the treatment of choice for women with breast cancer whenever 
possible [2]. Following mastectomy, chest wall irradiation is recommended in 
the presence of risk factors for recurrence (axillary lymph node involvement; 
incomplete or close resection margins; grade III tumour; lymphovascular 
invasion) and locoregional nodal irradiation may be recommended according to 
the axillary surgery received and the extent of nodal involvement. Despite 
successful locoregional treatment, more than half of women with operable breast 
cancer will die from metastatic disease if no further treatment is given, 
indicating the presence of occult micrometastatic disease in these women at the 
time of initial clinical presentation. In order to reduce the chances of tumour 
recurrence and improve breast cancer survival, adjuvant (post-surgery) systemic 
medical therapy is used and can be divided into:
1. cytotoxic chemotherapy
2. endocrine therapy (tamoxifen, aromatase inhibitors)
The benefits of systemic therapy, in term of disease-free and overall survival, 
have been clearly demonstrated in randomised clinical trials. Most notable have 
been the meta-analyses performed by the Early Breast Cancer Trialist’ 
Collaborative Group (EBCTCG) on both adjuvant prolonged polychemotherapy 
[3] and adjuvant tamoxifen therapy [4]. The meta-analysis for polychemotherapy 
demonstrated that, for women under the age of 50 years, the administration of 
polychemotherapy conferred an absolute survival benefit at 10 years of 7% and 
11% for node-negative and node-positive disease respectively. Further, a 
comparison of anthracycline-containing regimens with CMF-alone 
(cyclophosphamide, methotrexate and 5-fluorouracil) demonstrated an 
additional survival benefit of 3%. These benefits were irrespective of 
menopausal status, oestrogen-receptor status and the use of adjuvant tamoxifen. 
The benefits were smaller for women aged 50-69, with an absolute gain of 2% 
and 3% in 10 year survival rates for node-negative and node-positive disease
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respectively. No advantage was found for prolonged treatment beyond 3-6 
months.
For adjuvant tamoxifen therapy, the EBCTCG meta-analysis demonstrated a 
reduction in tumour recurrence at 10 years with tamoxifen therapy in women 
with oestrogen-recepector (ER) positive or ER-untested tumours. Five years of 
treatment was shown to be superior to either 1 or 2 years, and this translated into 
an absolute survival benefit of 5.6% and 10.9% for node-negative and node­
positive disease respectively at 10 years, with a 47% reduction in contra-lateral 
breast cancer. These benefits were irrespective of age, menopausal status and 
chemotherapy use. These findings and those on polychemotherapy have 
persisted in the 15 year analysis of disease recurrence and overall survival [5].
Newer systemic agents are currently under investigation in the adjuvant 
treatment setting with the aim of further improving treatment outcomes 
following the demonstration of efficacy of these agents in metastatic disease. 
These include the taxanes (docetaxel and paclitaxel), the aromatase inhibitors 
(arimidex, letrozole, exemestane) and the biological agent, trastuzumab, a 
recombinant humanized monoclonal antibody against the human epidermal 
growth factor receptor, HER-2.
1.1.2.2 Locally advanced breast cancer
Locally advanced breast cancer includes primary tumour extension into the chest 
wall or skin, inflammatory breast cancer, matted ipsilateral axillary nodal 
disease and inffaclavicular, supraclavicular or internal mammary lymph node 
involvement. For inoperable locally advanced breast cancer, the recommended 
first-line treatment modality is neoadjuvant chemotherapy (NAC) or primary 
systemic therapy (PST) [6]. This is aimed at downstaging the disease with a 
view to surgery and/or radical radiotherapy while also treating occult 
micrometastases. Operable locally advanced breast cancer may be treated in a 
similar fashion to early breast cancer, however, NAC has a role to play when 
primary surgery would entail a radical mastectomy, as NAC has the potential to 
downstage disease sufficiently to enable breast-conservation. A full discussion
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of neoadjuvant chemotherapy for patients with primary breast cancer is given in 
section 1.2.
1.1.2.3 Metastatic breast cancer
In metastatic breast cancer, treatment is aimed at the palliation of symptoms and 
may include one or a combination of surgery, systemic therapy and radiotherapy 
in conjunction with supportive care.
1.1.3 PROGNOSIS
The risk of disease relapse and death from breast cancer depends on both clinical 
and biological factors. The most powerful clinical prognostic factor is axillary 
lymph node status, followed by tumour size, as the probability of 
micrometastases increases with the number of axillary lymph nodes involved 
and tumour size [7]. Despite this, women with negative axillary lymph nodes 
still have a 20-30% risk of metastatic relapse while more than 35% of women 
with positive axillary disease remain disease free despite no adjuvant therapy. 
Biological prognostic factors include tumour grade, [8, 9], histological tumour 
type [10] and hormone receptor status [11]. Combination of these prognostic 
factors can be used to stratify patients according to their risk of relapse and thus 
guide adjuvant systemic therapy. The Nottingham Prognostic Index (NPI) is one 
such system for stratifying individual patient risk. The NPI combines tumour 
grade, tumour size and lymph node status to give an estimate of prognosis that is 
more discriminating than axillary lymph node status alone (figure 1.2) [12, 13]. 
More recently, a computer program known as “Adjuvant!” has been introduced 
to help facilitate in adjuvant treatment decision making in primary breast cancer 
(www.adjuvantonline.com). “Adjuvant!” calculates the individual patient’s 
prognosis according to age, disease stage and tumour grade, and provides an 
evidence-based estimate of the percentage benefit of different adjuvant systemic 
therapies for that individual patient.
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1.2 BREAST CANCER AND NEOADJUVANT 
CHEMOTHERAPY
Wide local excision of breast cancer followed by adjuvant breast irradiation is 
equivalent to mastectomy in terms of survival and is the treatment of choice for 
women with breast cancer whenever possible [2]. However, for some women 
breast conservation is not possible due to the size, position or distribution of the 
primary disease e.g. multifocal or multicentric disease. Neoadjuvant 
chemotherapy (NAC) (also known as primary systemic therapy (PST) or 
preoperative chemotherapy) refers to the administration of cytotoxic 
chemotherapy prior to locoregional treatment with surgery and/or radiotherapy 
in women with primary breast cancer. It is aimed at both downstaging the 
primary tumour to increase the chances of breast-conserving surgery where 
possible and treating potential micrometastatic disease. The neoadjuvant 
treatment setting has the added advantage of allowing an in vivo assessment of 
tumour chemo-responsiveness which has been proposed as a surrogate marker of 
response in micrometastatic disease.
1.2.1 HISTORY OF NEOADJUVANT CHEMOTHERAPY
NAC was first introduced into clinical practise in the 1970s for the treatment of 
inoperable locally advanced or inflammatory breast cancers and was aimed at 
both local disease control and the irradication of occult systemic micrometastatic 
disease. Several non-randomised trials demonstrated high response rates 
(approximately 70%) and in many, inoperable disease became operable. As a 
result, NAC has become the standard treatment option for this patient group [6].
At the same time, pre-clinical studies demonstrated that the presence of a 
primary tumour appeared to inhibit metastatic tumour growth and that removal 
of the primary tumour lead to both an increase in circulating growth-stimulating 
factors and an acceleration in metastatic tumour growth as measured by an 
increase in the labelling index in the residual tumour cells [14, 15]. This 
acceleration in tumour growth could be prevented, however, by the
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administration of cytotoxic chemotherapy prior to surgery [16]. These findings 
provided a biological rationale for the use of NAC in early operable breast 
cancers.
In the 1980s, a number of non-randomised phase II studies using various 
chemotherapy regimens demonstrated that NAC could be used in patients with 
large but operable breast cancers to downstage the primary tumour and thereby 
increase the breast-conserving surgery rate [17-22](Table 1.1). Clinical 
complete response (cCR) rates were between 10 and 66% (appendix 1. UICC 
clinical response criteria), with pathological complete response (pCR) rates up 
to 30%. It was still unknown whether preoperative treatment could result in 
improved progression-free and overall survival when compared with the same 
chemotherapy administered postoperatively. Indeed, there was concern that the 
delay in surgery may, in fact, increase the risk of metastatic spread. This lead to 
the first generation of NAC randomised controlled clinical trials (RCT) where a 
direct comparison was made between the same chemotherapeutic regimen 
administered either pre- or post-operatively.
1.2.2 FIRST GENERATION RCTS OF NAC
The largest of the first generation of RCT of NAC was the National Surgical 
Adjuvant Breast and Bowel Project (NSABP) B18 trial initially reported by 
Fisher et al. in 1998 [23]. This study randomised 1523 patients with stage I or II 
breast cancer to receive four cycles of doxorubicin and cyclophosphamide 
chemotherapy either pre- or post-operatively. The study demonstrated NAC to 
be equivalent to adjuvant chemotherapy in terms of disease-free survival (DFS) 
(66.7% versus 67.3%, p = 0.99) and overall survival (79.6% versus 80.0%, p = 
0.83) at 5 years of follow-up, a finding that persisted at 9-years follow-up 
[24](figure 1.3). The study also found that women receiving NAC were more 
likely to have breast-conserving surgery (67.8% in the pre-operative group 
versus 59.8% in the post-operative group). These findings were similar to those 
from other randomised studies of NAC [25-29] including the EORTC 10902 
trial [30] (table 1.2).
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Of importance, the NSABP-B18 study also demonstrated that the clinical and 
pathological response to NAC was a powerful predictor of outcome. At the 9- 
year follow-up analysis [24], there was a significant association between clinical 
response and DFS, relapse-free survival (RFS) and overall survival (OS). OS at 
9 years was 78% in patients with a cCR, 67% in patients with a clinical partial 
response (cPR) and 65% in clinically non-responding patients (cNR i.e. those 
patients with stable or progressive disease) (p = 0.005; p = 0.04 when adjusted 
for tumour size, clinical lymph node status and age at randomisation). 
Pathological response was also significantly associated with DFS, RFS and OS. 
For those patients in whom a pCR was achieved, OS was 85% compared with 
73% in patients achieving a cCR but having residual invasive cancer on 
pathologic examination (pINV). Overall primary tumour response graded as 
pCR, pINV, cPR or cNR was strongly associated with all outcome measures, 
and this association persisted after adjustment for tumour size, clinical lymph 
node status and age at randomisation (OS: p = 0.006; DFS: p = 0.00005; RFS: p 
= 0.0002) (figure 1.4).
The prognostic importance of pathologic lymph node status was also evaluated 
in the NSABP-B18. For both the preoperative and postoperative chemotherapy 
group, pathologic lymph node status was a strong predictor of outcome (p <
0.0001 for OS, DFS and RFS in both groups). In addition, in the preoperative 
chemotherapy group, there was a significant correlation between primary tumour 
response and the number of involved lymph nodes (p<0.0001). When primary 
tumour response was stratified according to pathologic lymph node status, it 
remained a significant predictor of DFS (p = 0.006) and RFS (p = 0.04), with a 
trend to significance for OS (p = 0.06). These finding, therefore, suggested that 
the primary tumour response may represent a true surrogate for micrometastatic 
disease chemosensitivity.
One issue that did arise from the NSABP-B18 was that of ipsilateral breast 
tumour recurrence (IBTR). There was a strong correlation between age and rate 
of IBTR (p = 0.00003), with a 13.3% recurrence rate in women aged 50 years or 
younger at randomisation compared with 5.2% in those older than 50 years. 
This was felt to reflect the study design, however, which had dictated that
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woman under 50 years of age did not received adjuvant tamoxifen therapy. 
Ipsilateral breast tumour recurrence (IBTR) in patients who had received 
preoperative chemotherapy was similar to those patients receiving adjuvant 
chemotherapy (10.7% versus 7.6% respectively, p = 0.12). There was a higher 
IBTR in those women in whom a mastectomy would have been necessary at 
presentation but who were subsequently downstaged by NAC to permit 
lumpectomy when compared with those women in whom breast-conservation 
would have been possible prior to preoperative chemotherapy (15.9% versus 
9.9%). When adjusted for age and clinical tumour size at diagnosis, however, 
this difference was not statistically significant and may have simply reflected the 
younger age of the surgically down-staged subgroup.
Thus, the 1st generation trials demonstrated that survival was equivalent for 
preoperative and postoperative chemotherapy administration and that primary 
tumour response was a strong predictor of outcome. These findings together 
with the development the taxane chemotherapy agents (paclitaxel and docetaxel) 
lead to the development of the second generation of neoadjuvant trials.
1.2.3 SECOND GENERATION NEOADJUVANT TRIALS
The second generation of neoadjuvant trials were aimed at assessing whether 
pathological complete response rates could be improved upon with newer 
chemotherapy drugs and/or schedules, and whether an increase in pCR rate 
would result in improved overall survival. In particular, docetaxel and paclitaxel 
were evaluated as they had demonstrated response rates of 30-60% in the first- 
line metastatic setting [31-33], including in patients with anthracycline-resistant 
disease [34, 35].
1.2.3.1 Docetaxel-containing trials
The Aberdeen TAX 3001 study was a landmark study [36]. Although a small 
study with only 162 patients, it compared eight cycles of the anthracycline-based 
chemotherapy regimen CVAP (cyclophosphamide, doxorubicin, vincristine and 
prednisolone) with four cycles of CVAP followed by four cycles of docetaxel.
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All patients were assigned to receive four cycles of CVAP and were then 
clinically reassessed. Those clinically responding patients (cCR or cPR) were 
randomised to either continue with CVAP for a further 4 cycles or to change to 
docetaxel for 4 cycles. All clinically non-responding patients (cSD or cPD) were 
changed to 4 cycles of docetaxel. In the responding randomised group, the study 
demonstrated a higher pCR rate with the addition of docetaxel (31% vs 15%; p =
0.06 on intent-to-treat analysis). This has subsequently translated into a 
significant improvement in 5-year DFS (90% versus 72%, p = 0.04) [37] 
demonstrating for the first time that a change in therapy that increases response 
rates may improve long-term survival. In addition, the study found that in those 
patients who failed to clinically respond to 4 cycles of CVAP, a change to 
docetaxel resulted in an overall clinical response rate of 55% with a pCR rate of 
2%.
The NSABP-B27 study is the largest neoadjuvant study to date [38]. The study 
recruited 2411 patients and was aimed at determining the effect of adding 
docetaxel to doxorubicin and cyclophosphamide (AC) chemotherapy, both in 
terms of clinicopathological response and survival in women with operable 
breast cancer. Patients were randomised into one of three arms: 4 cycles of 
preoperative AC followed by surgery (group 1); 4 cycles of preoperative AC 
followed by 4 cycles of docetaxel followed by surgery (group 2); or 4 cycles of 
preoperative AC followed by surgery followed by 4 cycles of docetaxel (group 
3). This randomisation would allow an assessment of the effect of adding 
docetaxel preoperatively on response in the breast and axilla (comparison of 
groups 1 and 2) while also permitting an assessment of whether the addition of 
docetaxel postoperatively was beneficial in certain patient subgroups e.g. those 
with residual tumour in the breast or axilla following AC (comparison of groups 
1 and 3). The preliminary results from the preoperative comparison have shown 
an increase in cCR and pCR rates with the addition of preoperative docetaxel to 
AC (from 40.1% to 63.6% [p<0.001] and from 13.7% to 26.1% [p <0.001] 
respectively). Further, the addition of docetaxel significantly increased the rate 
of pathologically negative lymph nodes (from 50.8% to 58.2%, p<0.001). The 
early follow-up data (median follow-up of nearly 70 months) has not yet shown 
any difference in terms of DFS or OS [39].
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1.2.3.2 Paclitaxel-containing trials
Paclitaxel was assessed in a phase III study conducted at the MD Anderson [40]. 
174 patients were randomised to receive preoperatively either 4 cycles of 
paclitaxel (P) or 4 cycles of 5-fluorouracil, doxorubicin and cyclophosphamide 
(FAC). This was followed by surgery and a further 4 cycles of FAC plus 
tamoxifen in those women aged 50 years and older with oestrogen receptor 
positive disease. The cCR rate were comparable in both groups (27% P versus 
24% FAC; p = 0.85 for all clinical response data) however, there was a higher 
pCR rate in the FAC group of 17%, with only 8% with P (no p-value given but p 
= 0.17 for all pathological response data). This difference has not translated into 
a survival difference (4 year DFS 81% for FAC and 85% for PAC-FAC, p = 
0.2).
The European Cooperative Trial in Operable Breast Cancer assessed P in 
combination with other agents [41]. This trial randomised 892 patients to one of 
3 treatment arms: adjuvant doxorubicin followed by cyclophosphamide, 
methotrexate and 5-fluorouracil (CMF); adjuvant doxorubicin and paclitaxel 
(AP) followed by CMF; or preoperative AP followed by CMF. 23% of the 
patients achieved a pCR following NAC with a significantly higher pathological 
LN negative rate compared with the adjuvant regimens (61% versus 38%). The 
beneficial effect of the addition of P to doxorubicin and CMF on long-term 
outcome remains to be seen.
1.2.3.3 Dose-dense scheduling
Dose density refers to the administration of chemotherapy with a shortened time 
interval between each cycle. The effect of dose-dense scheduling on response to 
preoperative chemotherapy has been assessed, however the effects on long-term 
outcome are as yet unknown.
A randomised trial at the MD Anderson assessed three P treatment schedules 
[42]. 258 patients were randomised to either receive 4 cycles of P (225mg/m2)
30
once every 3 weeks; 12 cycles of weekly P (80mg/m /week) if clinically lymph 
node (LN) negative; or 4 cycles of P (150mg/m /week given for 3 weeks 
followed by one week off every cycle) if clinically LN positive. Following 
surgery all patients received 4 cycles of FAC. The trial showed that the dose- 
dense schedules achieved significantly higher pCR rates when compared to the 
standard 3-week regimen (29% 14%, p<0.01).
The GERPARDUO study aimed to compare dose-dense doxorubicin and 
docetaxel (ADOC) given every 2 weeks, with granulocyte-colony stimulating 
factor (G-CSF) support, against conventional 3-weekly doxorubicin and 
cyclophosphamide followed by docetaxel (AC-DOC) [43]. The study aimed to 
recruit 1000 patients but was closed early by the Data Monitoring Committee 
following the second interim analysis which analysed the results from 395 
patients. This revealed higher cCR and pCR rates with the conventional 3- 
weekly AC-DOC schedule compared with the dose-dense regimen (57% versus 
32% and 22% versus 11%, respectively) with a similar rate of pathologically 
negative LNs (61%) for AC-DOC to that seen with this regimen in the NSABP- 
B27 study. These two trials tell us that, while paclitaxel is schedule-dependant, 
docetaxel is not. This information is important in planning future large adjuvant 
trials.
1.2.3.4 Biological agents
Following the demonstration of efficacy in the metastatic breast cancer, new 
biological agents are also being assessed in the neoadjuvant setting. In 
particular, trastuzumab, a recombinant humanized monoclonal antibody against 
the human epidermal growth factor receptor, HER-2, has been evaluated in 
combination with cytotoxic chemotherapy in with HER-2 positive disease. In a 
study of 42 women with operable breast cancer, Buzdar et al. randomised 
patients to receive 4 cycles of P followed by 4 cycles of 5-flourouracil, 
epirubicin and cyclophosphamide (FEC) with or without weekly trastuzumab 
[44]. The planned sample size was 164 patients, however, the study was 
terminated by the Data Monitoring Committee after the completion of treatment 
in only 34 patients due to a staggering 42% difference in pCR rate between the 2
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treatment arms (25% and 67% for chemotherapy alone and chemotherapy plus 
trastuzumab respectively, p=0.02). The long-term DFS and OS data from this 
trial is eagerly awaited in light of such a high pCR rate.
1.2.4 THIRD GENERATION NEOADJUVANT TRIALS
With the advances in molecular biology and imaging technology, a new 
generation of clinical trials have evolved aimed at determining whether it is 
possible to predict response to NAC on an individual patient level and thus tailor 
therapy appropriately. Prognostic factors, such as tumour size and nodal 
involvement at presentation, have not been shown to predict for response to 
NAC, although clinical response after 2 cycles of treatment with docetaxel, 
doxorubicin and cyclophosphamide chemotherapy was recently shown to be a 
predictor for pCR [45]. In the adjuvant setting, overexpression of the proto­
oncogene c-erbB-2 (HER-2) has been associated with a decreased response to 
cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy [46] 
and an increased response rate to doxorubicin [47, 48]. The expression of the 
hormone receptors (oestrogen receptor, ER, and progesterone receptor, PgR) is 
known to predict for response to endocrine therapy [4, 49-51] although in the 
metastatic setting, there have been mixed results regarding their role [52-55].
With the primary tumour in situ, the neoadjuvant treatment setting provides an 
ideal discovery platform for new potential markers of response to treatment. As 
already noted, clinical, radiological and pathological primary tumour response 
act as intermediate surrogates of long-term outcome while access to the primary 
tumour during treatment allows for in vivo testing for changes in molecular or 
functional biomarkers that may predict for response. Three approaches are 
currently under investigation:
1. Assessment of biologic markers
2. Genomic expression profiling
3. Functional imaging
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1.2.4.1 Biologic markers
With the advances in molecular biology has come the search for biological 
markers of tumour treatment response. Biomarkers commonly measured in 
routine clinical practise, such as ER, PgR and HER-2, have been evaluated, as 
well as more sophisticated markers, in particular, those reflecting upon apoptosis 
(e.g. apoptotic index (AI), bcl-2) and proliferation (e.g. S-phase fraction (SFP), 
Ki67 antigen, mitotic index (MI), [3H]-thymidine labelling index ([3H]-dT-LI)).
Makris et al. assessed ER, PgR, HER-2 (c-erbB-2), p53, Ki-67, bcl-2, SPF and 
ploidy on fine-needle aspiration cytology (FNAC) samples taken prior to 
treatment, at day 10 and at day 21 after the first treatment cycle in 90 women 
receiving neoadjuvant mitozantrone, methotrexate +/- mitomycin C 
chemotherapy plus tamoxifen [56]. They found a significantly higher clinical 
response rate in tumours negative for HER-2 compared with HER-2 positive 
tumours (93% versus 57% respectively) but no significant difference for the 
other baseline markers or any of the treatment-induced changes. With a larger 
patient number (n=158), however, they were able to demonstrate that positive 
ER status and a decrease in Ki-67 on day 10 or day 21 could also predict for 
good clinical response (GCR, defined as cCR plus minimal residual disease [a 
residual nodularity after a good response which is insufficient to be measured]) 
[57]. A recent analysis of their 10-year follow-up data found superior DFS and 
OS in those patients achieving a GCR compared with those achieving only a 
cPR, cSD or cPD, strengthening the possible role of these biomarkers as 
surrogates of long-term outcome following NAC [58]. Data from other patient 
series have failed to confirm the findings observed for tumour response 
according to ER and HER-2 status [17, 59-63], however, change in Ki-67 as a 
predictor of response has been demonstrated in other studies.
In a study of 106 patients treated with either primary tamoxifen (n=33), 
chemotherapy (n=33) or chemoendocrine treatment (n=40), Assersohn et al. 
found that the percentage change in Ki-67 in the first 21 days of treatment was 
significantly different between responders and non-responders receiving either 
tamoxifen or chemotherapy alone but not the combination [64]. In addition,
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using FNAC samples from a reproducibility cohort of 37 untreated patients, they 
found that a decrease in Ki-67 from baseline of 36% or more was required for 
that change to be deemed significant on an individual patient level. Using this 
cut-off, they were able to predict for response to chemotherapy and 
chemoendocrine therapy in 85% and 88% of patients respectively. Burcombe et 
al. showed similar results, with tumours displaying a greater than 75% reduction 
in Ki-67 following NAC being more likely to have a pathological response 
(p=0.004) [61]. Bottini et al. also found that Ki-67 expression was significantly 
reduced following NAC and that the reduction correlated with tumour response. 
However, although clinical response was a significant independent predictor of 
disease recurrence (p<0.03), reduction in Ki-67 was not [65]. A number of 
groups have assessed the baseline tumour proliferation rate and have 
demonstrated that a high rate may predict for response to treatment [60, 61, 63, 
66-69].
The results from studies assessing apoptotic markers have also given mixed 
results. In a small study of 28 patients, Chang et al. found an increase in Al 
could predict for response [70]. In a larger study of 65 patients, however, Archer 
et al. found that although there was a significant rise in Al 24 hours post-NAC in 
core biopsy samples, this increase failed to correlate with either clinical response 
or survival [69]. Using bcl-2 as a marker of apoptosis, others have also failed to 
demonstrate a relationship between apoptosis and response to NAC in PBC [56, 
63,67,71].
Thus, although some studies have shown promising results, the role of biological 
markers as predictors of response to NAC requires further evaluation. A 
summary of some of the studies of biologic markers to predict response to NAC 
is shown in table 1.3.
1.2.4.2 Genomic expression profiling
The development of high-throughput quantitation of gene expression and 
complementary DNA (cDNA) technology has now made it possible to study the 
expression of many genes simultaneously, thus enabling the characterisation of
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expression patterns in different breast cancers. This has been termed genomic 
expression profiling. Using this technology, Perou et al. were the first to 
demonstrate that individual breast tumours have a distinctive “molecular 
portrait” [72]. Using complementary DNA microarrarys, they assessed the gene 
expression patterns in 65 breast tumour samples from 42 patients. They found 
that the gene expressions from 2 tumour samples from the same patient were 
almost always more similar to each other than to gene expressions from tumours 
from other patients. Further, sets of co-expressed genes were identified that 
could be related to specific physiological variations between individual tumours. 
These findings have lead to the search for gene expression profiles that might 
predict for individual response to treatment. These molecular portraits or 
“signatures” might be able to distinguish molecular phenotypes associated with 
response to specific chemotherapy agents and hence provide a clinical test for 
predicting treatment response at an individual tumour level from the outset.
In a prospective study of 24 patients with PBC, Chang et al. assessed gene 
expression profiling according to response to neoadjuvant docetaxel 
chemotherapy [73]. They found differential patterns of expression of 92 genes 
that significantly correlated with clinical response to docetaxel, with sensitive 
tumours displaying higher expression of genes involved in the cell cycle, 
cytoskeleton, adhesion, protein transport, protein modification, transcription and 
apoptosis. These findings have been taken forward into a randomised 
multicentre trial to prospectively validate the docetaxel gene expression profile 
and to determine if the gene expression profile for response to doxorubicin and 
cyclophosphamide chemotherapy is different.
1.2.4.3 Functional imaging
The optimum method for assessing response to NAC is unclear. Clinical 
response at the end of treatment has traditionally been used as a surrogate 
marker of outcome. It has been shown to correlate with DFS and/or OS in a 
number of studies [58, 74, 75], including the largest neoadjuvant trial (NSABP- 
B18) at 9 years follow-up [24]. Not all studies have found this association, 
however [25, 26, 30, 76]. This may be because clinical assessment of the local
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response is a crude measure, dependant on several variables including primary 
tumour size, oedema, necrosis and subjective variation in tumour measurements. 
Indeed, clinical evaluation has been shown to frequently overestimate tumour 
size [77-81].
Radiological assessment by mammography and/or ultrasonography has been 
used as a more objective measurement of response, but neither has been shown 
to be superior to clinical assessment for predicting pathological tumour size 
following neoadjuvant chemotherapy [79, 82]. In addition, correlation between 
radiological response, as assessed by mammography or ultrasonography, and 
outcome has not been widely studied. Complete pathological response has been 
shown to be associated with improved outcome [24, 30], however, in most trials 
with anthracycline-based chemotherapy only a minority of patients display 
complete tumour regression (4-13%)[24, 29, 30, 83], thereby reducing the 
usefulness of pCR as a surrogate marker of outcome.
As a result, newer functional imaging technique are currently under evaluation 
for a potential role in the assessment of response to NAC. The standard 
radiological criterion for monitoring the response of breast tumours to treatment 
has been based on measurements of tumour size changes, however, this 
approach does not inform upon the mechanisms of tumour response. Functional 
changes within the tumour are likely to precede anatomical changes and 
therefore, the ability to monitor functional changes may inform upon tumour 
response earlier on in treatment. Advances in radiological technology have lead 
to the development of functional imaging techniques that provide a non-invasive 
method for assessing both tumour function and morphology. Theses techniques 
include dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), 
spiral computed tomography (spiral CT), colour Doppler ultrasound and 
positron emission tomography (PET). These techniques provide non-invasive 
methods for assessing the tumour microvasculature and have an increasing role 
in the evaluation of the effects of the novel antiangiogenic and vascular targeting 
agents. Additionally, PET is also able to inform upon other tumour properties 
such as cellular vitality (using [18F]-fluorodeoxy-D-Glucose) and cellular 
proliferation (using [18F]-fluorothymidine).
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PET and DCE-MRI have both been studied in the neoadjuvant chemotherapy 
setting in breast cancer. Smith et al. assessed [18F]-fluorodeoxy-D-Glucose 
([18FJ-FDG) PET to predict pathological response to NAC in 30 patients [84]. 
They found that the mean reduction in the dose uptake ratio (DUR) after one 
cycle of chemotherapy was significantly greater in primary breast cancers that 
subsequently demonstrated a pathological response to treatment (pPR or pCR) 
compared with those tumours that failed to respond. Further, after a single cycle 
of chemotherapy, PET was able to predict pCR with a sensitivity of 90% and 
specificity of 74%. They concluded that PET may have a role in identifying 
treatment non-responders early on in therapy thus enabling a therapy change and 
possible improve outcome.
DCE-MRI has been widely used in the assessment of residual disease following 
NAC in primary breast cancer and can assist in the planning of subsequent 
surgery [85-90]. More recently, functional DCE-MRI for predicting response to 
NAC has been assessed. Martincich et al. found a reduction in the early 
enhancement ratio after 2 cycles of NAC was associated with a major 
histological response to treatment, however, tumour volume reduction after 2 
cycles of NAC had the strongest predictive value for pathological response [91].
The role of multi-parameter functional MRI in predicting response to NAC early 
on in therapy is examined in the prospective study described in chapter 2. DCE- 
MRI and breast cancer is discussed in detail in section 1.4.
1.2.5 IN SUMMARY
In summary, neoadjuvant chemotherapy has a well-established role in the 
management of both operable and inoperable breast cancer. Clinical and 
pathological response to NAC have been shown to be predictors of long-term 
outcome and hence current trials are aimed at assessing whether an improvement 
in response rates might translate into improved survival. Strategies for 
increasing response rates include new chemotherapy regimens and schedules, as
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well as the use of new molecular biological techniques and functional imaging 
technology for identifying early response predictors.
1.3 BREAST CANCER AND ANGIOGENESIS
In solid tumours, growth beyond two millimetres cannot occur without vascular 
support [92]. Angiogensis is the formation of new blood vessels from the 
existing microvasculature and is known to be a prerequisite for solid tumour 
growth and metastasis [93]. Angiogenesis is regulated by multiple stimulatory 
and inhibitory angiogenic factors or chemokines (table 1.4). In normal 
physiological angiogenesis there is a balance between these factors but in 
tumours an “angiogenic switch” leads to an imbalance of chemokines favouring 
angiogenesis.
1.3.1 VASCULAR ENDOTHELIAL GROWTH FACTOR
The most potent pro-angiogenic factor in breast tumours is vascular endothelial 
growth factor-A (VEGF), initially termed vascular permeability factor due to its 
hyperpermeable effect on vessels [94]. VEGF is produced by both tumour cells 
and host cells in response to hypoxia and inflammation. Hypoxia-inducible- 
factor-1-alpha (HIF-1) is upregulated in response to hypoxia and leads to VEGF 
transcription and overexpression [95]. VEGF overexpression can also occur in 
normoxic conditions, suggesting alternative regulatory mechanisms that are 
independent of hypoxia, such as alterations in the genes involved in the control 
of VEGF expression [96].
VEGF induces endothelial cell migration, proliferation and hence 
neovascularisation within tumours [97]. The tumour vessels created lack the 
normal hierarchical structure, however, and are disorganised, chaotic and 
hyperpermeable [98]. It also acts as an endothelial cell survival factor [99]. 
Elevated levels of VEGF within breast tumours has been associated with a 
poorer overall prognosis when measured from the tumour cytosol [100, 101] or 
by immunohistochemistry [102, 103]. Levels of circulating VEGF have also
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been shown to be elevated in breast cancer patients compared with normal 
controls [104]. In one study, a decline in serum VEGF was shown to correlate 
with a partial response or stable disease following docetaxel chemotherapy in 
metastatic disease [105]. No correlation has been found between circulating 
VEGF levels and tumour VEGF expression [104, 106] although a correlation 
has been noted between serum VEGF levels and primary tumour bulk and 
intratumoural microvessel density [104].
In light of its central role in tumour angiogenesis, VEGF and its receptors 
(VEGF-R) have become potential therapeutic targets in cancer treatment. The 
VEGF-targeting agents currently under investigation include anti-VEGF 
monoclonal antibodies (e.g. bevacizumab[107]), the VEGF trap (a synthetic 
VEGF-R which binds circulating VEGF)[108], anti-VEGF-R monoclonal 
antibodies (e.g.DClOl [109]) and VEGF-R tyrosine kinase inhibitors (e.g. 
ZD6474[110], PTK/ZK [111]). Bevacizumab has obtained FDA approval for 
use with combination chemotherapy in first-line metastatic colorectal cancer. In 
metastatic breast cancer, a randomised phase III trial of capecitabine versus 
capecitabine/bevacizumab in women previously treated with an anthracycline 
and a taxane, has demonstrated a higher response rate with the combination 
therapy but no improvement in progression-free survival [112]. An on-going 
large randomised phase III trial of paclitaxel versus paclitaxel/bevacizumab in 
first-line metastatic breast cancer (ECOG E2100) is being conducted to 
determine whether there is a greater benefit from the addition of bevacizumab 
when patients have not been heavily pre-treated.
1.3.2 IMMUNOHISTOCHEMICAL QUANTIFICATION OF 
ANGIOGENESIS
1.3.2.1 Microvessel density
Quantification of the angiogenic status of tumours is currently performed by 
counting the number of microvessels in immunostained tissue sections. This 
gives an intratumoural microvessel density (MVD) which is a measure of the net 
effect of tumour angiogenesis and angioregression. A monoclonal antibody
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against one of the panendothelial cell antigens is used to highlight the tumour 
vasculature. Commonly used antibodies for assessing MVD in breast cancer are 
anti-factor VIII related antigen (FVIIIRAg or von Willebrand’s Factor, vWF), 
anti-CD34 and anti-CD31 [113]. However, these antibodies have different 
sensitivities and immunostaining characteristics. Anti-CD31 is also known to 
stain plasma cells, macrophages and occasional carcinoma cells [114], while 
anti-CD34 stains normal perilobular and periductal stroma within the breast 
preventing the assesssment of vessels around carcinoma in situ using this 
antibody [115]. The individual antibody used may influence the results for a 
tumour’s MVD. Comparisons have been made between the different antibodies. 
Lee et al. performed a comparison of these antibodies in seven breast cancers 
specimens [114]. They found anti-vWF staining to be the most reproducible, but 
that it stained fewer vessels than anti-CD31, although consistent staining with 
anti-CD31 was not possible. Anti-CD34 produced less intense staining 
compared with anti-vWF but was easily assessable. In a much larger study, 
Martin et al. evaluated the three antibodies in 174 primary breast cancer 
specimens [116]. They demonstrated that the use of antibodies to CD31 and 
CD34 identified more vessels than antibodies to vWF. Furthermore, they also 
found staining with anti-CD31 to be the least reliable method, staining only 87% 
of the sections compared with 98% with anti-CD34 and 99% with anti-vWF. 
Thus, the antibody employed for determining MVD is an important factor to be 
considered. The anti-CD34 mouse monoclonal antibody, antibody QBEnd/10 
(Novocastra Labs Ltd, UK, NCL-L-END™), was employed for determining 
MVD in the study of the effect of neodjuvant FEC chemotherapy on tumour 
angiogenesis in primary breast cancers described in chapter 3.
The most commonly used technique for quantifying MVD was first described by 
Weidner et al. [117]. They counted the total number of vessels within a 200x 
magnification field from selected areas with the highest vascularity (termed 
“vascular hotspots”). They included any staining endothelial cell or endothelial­
cell cluster that was clearly separate from adjacent microvessels, tumour cells 
and other connective-tissues elements in their count. Vessel lumens were not
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required for a structure to be defined as a microvessel. Using the anti-vWF 
antibody, they found MVD was an independent predictor of metastastic disease 
in women with breast cancer - mean MVD count of 101 per 200x field was 
observed in patients with metastases compared with only 45 per 200x field in 
those patients who were free of metastases (p = 0.003).
In a subsequent study using the same technique, Weidner et al. also found MVD 
to be a significant independant predictor for overall survival (OS) in women 
with early stage breast cancer [118]. They found all patients with >100 
microvessels per 200x field experienced tumour recurrence within 33 months 
from diagnosis, compared with <5% of patients with 33 or less microvessels per 
200x field and for those women with node-negative disease, MVD was the only 
significant predictor of overall survival (p<0.001).
A pathological hypothesis for these associations, and the rationale for counting 
vessels within the “vascular hotspot”, is the presence of both angiogenic and 
non-angiogenic cells within a tumour. Those cells with the angiogenic 
phenotype are more likely to produce a detectable metastasis if shed for the 
primary tumour than the non-angiogenic cells, and those cells with the highest 
angiogenic potential should be present within the vascular hotspot. Thus, MVD 
counted from the vascular hotspots should be an indicator of the proportion of 
these highly angiogenic cells and hence be a predictor of metastases and 
survival. An alternative hypothesis, however, is that an increased MVD may 
simply represent a larger vascular surface area across which tumour cells can 
escape and metastasise [119].
1.3.2.2 Chalkley point counting
More recently, Chalkley point counting has been evaluated as a method for 
quantifying angiogenesis in vascular hotspots. This technique employs a 25- 
point eyepiece graticule which is applied over the vascular hotspot at 250x field. 
The graticule is orientated such that the maximum number of points hit on, or 
within, the areas of immunohistochemically highlighted microvessels. The 
Chalkley count is the number of grid points that hit stained microvessels and
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gives a relative area estimate rather than a true vessel count. The advantage of 
this method is a reduction in bias that may occur in the observer-dependent step 
of deciding whether two adjacent immunostained structures represent one or two 
separate blood vessels. Using this method and the anti-CD31 antibody, Fox et al. 
found tumour microvessel density, as quantified by Chalkley point counting, 
was a significant predictor of RFS (p=0.01) and OS (p=0.028) in 109 patients 
with node-negative breast cancer [120]. In a larger study of 836 patients with a 
median follow-up of over 11 years, Hansen et al. confirmed that tumour 
angiogenesis, as assessed by Chalkley counting using the anti-CD34 antibody, 
was an independent prognostic factor for DFS and OS in both lymph node 
negative and lymph node positive breast cancer patient groups [121].
1.3.3 CLINICAL AND THERAPEUTIC RELEVANCE OF TUMOUR 
ANGIOGENESIS
1.3.3.1 Angiogenesis and prognosis in breast cancer
As mentioned in sections 1.3.2.1 and 1.3.2.2, a number of studies have shown 
tumour angiogenesis, as quantified by MVD or Chalkley count, to be an 
independent prognostic factor for both relapse-free and overall survival in breast 
cancer [117, 118, 120, 121]. Indeed, more than 40 retrospective studies have 
been published with the majority reporting a positive association between MVD 
and outcome. As such, MVD may be useful in guiding, for example, adjuvant 
treatment decisions in those patients considered to be otherwise low-risk for 
recurrent disease e.g. negative lymph node status. However, not all investigators 
have confirmed the prognostic value of MVD (data reviewed in Fox 1997 and 
Hasan 2002 [122, 123]). Possible explanations for the conflicting results 
regarding the prognostic value of MVD include: type of endothelial antibody 
employed; counting technique used; region of tumour assessed; and cut-offs 
defined for “increased vascularity” [122]. In light of this, the College of 
American Pathologists, in its consensus statement in 1999 on prognostic factors 
in breast cancer, ranked MVD in category III, which encompasses “all factors 
which are not sufficiently studied to demonstrate their prognostic significance” 
[124].
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In order to reduce the methodological variabilities of angiogenesis quantification 
in tumour tissue sections, the “International Consensus on the methodology and 
criteria of evaluation of angiogenesis quantification in solid human tumours” 
was published in 1996 [113] and updated in 2002[125]. It currently recommends 
Chalkley counting, using the anti-CD34 antibody, as the standard method for the 
quantification of angiogenesis and suggests the introduction of quality control 
through reference slide sets by international collaborative groups. In addition, it 
suggests large prognostic and predictive studies comparing manual with 
automated hotspot selection. The consensus also suggests a comparison of MVD 
assessment with candidate surrogate markers of angiogenesis, for example, the 
fibrotic focus (FF), a scar-like area replacing necrosis in the centre of an 
invasive ductal carcinoma thought to result from previous and on-going intra­
tumoural hypoxia [126].
The predictive value of MVD with regards to treatment response, whether that 
be to conventional chemotherapy or novel antiangiogenic agents, is currently 
under assessment, as is the interpretation of changes in MVD during and 
following therapy. In a series of 577 node-positive breast cancers treated with 
adjuvant chemotherapy as part of the Cancer and Leukemia Group B protocol 
8541, Guidi et al. found no association between MVD and either RFS or OS. 
Further, MVD failed to predict outcome to treatment with dose intensification or 
tamoxifen [127].
In a neoadjuvant chemotherapy study, Makris et al. found that, despite a lower 
Chalkley count in patients who had received NAC for primary breast cancer 
prior to surgery, compared with patients who had undergone primary surgery, 
the Chalkley count did not correlate with the clinical response to NAC [128]. 
Similarly, Bottini et al. found that despite a reduction in MVD following NAC, 
neither baseline nor the change in MVD predicted for tumour response [129]. In 
the metastatic setting, Tynninen et al. have also demonstrated a failure of MVD 
to predict for treatment response [130]. These results suggest MVD does not 
predict for therapeutic efficacy, certainly in response to conventional cytotoxic 
chemotherapy, and that changes in MVD do not appear to be related to the
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treatment response. Interestingly, a study of neoadjuvant tamoxifen therapy in 
locally advanced breast cancer did demonstrate a significant association between 
clinical tumour response and change in MVD, as assessed by Chalkley count, 
with reduction in MVD in responding tumours and an increase in non­
responding tumours [131]. This positive finding may relate to the longer 
duration of treatment compared with the chemotherapy studies, however, it is 
worth noting that no correlation was observed between tumour proliferation and 
MVD in this study.
Thus, MVD alone appears to be unhelpful as a predictor of treatment response to 
NAC. This may be related to the failure of MVD to inform upon the qualitative, 
or functional, aspect of tumour neovascularisation. Alternative measures that 
reflect the functional status of the tumour microvasculature may be more useful 
and this forms the basis of the study described in chapter 3 examining the effect 
of neodjuvant FEC chemotherapy on tumour angiogenesis in primary breast 
cancers, as assessed quantitatively using MVD and qualitatively using pericyte 
coverage index. Quantitative measures of angiogenesis are discussed in more 
detail in section I.3.3.2.
In relation to antiangiogenic therapy, Hlatky et al. have also proposed that MVD 
cannot be used as a predictor of treatment efficacy, nor can a reduction in MVD 
be used to reflect a response to antiangiogenic treatment [132]. They argue that 
MVD does not provide a direct measure of the angiogenic activity or angiogenic 
dependence of a tumour, but simply reflects the intercapillary distance within a 
tumour which is determined by both angiogenic and non-angiogenic factors. For 
example, lower MVD counts have been observed in some tumours compared 
with their corresponding normal tissue despite active angiogenesis within the 
tumours and probably reflects the lower oxygen consumption of tumour cells 
and their increased tolerance of tissue hypoxia [133]. Further, tumours with low 
MVD counts have been shown to respond to antitangiogenic therapy [134] and 
therefore MVD alone cannot be used to predict for treatment efficacy. In 
addition, in terms of assessing treatment efficacy, change in MVD in itself 
cannot be used as a measure of vascular inhibition as it is the result of the 
combined effect of vascular dropout and tumour-cell dropout. Thus, following
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antiangiogneic therapy, initial capillary inhibition and elimination leads to a 
decrease in MVD, followed by a slowing in the decrease in MVD or even an 
increase in MVD as the tumour cells die in response to the loss of their 
supporting vasculature. The tightness of the coupling between the vascular and 
cellular dropout determines both the extent to which the MVD fluctuates during 
treatment and the time it takes to return to the pre-treatment MVD level 
following drug elimination, the so-called “restoration time”. These factors are 
likely to vary between different tumour types and if the restoration time is less 
than the time between tumour biopsies then the change in MVD will provide 
little information (figure 1.5). Thus, bearing these problems in mind, attention 
has focussed on more qualitative, or functional, measures of tumour 
angiogenesis and whether they might be more able to predict for treatment 
response.
1.3.3.2 Qualitative measures of angiogenesis
Qualitative measures of angiogenesis aim to assess vascular differentiation and 
functionality. These aspects of tumour angiogenesis are currently being 
evaluated using new parameters that measure endothelial cell phenotypic 
characteristics, such as activation and differentiation. These new parameters 
include: biochemical markers known to be upregulated in vascular endothelial 
proliferation (e.g. CD 105 (also known as endoglin), Kdr); differentiation 
markers present on mature vessels (e.g. LH39); the endothelial cell proliferation 
index (ECP index); and pericyte coverage index (PCI). These new qualitative 
measures of tumour angiogenesis may be more informative than more simply 
obtained MVD alone in terms of determining prognosis or predicting response to 
therapy.
Eberhard et al. assessed the functional angiogenic status of six different tumour 
types (glioblastomas [n=30], renal cell carcinomas [n=22], colon carcinomas 
[n=18], breast carcinomas [n=24], lung carcinomas [n=15] and prostate 
carcinomas [n=19]) and compared it with the physiological angiogenesis of the 
cyclic bovine corpus luteum [133]. They evaluated: MVD count (using anti- 
CD34, lectin BS-I or anti-vWF); proliferating capillary index, also known as
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endothelial cell proliferation, ECP, (using double immunostaining with a marker 
of proliferation [anti-PCNA or anti-Ki67] and a panendothelial marker [anti- 
CD34 or lectin BS-I]); proliferating tumour versus endothelial cell index (the 
ratio of proliferating tumour cells to proliferating endothelial cells); and 
microvessel pericyte coverage index (using double immunostaining with a 
panendothelial marker [anti-CD34 or anti-vQWF] and a mural cell marker [anti- 
alpha-smooth muscle actin (anti-a-SMA]). They found all tumour types to have 
high MVD counts, with significantly higher counts in glioblastomas and renal 
cell carcinomas (figure 1.6). Interestingly, they observed the tumour MVD 
counts to be lower compared with those of the corresponding normal tissues 
except for prostate cancers. Using endothelial cell proliferation as the marker of 
the angiogenesis, they found active angiogenesis in all tumours but with 
significant differences between and within tumour types (figure 1.6 and 1.7). 
Further, the rate of angiogenesis was higher in the physiological angiogenesis in 
the ovarian corpus luteum.
The functional status of the tumour bed was assessed using microvessel pericyte 
coverage index (MPI), as pericyte recruitment to microvessels is thought to 
reflects vessel maturation [135-137]. Again varying degrees of vascular 
maturation was observed both between and within tumour types, with breast 
carcinomas exhibiting the highest MPI values, and glioblastomas and renal cell 
carcinomas the lowest. Thus, tumours differ in their degree of angiogenesis and 
the functional status of their vascular bed. This variation occurs both between 
and within tumour types and, as such, may result in a differential response to 
new antiangiogenic therapies. Determining the quality of the tumour vascular 
bed may be important, therefore, in the design and selection of antiangiogenic 
therapies for individual tumours.
Kakolyris et al. evaluated vascular differentiation and remodelling in 12 normal 
breast samples and 50 breast cancer specimens using the monoclonal antibody 
LH39 [138, 139]. LH39 has been shown to recognise a basement membrane 
epitope present in the lamina lucida of mature vessels but not in newly formed 
vessels [140, 141]. By defining mature vessels as those staining with both anti-
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CD31 and LH39 antibodies, and immature (remodelling) vessels as those 
staining only with anti-CD31, a vascular maturation index (VMI) was derived 
(the percentage fraction of mature vessels over the total number of vessels). The 
VMI was found to be higher in the normal breast samples compared with the 
breast cancers (median VMI 66.5% and 8.8% respectively). Further, a 
significant inverse correlation was found between VMI and nodal status and 
thymidine phosphorylase expression. No association was found between VMI 
and a quantitative measure of angiogenesis (Chalkley count using anti-CD31) or 
VEGF expression. These findings again suggest that the quality of the tumour 
microvasculature may provide additional information regarding the tumour 
vascular efficiency compared with vessel count alone. In particular, the degree 
of vascular maturation and remodelling may provide valuable mechanistic and 
prognostic information about individual tumours, while also providing a 
potential therapeutic target that is able to exploit the difference between normal 
tissues and cancer.
Kumar et al. assessed the prognostic value of the Transforming Growth Factor (3 
receptor, CD 105, in a series of 106 breast cancers and compared it with CD34 
[142]. Anti-CD 105 antibodies have been shown to preferentially bind 
“activated” endothelial cells in vitro and in tissues undergoing active 
angiogenesis. Further, it has been shown that CD 105 is strongly expressed in 
tumour blood vessels but only weakly expressed, or not at all, in the blood 
vessels of normal tissues [143]. CD 105 staining allows a distinction to be made 
between vessels created by active tumour angiogenesis and normal blood vessels 
entrapped, or co-opted, by the tumour. They found MVD using anti-CD 105 was 
an independent prognostic factor in breast cancer whereas MVD using anti- 
CD34 was not. Thus, MVD using anti-CD 105 antibody may give a more 
accurate reflection of active tumour angiogenesis and hence explain its greater 
prognostic value.
More recently, real-time assessment of tumour microvasculature functionality 
has been made possible through functional imaging techniques, such as DCE- 
MRI, PET and functional multi-detector CT. These techniques are being used to
47
assess both baseline tumour vascular characteristics and the changes that occur 
following treatment with both conventional and novel anticancer agents. 
Functional imaging has become particularly important in the assessment of 
antiangiogenic and vascular targeting agents, where conventional response 
assessments according to changes in tumour size may not occur or may be 
delayed. The pathophysiological correlates of these functional imaging 
parameters remain to be fully assessed and an evaluation of the 
pathophysiological correlates of multi-parameter functional MRI is discussed in 
the study described in chapter 4.
The effect of neodjuvant FEC chemotherapy on tumour angiogenesis in primary 
breast cancers, as assessed quantitatively using MVD and qualitatively using 
pericyte coverage index, is examined in the prospective study described in 
chapter 3.
Thus, to summarise, the assessment of qualitative measures of tumour 
angiogenesis may give a more accurate assessment of the angiogenic activity 
and angiogeneic dependence of a tumour, and inform upon specific individual 
tumour features. This will improve our understanding of tumour biology and 
help explain some of the differential treatment responses that can be seen both 
between and within tumour types to the same treatment. They may also assist in 
the design and use of targeted novel therapies, for example, the use of an 
antiangiogenic agent directed at mature vasculature in those tumours with a high 
pericyte coverage index. In addition, these qualitative parameters they may act 
as useful predictive markers for treatment response or provide additional 
prognostic information.
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1.4 MULTI-PARAMETER FUNCTIONAL MRI AND 
BREAST CANCER
1.4.1 INTRODUCTION
With the advent of antiangiogenic and vascular targeting agents in the treatment 
of cancer, the importance of functional imaging techniques and their role in 
assessing tumour response to treatment has increased dramatically. Multi­
parameter functional vascular MRI provides a non-invasive imaging method for 
assessing tumour microvasulature and exploits the differences in tissue 
vascularity between benign and malignant processes to enable diagnosis and 
monitor response. Multi-parameter functional vascular MRI can be divided into 
non-enhanced and contrast media-enhanced methods (dynamic contrast- 
enhanced MRI [DCE-MRI]). The role of functional MRI in the evaluation, 
treatment and follow-up of patients with known or suspected breast cancer is 
now well established, but continues to expand with the developments in MRI 
software, processing and contrast media. The current role of functional MRI in 
breast cancer is discussed, with particular emphasis on DCE-MRI.
1.4.2 OVERVIEW OF MRI PRINCIPLES
Water molecules make up 60-70% of the constituents of body tissues. The !H 
nuclei that are contained in water molecules have a positive charge and are 
constantly spinning. As they spin, the moving positive charge produces an 
electric current and an associated magnetic field (they behave like little 
magnets). When placed in an external magnetic field, such as in an MRI 
machine, the protons align themselves either north or south to this field. More 
protons are aligned north to the external magnetic field, producing a net 
longitudinal magnetic moment in this direction. They continue to spin, like a 
spinning top, and this motion known as precession. The precession frequency, 
co0 (Lamor frequency) is determined by the magnetic field strength, Bo , by the 
equation:
<u0 =yB0
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where y  is a constant, the gyromagnetic ratio. By the use of radiofrequency (RF) 
wave pulses, the proton alignment can be temporarily altered, changing the 
longitudinal magnetisation and the protons become aligned and so precess in 
phase, producing a magnetic moment in a transverse plane. Once the pulse stops, 
the protons relax back to their original position, and gradually precess out of 
phase due to interactions with locally fluctuating magnetic fields produced by 
the protons themselves (spin-spin interaction). As they relax, they emit a RF 
signal that can be detected in an external receiver or coil, in which an electrical 
current is induced. The RF signal intensity depends on the type of RF pulse 
initially used to perturb their natural alignment and on the structure and water 
content of the tissues. The relaxivity of a tissue can be described in terms of 
spin-lattice (longitudinal relaxation rate [Tl]), which reflects the rate that the 
spinning protons are able to achieve their original longitudinal orientation by 
energy transfer to the surrounding environment, and spin-spin (transverse 
relaxation rate [T2]) which reflects the rate that the spinning go out-of-phase due 
to local magnetic field inhomogeneities.
The use of static magnetic field gradients in orthogonal planes allow encoding of 
spatial information of the emitted RF signals and subsequent construction of 2D 
or 3D images of the signal intensity. The RF pulses and field gradients can be 
adjusted in multiple ways to give different signal intensities for a given tissue -  
for example on a Tl weighted image fat appears bright, but intermediate on a T2 
weighted image. This gives MRI an advantage over CT examination of excellent 
soft tissue contrast, without the use of ionising radiation, and the ability to image 
in any plane.
1.4.3 DYNAMIC CONTRAST-ENHANCED MRI (DCE-MRI)
DCE-MRI uses extrinsic paramagnetic contrast media to increase the distinction 
between benign and malignant disease. Paramagnetic substances have small 
local magnetic fields which induce a shortening of the relaxation times of the 
protons in the surrounding tissues, so-called proton relaxation enhancement. 
This results in a change in the signal intensity of the tissues. The most
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commonly used contrast medium is gadopentetate dimeglumine (Gd-DTPA) 
which is a low molecular weight agent (<1000Daltons) that rapidly diffuses 
from the intravascular space to the extravascular extracellular space (EES). The 
rate of diffusion into the EES is determined by the permeability of the 
capillaries, the surface area of the capillaries and the blood perfusion to the 
tissue.
DCE-MRI exploits the intrinsic differences that affect contrast medium 
behaviour in a variety o f tissue types to aid in the diagnosis of benign versus 
malignant disease processes, and, as such, has emerged as a powerful imaging 
tool in the management of patients with breast cancer. Early breast MRI studies 
showed that breast cancers enhanced following contrast-agent administration 
[144, 145], however benign breast diseases, such as fibroadenoma, fibrocystic 
disease, radial scar and mastitis, were also found to enhance [90, 145-148]. 
Thus, the presence of enhancement alone should not be used to distinguish 
malignant from benign disease. The optimal interpretation of DCE-MRI in the 
breast employs a combination of the morphological and functional 
characteristics of a lesion.
1.4.4 DCE-MRI AND BREAST CANCER
DCE-MRI studies can be performed to be sensitive to the presence of contrast 
medium in the EES which reflect on microvessel permeability, extracellular 
leakage space and perfusion. Such sequences are called Tl-weighted (or 
relaxavity) DCE-MRI. Similarly, sequences can be performed that are sensitive 
to the vascular phase of contrast medium delivery and reflect on tissue perfusion 
and blood volume. Such sequences are called T2* (or susceptibility) DCE-MRI 
[149].
1.4.4.1 Tl-weighted DCE-MRI of breast cancer
Tl-weighted DCE-MRI sequences are sensitive to the presence of contrast 
medium in the EES. The presence of diluted contrast medium in the EES leads 
to shortening of the Tl relaxation rate of the tissue and thus causes tissue
enhancement. A large body of literature has shown that breast cancers enhance 
earlier and to a greater extent than benign breast diseases on Tl-weighted DCE- 
MRI. This difference is most marked in the early period (1-3 minutes) after 
bolus contrast medium administration [144, 150-152]. There is, however, an 
overlap in the enhancement rates of benign and malignant lesions [145-147] and 
therefore any kinetic parameter used for tissue characterisation has to take into 
consideration the relative contrast medium behaviour in different tissues.
1.4.4.1.1 Data acquisition, analysis and processing
Most Tl DCE-MRI studies employ gradient-echo sequences to monitor the 
tissue enhancing effects of contrast media. The commonest contrast medium 
used is gadopentetate dimeglumine (Gd-DTPA) at a dose of 0.1 mmol/kg body 
weight (b.w.). Gradient-echo sequences have good contrast medium sensitivity, 
yield images with high signal to noise ratio and enable data acquisition to be 
performed rapidly. The degree of signal enhancement seen on Tl-weighted 
images is dependent on both physiological and physical factors and these 
include tissue perfusion, capillary-permeability to contrast agent, volume of the 
extracellular leakage space, native Tl-relaxation rate of the tissue, contrast agent 
dose, imaging sequence, parameters utilised and on-machine scaling factors 
[153].
1.4.4.1.2 Pulse sequence timing
The optimal timing for breast MRI sequences is dependent on the goal of 
imaging. High-resolution and short imaging-time represent competing 
examination strategies on currently available equipment. If high sensitivity is 
required, then a single high sensitivity, high resolution, fat suppression 3D 
technique (with voxel sizes less than 1 mm) can be used. This can be performed 
in 2-4 minutes which is within the time window where the differential 
enhancement between malignant and benign lesions is greatest. Using this 
technique, however, image interpretation has to be based on morphological 
characteristics alone.
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If the goal is to maximise specificity, then repeated data acquisitions are 
recommended. On current MRI system’s, higher temporal resolution 
necessitates reduced spatial resolution and/or decreased coverage. The highest 
specificity MRI breast studies have used 2D dynamic techniques with data 
acquisition rates of 1-12 seconds. Higher temporal resolution techniques appear 
to improve the specificity of examinations because of better characterisation of 
the signal intensity-time curve. One study has suggested the optimal data 
acquisition rate to be 1-2 seconds [150]. Unfortunately, the temporal 
requirements of fast dynamic imaging limits the spatial resolution and coverage, 
and thus multi-focal disease may be overlooked. If multi-focality is a concern, 
volume coverage at the slower data acquisition rates are preferable.
A combination of both kinetic and morphologic information is best at achieving 
optimal discrimination between benign and malignant lesions. Therefore, as a 
compromise, a dynamic high resolution 3D technique (slower dynamic 3D 
technique) is used by many where each time point is acquired every 45-90 
seconds. This approach does not require prior knowledge of lesion location. 
Both Kuhl et al [154] and Liu et al. [155] have reported on the value of such 
techniques where an integration of contrast agent kinetics and architecture 
evaluation (morphology) is performed. An important factor, however, is 
concordance between the kinetic information and the morphologic features. This 
is because some malignant lesions, including invasive ductal and lobular 
carcinomas and certain ductal carcinoma in-situ lesions, do not enhance rapidly 
but morphology can suggest the presence of malignancy e.g. architectural 
distortion or mass with spiculated borders. Such lesions must be treated as 
suspicious. However, it should be noted that not all such lesions will be 
malignant, with fibrocystic disease and sclerosing adenosis being causes of false 
positive results.
Thus, if the goal is to determine the likelihood that a previously identified lesion 
is malignant, then the best strategy is to use the minimal number of slices 
necessary to cover the lesion and to obtain a series of acquisitions with high 
temporal resolution. However, if the goal is to detect multicentric or multi-focal 
disease, search for a primary tumour or demonstrate the extent of a known
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cancer, then good spatial resolution and whole breast coverage are essential and 
is best achieved with a 3D MR technique.
1.4.4.1.3 Post-processing of data
A breast MRI study can yield many hundreds of images, the analysis of which 
can be very time consuming. This can be eased with dedicated workstations and 
specialist software. Specialist software is available which incorporates functions 
such as simple subtraction, multiplanar imaging capability, maximum intensity 
projections (MIP) and signal-intensity time analysis. These are the minimum 
tools required for the analysis of breast MRI. More sophisticated tools that are 
not widely available include tumour segmentation with volume estimation, 
image fusion, automated detection and classification of abnormalities (computed 
assisted diagnosis or CAD) and 3D image registration.
In practice, subtraction images are performed first. Early subtraction studies are 
obtained by subtraction of the images obtained at approximately 90-120 seconds 
from the pre-contrast images; late subtraction studies comprise images obtained 
after 5 minutes minus the pre-contrast images. The subtraction images will 
display any significant patient motion which can generate pseudolesions. If 
significant motion is present, then the images can be realigned using 3D 
registration software [156] or the appropriate individual non-subtracted images 
of the dynamic series can be reviewed for morphological and kinetic analysis.
Both early and late subtraction images are inspected for the presence of 
enhancing lesions. The morphological and kinetic descriptions of any lesions 
should follow the MRI lexicon adapted from the American College of Radiology 
Breast Imaging and Data Reporting System terminology for breast MRI [157]. 
Morphological features that suggest the possibility of malignancy include: a 
mass with irregular or spiculated borders; a mass with peripheral enhancement; 
and ductal enhancement. Features suggesting benign disease include: a mass 
with smooth or lobulated borders; a mass demonstrating no contrast 
enhancement; a mass with non-enhancing internal septations; and patchy 
parenchymal enhancement.
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Kinetic analysis in everyday practise uses the region of interest (ROI) method. 
The early subtraction images are used to determine the position for ROI 
placement. If enhancement is low or minimal, then the late subtraction data set 
can be used. If no enhancement is seen, the baseline data (non-enhanced) is used 
for ROI placement. When lesion enhancement is homogenous the entire outline 
of the lesion is used. The outer limit of the lesion acts as a boundary of the ROI 
to minimise partial volume effects. When lesion enhancement is heterogeneous 
on the early subtraction images, the maximally enhancing area of the lesion is 
used excluding areas of necrosis, artefacts and adjacent blood vessels. The ROI 
is chosen in order to be constant in position and size for each image in the series 
under analysis. The ROI must be small enough (at least 3-5 pixels) but not too 
small, because a ROI of 1-2 pixels may include a vessel and is likely to have 
increased pixel noise. In small lesions it is essential to check that the ROI is 
placed without partial volume averaging which may occur in the through-plane 
direction. An ROI is also placed on background (air surrounding breasts) away 
from phase encoding artefacts and another placed on an area of fat adjacent to or 
parallel with the enhancing region within the breast if possible. These additional 
ROIs help to scale the y-axis of the signal intensity time curves and aid 
interpretation.
The simplest way of assigning pathological significance to signal intensity-time 
curves is to provide a description of the initial enhancement period (1-2 minutes) 
followed by an assignment of the late enhancement pattern. The initial 
enhancement can be described as fast, medium or slow, and the late pattern as 
persistant, plateau or wash-out (pattern I-III) (Figure 1.8). This scheme has been 
widely adopted following its initial clinical evaluation by Kuhl et al. [154]. They 
examined 263 breast lesions and found that the distribution of curve types in 101 
malignant lesions was type I, 8.9%; type II, 33.6%; and type III, 57.4% and in 
165 benign lesions was type I, 83.0%; type II, 11.5%; and type III, 5.5%. The 
diagnostic efficacy of pattern evaluation of the signal intensity-time curves were: 
sensitivity, 91%; specificity, 83%; and diagnostic accuracy, 86%. This compared 
with enhancement rate: sensitivity, 91%; specificity, 37%; diagnostic accuracy, 
58%. It is important to note that heterogeneity of curve shapes within a lesion
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are also diagnostically informative. A malignant tumour may well enhance with 
type I and II shapes but the heterogeneous nature of enhancement and variety of 
curve shapes in different anatomical areas is strongly suggestive of malignancy.
1.4.4.1.4 Data quantification and limitations
Signal enhancement seen on a dynamic acquisition of Tl-weighted images can 
be measured in two ways:
1. by the analysis of signal intensity changes (semi-quantitative)
2. by quantifying contrast agent concentration change using pharmacokinetic 
modelling techniques (quantitative).
Semi-quantitative parameters describe tissue signal intensity enhancement using 
of a number of descriptors. These parameters include onset time (time from 
injection or appearance in an artery to the arrival of contrast medium in the 
tissue[150]); gradient of the upslope of enhancement curves; maximum signal 
intensity; and washout gradient. As the rate of enhancement is important for 
improving the specificity of examinations, parameters that include an additional 
time element are also used (e.g. maximum intensity time ratio[151]; maximum 
focal enhancement at one minute [144, 158]). The uptake integral or initial area 
under the time signal curve (initial AUC) has also been studied[159].
Semi-quantitative parameters have the advantage of being relatively 
straightforward to calculate but have a number of limitations. These limitations 
include the fact that they do not accurately reflect contrast medium 
concentration in the tissue of interest and can be influenced by scanner settings 
(including gain and scaling factors) which can alter baseline values and therefore 
can alter calculated semi-quantitative parameter values. Semi-quantitative 
parameters have a close but complex and undefined link to underlying tissue 
physiology and contrast agent kinetics. These factors limit the usefulness of 
semi-quantitative parameters and make comparisons between patients and 
system difficult.
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Quantitative techniques use pharmacokinetic modelling techniques that are 
usually applied to tissue contrast agent concentration changes. Quantitative 
analysis requires conversion of the MRI signal intensities to Tl-relaxation rates 
and then Gd-DTPA concentrations [160]. Concentration-time curves are then 
mathematically fitted using one of a number of recognised pharmacokinetic 
models, e.g. Tofts’model[161], and quantitative kinetic parameters are derived 
for tumour regions of interest and on a pixel by pixel basis (Figure 1.9). 
Examples of modelling parameters include the volume transfer constant of the 
contrast agent, Ktrans, formally called permeability-surface area product per unit 
volume of tissue; leakage space as a percentage of unit volume of tissue, ve; and 
the rate constant, kq, (also called K2 1). These standard parameters are related 
mathematically (keP = Ktrans / ve)[162].
The transfer constant (Ktrans) describes the transendothelial transport of low 
molecular weight contrast medium by diffusion. If the delivery of the contrast 
medium to a tissue is insufficient (flow-limited situations or where vascular 
permeability is greater than inflow) then blood perfusion will be the dominant 
factor determining contrast agent kinetics and Ktrans approximates to tissue blood 
flow per unit volume. The latter situation is commonly found in breast tumours. 
If tissue perfusion is sufficient and transport out of the vasculature does not 
deplete intravascular contrast medium concentration (non-flow limited 
situations, e.g. in areas of breast fibrosis or in the irradiated breast) then 
transport across the vessel wall is the major factor that determines contrast 
medium kinetics. Ktrans then approximates to permeability- surface area product. 
As low molecular weight contrast media do not cross cell membranes, the 
volume of distribution is effectively the EES (also called leakage space, ve). The 
rate constant or keP describes the rate at which the contrast agent diffuses back 
into the vasculature from the EES. This tissue compartmental model is shown in 
figure 1.10.
The quantitative parameters discussed above are more complicated to derive 
compared to those derived semi-quantitatively which deters their use at the 
workbench. The model chosen may not exactly fit the data obtained, and each 
model makes a number of assumptions that may not be valid for every tissue or
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tumour type[162, 163]. Nonetheless, if contrast agent concentration can be 
measured accurately and the type, volume and method of administration are 
consistent, then it may possible to directly compare pharmacokinetic parameters 
acquired serially in a given patient and in different patients imaged at the same 
or different scanning sites [164,165].
1.4.4.2 Clinical validation of T l W DCE-MRI
A number of studies have attempted to correlate the morphological findings on 
breast T1W DCE-MRI with key histological features [166-168]. Early rim 
enhancement appears to correlate with high MVD (periphery more than centre), 
increased expression of VEGF, relatively small amounts of fibrosis and small 
cancer cell nests. Delayed peripheral (rim) enhancement appears to correlate 
with larger amounts of fibrosis and exuberant inflammatory infiltrate while 
delayed central enhancement appears to correlate with the presence of internal 
fibrosis and necrosis. Vascular density in malignant tissue is higher than normal 
parenchyma but there is an overlap with some benign lesions including 
fibroadenomas and inflammatory and proliferative processes [169, 170]. A 
number of studies have assessed whether there is a correlation between the 
kinetic DCE-MRI parameters and immunohistochemical staining in breast 
cancer. Broad correlations between Tl kinetic parameters estimates and MVD 
have been shown by some studies [170, 171] while others have found no 
correlation [172, 173]. It appears that factors other than MVD are important in 
determining the degree of tissue enhancement, such as VEGF expression [166] 
although some have found no correlation between VEGF expression and the 
degree of enhancement [174]. The issue of visible tumour vascularity (as 
assessed by immunohistochemistry) versus functional tumour vascularity (as 
assessed by DCE-MRI) remains to be addressed.
1.4.4.3 Clinical experience with T1W DCE-MRI
1.4.4.3.1 Screening
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It is estimated that 5-10% of all breast cancers have a dominantly inherited 
component depending on the population studied. Two high penetrance genes 
have been identified that predispose to breast cancer, BRCA1 and BRCA2, and 
germline mutations in these genes are responsible for the majority of these 
inherited breast cancers and are associated with breast cancer at a younger age. 
For women carrying either of these two genes, there is a cumulative lifetime risk 
of developing breast cancer of 40-85% depending on the type of mutation and 
population being studied. In addition, there are many familial breast cancers not 
attributed to either BRCA1 or BRCA2. Currently, approaches to reducing the 
risk of developing breast cancer in these patients includes prophylactic 
mastectomy [175, 176], ovarian ablation [177] and chemoprevention [178, 179]. 
In addition to their toxicity and, in the case of prophylactic mastectomy, 
disfigurement, none of these methods can eliminate the risk entirely and hence 
screening is now under investigation. Although some studies have demonstrated 
screening mammography can be efficacious for women as young as 40 years old 
[180, 181], the value of screening young women at high genetic risk with 
mammography remains to be confirmed. It has been suggested that 
mammography has low sensitivity when screening women with BRCA1/2 
carriers due to young age and hence increased breast density, a higher tumour 
growth rate and atypical mammographic and histopathological characteristics 
[182]. Additionally, there is concern regarding the radiation exposure from 
mammography in youung women with inherited abnormalities in DNA repair, as 
in BRCA-1 and BCRA-2 mutations. In light of this, T1W DCE-MRI has been 
evaluated as a screening test for women at high genetic risk of developing breast 
cancer.
Many studies of breast MRI in women at high genetic risk have reported while 
some studies are still ongoing. Details of the sensitivities and specificities of 
MRI screening in the literature to date, and the comparisons with conventional 
screening methods, are shown in Table 1.5. Most studies have found high 
sensitivity for detecting early cancers but lower specificity. Breast MRI does 
have a number of limitations as a screening tool, however, due to both technical 
(e.g. the requirement of intravenous of contrast medium; long examination and 
analysis times; variable specificity (53-97%) and biological reasons (e.g.
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limitations when characterising some lobular and medullary carcinomas; limited 
ability to detect ductal carcinoma in-situ and small invasive cancers [see 
sections 1.4.4.3.3 and 1.4.4.3.4), Further, to date there is no evidence that early 
diagnosis of breast cancer in high risk women results in a decrease in breast 
cancer-specific mortality. As such, recommendation of breast screening in this 
patient group with DCE-MRI cannot be made with certainty. It is worth 
mentioning, however, that DCE-MRI screening may benefit other young women 
with increased risk of breast cancer from other causes, such as childhood or 
young adult cancer survivors previously treatment with thoracic irradiation e.g. 
mantle irradiation in the treatment of Hodgkin’s disease [183].
1.4.4.3.2 Axillary lymphadenopathy and the unknown primary tumour
Less than 1% of patients with breast cancer present with palpable axillary 
lymphadenopathy with no clinically or mammographically detectable breast 
lesion (carcinoma of unknown primary (CUP) syndrome) [184]. Following the 
histological confirmation of adenocarcinoma from the axillary disease, treatment 
usually involves either ipsilateral mastectomy or breast irradiation with axillary 
node dissection followed by systemic therapy as appropriate (chemotherapy 
with/without endocrine therapy). However, a third of patients undergoing 
mastectomy have no primary tumour identified on pathology [185, 186], while 
radiotherapy alone to the breast has been associated with an increased risk of 
local recurrence [187]. In light of this, a number of studies have assessed the 
role of DCE-MRI for detecting occult primary breast cancers to aid in the 
treatment decision process.
Orel et al. reported on 22 women presenting with malignant axillary lymph 
nodes and negative clinical and mammographic examinations [188]. MRI 
identified a primary breast cancer in 19 of the 22 patients (86%) with the lesion 
sizes measuring between 4 and 30mm. Two patients with invasive ductal 
carcinoma (2mm; 17- and 20- mm) had false negative MRI results. Olsen et al. 
assessed 40 patients with isolated axillary adenocarcinoma from an unknown 
primary, again with no detectable breast lesion either clinically or 
mammographically [189]. MRI identified a primary breast lesion in 28 of the 40
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women. Of the 12 patients with a negative MRI study, 5 underwent mastectomy 
but tumour was found in only one of the specimens. A number of smaller studies 
have revealed similar results [190, 191]. Thus, contrast-enhanced MRI can 
detect occult breast cancer in patients presenting with malignant axillary disease 
from an unknown primary source where clinically breast examination and 
mammography are normal (Figure 1.11). Given the poor performance of 
mammography in this situation [187, 192], MRI of the breast should now be 
considered the investigation of choice in this clinical situation (Table 1.6).
1.4.4.3.3 Lobular cancer
Lobular carcinoma of the breast is characterised pathologically by infiltration of 
the carcinoma cells in a “single-file” (“Indian-files”) fashion. This induces a 
less prominent desmoplastic reaction and, as a result, mammography and 
ultrasound tend to have a low sensitivity for invasive lobular carcinoma (ILC). 
In addition, lobular carcinomas are associated with an increased incidence of 
multifocality (additional tumour within the same quadrant as the index lesion) 
and multicentricity (additional tumour within a separate quadrant to the index 
lesion) and disease extent can often be underestimated resulting in incomplete 
excision with breast-conserving surgery [193].
DCE-MRI for both diagnosis and assessment of disease extent of ILC has been 
evaluated and demonstrated diagnostic superiority over the conventional 
imaging modalities. In one series of 17 patients with ILC, MRI detected 30 
lesions compared with 21 on conventional imaging, while also identifying 
multiple lesions in 7 cases and contralateral disease in 1 patient [194]. Qayyam 
et al. [195] compared the DCE-MRI characteristics of ILC with the 
histopathological finding in 13 patients. They described 3 patterns for ILC and 
the histopathological correlates: a solitary mass with irregular margins (n=4) 
which corresponded with the same morphology on pathological assessment; 
multiple lesions either connected by enhancing strands (n=6) or separated by 
non-enhancing intervening tissues (n=2) which correlated with non-contiguous 
tumour foci with malignant cells streaming in single-file fashion in the breast 
stroma or small tumour aggregates separated by normal tissue; and enhancing
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septa only (n=l) corresponding with streaming of tumour cells in the breast 
stroma.
Yeh et al. [196] assessed the morphological and functional DCE-MRI features in 
a series of 15 cases of ILC presenting with a palpable mass or an unknown 
primary. The functional parameter measured was the extraction flow (EF) 
product, a quantitative measure of contrast medium uptake. They found the 
range of EF product to be 25 to 120 with the majority of cases within the 30s 
(level for normal breast is 25 or less). In 2 tumours, however, a substantial part 
of the tumour demonstrated an EF product within the normal range. A focal 
mass was found in 8 cases (7 irregular and 1 round; six ill-defined and 2 
spiculated margins) but a mixture of enhancement patterns was seen. Multi-focal 
disease was demonstrated in 4 cases and an unsuspected contralateral tumour in 
1 case. They concluded that the combination of morphology and functional 
characteristics on DCE-MRI is able to detect the majority of cases of ILC 
despite the variability seen. Caution is still required, however, as some lesions 
display features similar to normal breast.
1.4.4.3.4 Ductal Carcinoma in-situ (DCIS)
DCE-MRI has been used for the detection of ductal carcinoma in-situ (DCIS). 
DCIS is usually diagnosed by x-ray mammography due to the presence of 
microcalcification and currently accounts for approximately 20% of screening- 
detected cancers. DCIS can be successfully treated with either mastectomy alone 
or wide local excision followed by adjuvant breast irradiation but relies on 
complete excision of disease. Often this is only achievable with mastectomy due 
to the high rate of multifocal and multicentric disease [197-200]. Several 
investigators have described the morphological and kinetic features of DCIS on 
MRI although most of these studies have had small patient numbers. In a 
relatively large study, Neubauer et al. retrospectively evaluated the DCE-MRI 
features of 39 consecutive patients with pure DCIS [201]. They defined 
categories for signal increase (Cl = normal, C2 = slow, continuous, C3 = strong 
initial and slow further increase, C4 = strong initial increase followed by a 
plateau phenomenon, and C5 = strong initial increase followed by a washout
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phenomenon) and morphological patterns (MO = no pattern observed, M l = 
linear or linear-branched, M2 = segmental dotted or granular, M3 = segmental 
homogeneous, and M4 = focal spot-like). C4 and C5 signal intensity-time 
patterns were considered suspicious of malignancy and 62% of DCIS 
demonstrated this pattern. In terms of enhancement, segmental enhancement was 
seen in 82% and segmental dotted or granular patterns (M2) were seen in 73%. 
When signal increase and morphology were taken together, 70% of non-high 
grade and 92% of high grade DCIS were correctly identified as being suspicious 
for malignancy. They concluded that segmental enhancement is a hallmark of 
DCIS (with hormone effects as the main differential diagnosis) and that the 
combination of morphology and signal intensity enhancement considerably 
improves the rate of detection. Gilles et al, have reported similar findings and 
also noted that early enhancement on DCE-MRI in patients with DCIS is 
associated with angiogenesis in the stroma that surrounds ducts involved by 
DCIS [202]. However, it should be remembered that not all ductal enhancement 
on breast MRI is due to DCIS. Liberman reported that ductal enhancement can 
also be caused by atypical ductal hyperplasia, lobular carcinoma in-situ, 
fibrocystic change, ductal hyperplasia, and fibrosis [203]. Therefore, the clinical 
utility of MRI in the evaluation of DCIS remains uncertain.
1.4.4.3.5 Tumour staging: Tumour volume determination, multicentricity and 
multifocality
An accurate assessment of the primary tumour extent is crucial for deciding the 
best management for breast cancer patients. It is particularly important when 
considering the feasibility of breast-conserving surgery. An inaccurate 
assessment can lead to incomplete tumour excision thus resulting in either the 
need for a second surgical procedure or a high rate of recurrence following 
“apparent” curative surgery. Unfortunately, clinical examination, mammography 
and breast ultrasonography are poor at accurately defining the primary tumour 
extent and are capable of both overestimating and underestimating the 
histologically defined tumour size [77, 80, 204, 205]. As a result, the role of 
T1W DCE-MRI in this setting has been examined and a number of studies have 
shown MRI to be superior to both mammography and ultrasonography [89, 206-
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208]. When comparing the largest pathological cancer diameter with the tumour 
size defined by each technique, Davies et al. found MRI to have the highest 
correlation coefficient (r=0.98) when compared with ultrasonography (r=0.45) 
and mammography (r=0.46). MRI also had the smallest standard error of 0.34 
compared with 0.78 and 1.04 for ultrasonography and mammography 
respectively [206]. Esserman et al. has also demonstrated MRI to be superior to 
mammography with a 98% accuracy for defining anatomic tumour extent 
compared to only 55% for mammography [89]. In addition, MRI can identify 
synchronously contralateral occult primary tumours in between 3% and 24% of 
women presenting with breast cancer [209-212].
The presence or absence of tumour multifocality and/or multicentricity is critical 
when planning the optimal surgical management of breast cancer. It now well 
established that MRI can identify additional sites of tumour, not detected using 
conventional imaging, in between 6 and 34% of women with known breast 
cancer. MRI identifies multifocal disease in 1-20% of women and muticentric 
disease in 2-20% [90, 209, 213-217]. Kramer et al. demonstrated MRI to have a 
sensitivity for the diagnosis of multicentricity of 89% compared with 79% for 
ultrasonography, 66% for mammography and only 47% for clinical examination 
[218]. Thus, more accurate depiction of tumour size and prediction of the 
distribution of tumour by MRI may help to achieve definitive surgery in one 
procedure [219, 220]. This benefit can be expected to be greater in cases where 
mammography and ultrasound have difficulties, for example, in patients with 
dense breasts or invasive lobular carcinoma. It should be remember, however, 
that there is the potential to increase the number of mastectomies and so 
specificity for individual lesions must be high [221]. If doubt exists, a biopsy to 
document additional disease is recommended prior to definitive surgery.
1.4.4.3.6 DCE-MRI and Neoadjuvant chemotherapy
As discussed in section 1.2.2, neoadjuvant chemotherapy delivered prior to 
definitive surgery in primary breast cancer provides equal survival to primary
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surgery followed by adjuvant chemotherapy, while increasing breast- 
conservation rates due to tumour down-staging.
A proportion (2-30%) of patients receiving NAC will fail to response to 
treatment and will have a worse outcome [23, 29, 75]. The ability to identify 
non-responders early during treatment would enable the use of alternative 
therapies which may be more beneficial [36]. Currently, measurement of breast 
tumour size is used to monitor response to treatment and assess the volume of 
residual disease after treatment. Recently, von Minckwitz et al. demonstrated 
that clinical response after two cycles of NAC could predict for pCR [45], 
however, many studies evaluating NAC in patients with breast cancer have 
shown that clinical examination frequently overestimates tumour size [77-81]. 
Further, change in tumour size often becomes apparent only after several cycles 
of chemotherapy. Conventional imaging with X-ray mammography & 
ultrasonography are also imperfect techniques and neither has been shown to be 
superior to clinical assessment for predicting pathological tumour size [82]. 
Therefore, DCE-MRI has two potential roles to play in the assessment of 
patients receiving NAC. Firstly, DCE-MRI may help in the early identification 
of non-responding patients thus allowing treatment intervention that may be 
more beneficial. Secondly, DCE-MRI may provide a more accurate assessment 
of residual tumour at the end of NAC and thus aid in the decision regarding 
surgery.
1.4.4.3.7 Monitoring Tumour Response
DCE-MRI evaluates response on the basis of both change in tumour size and on 
the amount and speed of enhancement. The value of DCE-MRI as an early 
predictor of the efficacy of NAC in patients with breast cancer has not been fully 
evaluated and is the subject of the prospective study discussed in chapter 2. Both 
Knopp and Hayes et al. have, however, shown that successful treatment causes 
decreases in the rate and magnitude of enhancement and that poor response 
results in persistent abnormal enhancement [222, 223]. Esserman et al. have 
suggested that the morphological MRI appearances of breast cancer prior to
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therapy can predict likelihood of response but this has not been verified by other 
workers [224].
1.4.4.3.8 Evaluating Residual Disease
Currently, tumour size is used to assess the volume of residual disease after 
NAC by clinical examination, x-ray mammography and/or ultrasound. Each of 
these techniques, however, overestimates the extent of residual disease at the 
end of treatment [225-229]. Clinical palpation is an imperfect evaluation method 
because of intervening skin and soft tissue and is unable to distinguish active 
disease from post-chemotherapy fibrosis. Assessments by x-ray mammography 
are hampered by radiographic magnification and it may be difficult to 
distinguish residual tumour from post-chemotherapy fibrosis [227, 228]. It is 
also well-recognised that some tumours are simply not visualized in patients 
with radiographically dense breasts. In some patients, ultrasound appears better 
in assessing tumour response and Doppler ultrasound of residual disease is being 
evaluated [229].
Feldman et al. made the observation that there was a significant difference 
between the clinical and pathological evaluation of residual disease, such that 
the improved patient survival achieved in those with complete pathological 
response (p=0.002) would not be appreciated if  patients had been judged 
clinically (p=0.09) [226]. Women with normal examinations may well have 
residual active disease requiring further treatment. Further, in some cases, small 
volumes of residual disease after NAC can be difficult to target at operation. In a 
study of 80 women, Sever et al. assessed the value of insertion of an intra- 
tumoural coil prior to NAC in order to guide surgery, particularly in those 
obtaining a cCR [230]. Of the 80 women treated, 47 achieved a cCR (59%), with 
19 women (24%) also achieving a radiological CR on mammography and breast 
ultrasound. In these 19 patients, localisation was possible exclusively by use of 
the coil and in 11 patients, residual disease was found. Further, in 3 of the 11 
patients, widespread microscopic disease was found and these subsequently 
required mastectomy. This study demonstrates that clinical and conventional 
radiological assessment of disease following NAC may not accurately reflect the
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true pathological extent and thus, more accurate methods of assessing residual 
disease would improve the selection and precision of subsequent treatment 
methods.
Several studies have shown that contrast enhanced MRI is the most accurate 
technique for evaluating pathological response and volume of residual active 
disease at the end of treatment [231-238]. Non-dynamic fat suppressed breast 
MRI assesses the presence of residual disease better than mammography when 
the presence of residual abnormal enhancement on post-contrast images is used 
[233]. Interestingly, many have observed that the fibrosis observed after 
chemotherapy is hylanised and does not arise from granulation tissue (seen post- 
operatively) [239] and this enables residual active disease to be depicted as an 
area of persistent abnormal enhancement [240, 241]. Microscopic disease can of 
course not be detected, but MRI can indicate the extent of remaining tumour 
tissue on which to plan breast conserving surgery.
1.4.4.3.9 Detecting relapse
The surgical management of primary breast cancer depends on a number of 
factors including tumour size, position, multicentricity, patient choice and 
contraindications to radiotherapy. Breast-conserving surgery with radiotherapy 
is now known to be equivalent to mastectomy in terms of survival and is 
generally the treatment of choice for early stage breast cancer [2, 242, 243]. In 
some studies, however, breast-conservation has been associated with a higher 
rate of local recurrence compared to mastectomy although, despite this, overall 
survival has remained equivalent. [242, 243]. Early detection of local recurrence 
is important as many patients can be successfully treated by salvage mastectomy 
[244, 245].
The recommended follow-up for local recurrence is involves routine clinical 
examination and mammography [246, 247]. Ultrasonography and core biopsy 
are used to confirm the diagnosis of recurrence. In the first six months after 
surgery, mammograms show a general increased density, architectural
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distortion, skin thickening, asymmetric densities, dystrophic calcification and 
features of fat necrosis [248-250]. Mammographic changes are most helpful in 
suggesting recurrence six months to one year later after surgery. It is well 
recognised that features of scar tissue can mimic those of recurrent cancer on 
mammography [251] and, therefore, any increase in the extent of the post 
surgical abnormality or the development of a mass within the area of distortion 
must be regarded as suspicious. The overall positive predictive value of cancer 
detection in the treated breast using mammography is thought to be around 72% 
[252] with a false negative rate of 5-15% [253].
As a result, the role of DCE-MRI in detecting tumour recurrence in the 
surgically operated breast has been assessed. Some studies previously reported 
that non-enhanced T2 weighted sequences alone could be used to differentiate 
tumour from scar tissue as recurrent tumour demonstrated a higher signal 
intensity than dysplastic tissue and fibrosis [254, 255]. However, other groups 
failed have to show this [148, 152, 256, 257] and therefore un-enhanced MRI 
scans must be considered unreliable.
In contrast, a number of studies have now shown the benefit of DCE-MRI for 
detecting recurrent tumour in the previously treated breast and relies on the 
different enhancement pattern of malignant disease compared with benign post­
treatment changes such as scarring and fat necrosis. On Tl weighted sequences 
following Gd-DTPA contrast medium rapid, early (within 3 minutes) and avid 
enhancement is seen in recurrent tumour compared with slower enhancement of 
lower magnitude in benign disease [152, 256-259] [260, 261]. Gilles et al. also 
noted nodular enhancement to be associated with invasive carcinoma while 
linear enhancement was seen with ductal carcinoma in-situ [152]. Mussurakis et 
al. reported significant differences between benign and malignant lesions for 
enhancement index, maximum uptake, amplitude of uptake, wash-in rate, wash­
out rate and the reciprocal of half the time to maximum. The respective 
sensitivity and specificity for each parameter was: enhancement index, 1.00 and
0.96; maximum uptake, 1.00 and 0.96; amplitude of uptake, 0.91 and 0.94; 
wash-in rate, 0.82 and 0.47; wash-out rate, 0.91 and 0.59; and the reciprocal of 
half the time to maximum, 1.00 and 0.51 [260].
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The timing of DCE-MRI following surgery is an important factor in the 
accuracy of the technique, however, as benign proliferative disease and recent 
fat necrosis may mimic malignant recurrence within 6 months of surgery and 9 
months of breast irradiation [258, 262]. Indeed, in some patients post-operative 
scarring may continue to enhance up to 18 months post-treatment although 
beyond that time no significant enhancement is seen [263]. The absence of focal 
enhancement, even in the first year post-treatment, is thought to be able to 
exclude recurrent malignancy with a negative predictive value of 100% [264].
When compared with other techniques for detecting local recurrence, DCE-MRI 
has a consistently high sensitivity (91%-100%) with an associated high 
specificity (88%-93%) [218, 265-267]. This compares with sensitivities for other 
techniques as follows: clinical examination alone, 51%-89%; mammography 
alone 50%-67%; ultrasound 85%; and cytology 79% [218, 265, 267]. Of note, 
Drew et al. showed clinical examination combined with mammography to have 
100% sensitivity but a poor specificity at 67% [265].
MRI may reveal other lesions in the post surgical breast, which can confound 
evaluation by clinical examination, mammography or ultrasound. These include 
seromas, haematomas, oil cysts, fat necrosis and areas of residual or recurrent 
DCIS. Many of these have characteristic appearances on MRI and hence 
definitive diagnoses can be made.
1.4.4.4 T2*-weighted DCE-MRI of breast cancer
1.4.4.4.1 Data acquisition
T2*-weighted (susceptibility) DCE-MRI sequences are sensitive to the vascular 
phase of contrast medium delivery and reflect on tissue perfusion and blood 
volume. Such perfusion-weighted images of the breast can be obtained using 
"bolus-tracking techniques". These monitor the passage of contrast material 
through a capillary bed as it produces magnetic field (Bo) inhomogeneities
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which result in a decrease in signal intensity of surrounding tissues [268, 269]. 
The decrease in signal intensity of tissues can be observed with susceptibility- 
weighted sequences. The degree of signal loss observed is dependent on the 
vascular concentration of the contrast agent together with the microvessel size 
[270] and density. The signal to noise ratio (SNR) of such images can be 
improved by using high doses of contrast medium (i.e., > 0.2-mmol/kg body 
weight) [271]. High specification MR systems are ideally suited to this task and 
allow multi-slice acquisitions. Such studies are also possible on conventional 
MRI systems using standard gradient-echo techniques but the need to acquire 
data at a 1-2 second resolution requires that the matrix size is relatively coarse 
and often limited to 1-2 slices.
1.4.4.4.2 Data quantification and limitations
Tracer kinetic principles can be used to provide estimates of relative blood 
volume (rBV), relative blood flow (rBF) and mean transit time (MTT) derived 
from the first-pass of contrast agent through the microcirculation [268, 269, 272] 
(Figure 1.12). These variables are related by the central volume theorem 
equation
BF = BV/MTT.
The most robust parameter which can be extracted reliably from first pass 
techniques is rBV, which is obtained from the integral of the time series data 
during the first pass of the contrast agent [273]. This cannot readily be done for 
the breast because of the loss of compartmentalization of the contrast medium. 
Solutions to counter Tl enhancing effects of gadolinium chelates include pre­
dosing with contrast medium to saturate the leakage space, and idealized model 
fitting where the time series data is fitted to a gamma-variate function from 
which the parameters rBV, rBF and MTT are derived (Figure 1.13). From a 
practical perspective, it is not always necessary to quantify T2*-weighted DCE- 
MRI data to obtain insights of the spatial distribution of tissue perfusion. Simple 
subtraction images can demonstrate the maximal signal attenuation (also termed
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relative maximum signal drop, rMSD), which has been strongly correlated with 
relative blood flow and volume in tumors [274, 275]. Subtraction analysis 
should only be done, however, if there is a linear relationship between rBV and 
rBF, that is when MTT is in a narrow range. This is often the case in non- 
necrotic breast tumours (Figure 1.14).
1.4.4.5 Clinical experience with T2*W DCE-MRI
To date, clinical experience with T2*W DCE-MRI is limited. Both Kuhl et al. 
and Kvistad et al. have evaluated the value of T2*W DCE-MRI for 
characterising breast lesions using visual assessments [276, 277]. Both studies 
showed strong decreases in signal intensity in malignant tissues whereas 
susceptibility effects in fibroadenomas were minor. Thus, it was possible to 
differentiate carcinomas from fibroadenomas with high specificity using T2*W 
characteristics despite significant overlap in Tl enhancement patterns. The 
pathophysiological explanation probably relates to differences in the 
microvessel arrangements, density and size between malignant tumours and 
fibroadenomas. Weind et al. conducted a histopathological study comparing 
microvessel distributions in invasive breast cancer and fibroadenomas that shed 
light on these observations [278]. They showed that there was complete overlap 
in MVD counts between the breast cancers and the fibroadenomas but the 
distribution of microvessels was distinctive. Microvessel distribution in the 
breast carcinomas showed marked regional variations with fewer vessels seen 
within the centre of tumours compared to the periphery whereas the microvessel 
distribution in fibroadenomas was more evenly spread within the stroma. Other 
investigators have also shown microvessel density “hot spots” in breast cancers 
[167, 279]. Both Kuhl et al. and Kvistad et al. comment that the T2* effects 
occurred in focal areas which may correspond to the "hot spot" MVD counts in 
tumours.
The role of T2*W DCE-MRI for evaluating response to neoadjuvant 
chemotherapy in primary breast cancer is examined in chapter 2.
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1.4.5 NON-ENHANCED MRI METHODS -  BOLD MRI
Non-enhanced MRI techniques use intrinsic paramagnetic substances to provide 
the contrast between tissues. Blood oxygen level dependant (BOLD) MRI is an 
example of a non-enhanced MRI method. This technique uses 
deoxyhaemoglobin as an “intrinsic” contrast medium. Deoxyhaemoglobin is a 
paramagnetic substance under normal circumstances and thus its presence 
affects the signal intensity of the surrounding tissues. BOLD MRI can therefore 
provide a potential method for assessing the level of tissue oxygenation. 
Gradient-echo T2 * weighted images that are sensitive to changes in blood 
volume, blood flow and blood oxygenation are used.
Vascular function can be evaluated by analysis of BOLD contrast changes in 
response to hyperoxia and hypercapnia [280]. Clinical application of this 
technique has revealed high signal enhancements in response to carbogen (5% 
CO2 : 95%02) inhalation in human tumours [281]. The primary advantage of 
BOLD MRI is that there is no need to administer contrast material. Further, 
BOLD contrast is not sensitive to fluctuation in permeability. A major 
reservation for intrinsic contrast imaging is the low contrast to noise ratio in the 
images obtained.
The role of BOLD MRI for evaluating response to neoadjuvant chemotherapy in 
primary breast cancer is examined in chapter 2 and an assessment of the 
pathophysiological correlates of the BOLD MRI parameter, R2* is discussed in 
chapter 4.
1.5 SUMMARY AND AIMS OF THESIS
The neoadjuvant treatment setting in primary breast cancer provides a platform 
for the in vivo assessment of tumour chemo-responsiveness and the underlying 
response mechanisms. In addition, response in the primary tumour may act as a 
surrogate marker of response in occult micrometastatic disease. With the advent 
of novel therapies that target the tumour vasculature, it is important to
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understand of the effects of conventional cytotoxic chemotherapy on the tumour 
vasculature. This will help in the rational design of future treatment regimens 
combining conventional and novel anticancer agents.
Thus, the aims of the research in this thesis are:
1. To assess the vascular effects of neoadjuvant conventional cytotoxic 
chemotherapy in primary breast cancer using multi-parameter 
functional MRI (DCE-MRI and BOLD-MRI) performed prior to and 
during chemotherapy treatment and to determine whether the 
baseline parameter values or treatment changes predict for 
clinicopathological response.
2. To evaluate the effect of neoadjuvant chemotherapy on the 
quantitative and qualitative measures of tumour angiogenesis, as 
assessed using immunohistochemical staining techniques, and to 
determine whether the baseline parameter values or treatment 
changes predict for clinicopathological response.
3. To assess the pathophysiological correlates of the DCE-MRI and 
BOLD MRI kinetic parameters in primary breast cancers.
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Table 1.1. Non-randomized studies of neoadjuvant chemotherapy
Study No. Chemotherapy
cCR
(%)
pCR
(%)
Bonadonna et al.[17] 161 CMF x 3-4, FAC x 3-4, FEC x 3 17 4
Hortobagyi et al.[18] 174 FAC x 3 17 NK
Gardin et al.[19] 125 FAC x 3 10 4
Smith et al. [20] 50 EcisF x 8 66 NK
Chollet et al.[21] 50 ACVF 51 30
Kuerer et al. [22] 156 FAC x4 NK 19
Abbreviations: CMF, cyclophosphamide, methotrexate, 5-fluorouracil; FAC, 5-fluorouracil, doxorubicin, 
cyclophosphamide; FEC, 5-fluorouracil, epirubicin, cyclophosphamide; EcisF, epirubicin, cisplatin, 5- 
fluorouracil; ACVF, doxorubicin, cyclophosphamide, vinorelbine, 5-fluorouracil.
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Table 1.2. First generation randomised controlled trials of neoadjuvant
chemotherapy
Study No. Group Schedule Time of 
follow-up
OS P
value
Fisher et al. [23] 
(Wolmark et al. [24])
1523 Preop AC-S 5 years 
(10 years)
80%
(69%)
0.83
(0.80)
Postop S-AC 80%
(70%)
Mauriac et al. [25] 272 Preop EVM -  MTV -S&/or RT 10 years 55% NS
Postop S -  EMV-MTV 55%
Semiglazov et al. [26] 271 Preop TMF-RT-S-TMF 5 years 86% >0.05
Postop RT-S-TMF 78%
Scholl et al. [27] 414 Preop FAC-S-RT 54 months 86% 0.04
Postop RT-S-FAC 78%
Powles et al.[28] & 
Makris et al. [29]
309 Preop MMMT -S-MMMT 48 months NS
Postop S-MMMT
van der Hage et al. 
[30]
698 Preop FEC-S 4 years 82% 0.4
Postop S-FEC 84%
Abbreviations: OS, overall survival; AC, doxorubicin & cyclophosphamide; S, surgery; EVM, epirubicin, vincristine, 
methotrexate; MTV, mitomycin, thiotepa, vindesine; RT, radiotherapy; TMF, thiotepa, methotrexate, 5-fluorouracil; 
FAC, 5-fluorouracil, doxorubicin, cyclophosphamide; MMMT, methotrexate, mitoxantrone, mitomycin, tamoxifen; 
FEC, 5-fluorouracil, epirubicin, cyclophosphamide.
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Table 1.3. Studies of biologic markers to predict response to NAC in
primary breast cancer
Patient
no.
Treatment Markers
assessed
Biologic markers 
predicting 
response
Other markers 
predicting 
response
Makris et al. 
1997(56]
90 2M/3M + tamoxifen ER, PgR, c-erbB-2, 
p53, Ki-67, bcl-2, 
SPF, ploidy
None c-erZ>B-2 negative
Chang et al. 1999 
[571
158 2M/3M +  tamoxifen Tumour size, nodal 
disease, ER, PgR, c- 
erbB-2, p53, bcl-2, 
Ki67, SPF, ploidy
Decrease Ki67 on 
dlO ord2I
ER positive; c-erbB- 
2 negative
Assersohn et al. 
2003(64]
106 Anthracycline or 
anthracenedione-based 
chemotherapy +/- 
tamoxifen; tamoxifen 
alone
Ki-67 Change Ki-67 on 
d21
Burcombe et al. 
2005(61]
118 Anthracycline or
anthracenedione-based
chemotherapy
ER, PgR, HER-2, Ki- 
67
>75% reduction Ki- 
67 at end o f  
treatment
None
Bottini et al 
2001(65]
157 CMF+tamoxifen;
epirubicin
Ki67, p53, bcl2, c- 
erbB2, ER, PgR
Change Ki-67at end 
o f  treatment
None
Chang et al. 
2000(70]
28 2M A l, Ki67, SPF, ploidy Increase Al; 
decrease Ki67 on 
d21
Archer et al. 
2003 [69]
65 Antracycline-based Al, Ki-67, HER-2 High Ki-67, high GI 
(Ki-67/AI ratio)
None
Collecchi et al. 
1998[67]
70 FEC [3H]-dT-LI, bcl-2 High [3H]-dT-LI
Faneyte et al. 
2003(63]
97 Antracycline-based Tumour size, bcl-2, 
ER, p53, HER-2, Ki67
High Ki67; positive 
p53
Large tumour size; 
ER negative
Penault-Llorca et 
al. 2003(59]
115 Antracycline-based Grade, ER, PgR, HER- 
2, Ki67, p53
None HER-2 positive
Vincent-Salomon 
et al. 2004(66]
55 CAF ER, PgR, SPF, MI, 
Ki67
High MI; high SPF; 
high Ki67
ER negative, PgR 
negative
Kallab et al 2004 
[711
26 DT ER, PgR, HER-2, 
Ki67, bcl-2, p53,p21, 
EGFR, p-glycoprotein
None None
2M= mitoxantrone, methotrexate; 3M= 2M + mitomycin C;ER= oestrogen receptor; PgR=progesterone receptor; SPF=S-phase fraction; 
CMF= cyclophosphamide, methotrexate, 5-fluorouracil; FEC=5-fluorouracil, epirubicin, cyclophosphamide; [3H]-dT-LI = [3H]- 
thymidine labelling index; CAF = cyclophosphamide, 5-fluorouracil, doxorubicin; MI=mitotic index; DT = doxorubicin, docetaxel; 
EGFR=epidermal growth factor receptor
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Table 1.4. Examples of endogenous proangiogenic and antiangiogenic 
factors that regulate angiogenesis
PROANGIOGENIC FACTORS ANTIANGIOGENIC FACTORS
Vascular endothelial growth factor 
Acidic & basic fibroblast growth factors 
Platelet-derived growth factor 
Transforming growth factors a , P 
Prostaglandins El, E2 
Epidermal growth factor 
Tumour necrosis factor-a 
Interleukin-8 
Vascular integrin a vP3 
Matrix metalloproteinases
Thrombospondin 
Angiostatin 
Endostatin 
Vasostatin 
Interferon-a, P, y 
Interleukin-12 
Platelet factor 4
Tissue inhibitors of metalloproteinase
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Table 1.5. Comparison of MRI screening for breast cancer in high-risk groups with clinical examination, mammography and ultrasonography
Country
(City)
Study
No.
wom en
reported
No.
BRCA1
or
BRCA2
carriers
No.
cancers
detected
M RI Results
O ther m odalities tested
Sensitivity Specificity
Clinical examination M ammography Ultrasound
Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity
Canada
(Toronto)
WARNER et al. 
(2001)[282]
196 96 6 100% 91% 33% 99.5% 33% 99.5% 60% 93
Germany
(Bonn)
KUHL et al. 
(2000)[283]
192 15 100% 95% 33% 93% 33% 80%
Italy
(Rome)
PODO et al. (2002) 
[284]
105 8 100% 99% Not
Stated
Not
stated
Netherlands
(Nijmegen)
STOUTJESDIJK et al. 
(2001) [285]
179 13 100% 93% 42% 96%
Netherlands
(Rotterdam)
TILANUS-
LINTHORST et al. 
(2000)[286]
109 3 100% Not
stated
Not
stated
Netherlands
(Rotterdam)
KRIEGE et al. 
(2004)[287]
1909 358 51 80% 90% 18% 98% 33% 95%
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Table 1.6. Current and potential new indications for breast MRI
Indication Comments
Problematic mammogram Mammographic and ultrasound evaluation should be done first 
and MRI in selected patients with equivocal or suspicious 
findings.
Staging breast cancer when multiple 
or bilateral tumours are suspected
MRI improves accuracy of staging, detecting multicentricity 
and multifocality particularly for large tumours in the 
radiographically dense breast and lobular cancers. MRI has a 
high negative predictive rate. Unsuspected contralateral 
malignancy can be detected in 5-10% of lobular cancer cases.
High risk screening: breast cancer 
gene carriers and history of mantle 
irradiation for lymphoma at young 
age
MRI may be a valuable adjunct in these high risk patients but 
MRI is NOT appropriate for general breast cancer screening.
Lobular cancer Tumour extent can be difficult to detect with mammography, is 
commonly multifocal/multicentric or bilateral (approximately 
10%) and is a frequent cause of positive surgical margins.
Metastatic cancer in axillary lymph- 
nodes without detectable lesion on 
conventional imaging
MRI can locate a primary breast tumour in the majority, 
enabling breast conservation surgery
Monitoring response to neoadjuvant 
chemotherapy
Helpful for identifying the extent of residual active disease 
following completion of chemotherapy for locally advanced 
breast cancer. Monitoring response to treatment during therapy 
is experimental.
Positive surgical margins following 
breast conservation surgery
MRI can identify the extent of residual disease
Distinguishing tumour recurrence 
from surgical scar and other causes 
of a mass following breast surgery
Recommended 6 months or more after surgery
Suspected implant rupture or 
suspected cancer in patients with 
history of liquid silicone injection
79
Figure 1.1. Age-standardised incidence of and mortality from female breast 
cancer in England and Wales (Rate per 100,000). (Taken from  National 
Statistics, www.statistics.gov. uk) [ 1 ]
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Figure 1.2. The Nottingham Prognostic Index (NPI)
NPI = (0.2 x size [cm]) + grade + lymph node status
No lymph nodes positive =1 
< 4 lymph nodes positive =2 
> 4 lymph nodes positive =3
Grade 1 -  3
NPI Prognosis 10 year overall survival
<2.4 Excellent 94%
<3.4 Good 83%
<4.4 Moderate 70%
<5.4 Moderate II 51%
>5.4 Poor 19%
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Figure 1.3. Overall survival and disease-free survival according to 
treatment through 9 years of follow-up from the NSABP-B18 trial (Postop = 
postoperative chemotherapy; Preop = preoperative chemotherapy). Taken 
from  Wolmark et al, 2001.[24J
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Figure 1.4. Comparison of outcome of patients treated with preoperative 
chemotherapy according to primary breast tumour response through 9 
years of follow-up from the NSABP-B18 trial. Taken from  Wolmark et al, 
2001.[24J
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Figure 1.5. Microvessel density in a shrinking tumor is determined by the 
combined effects of capillary dropout and tumor cell dropout. The time- 
dependent coupling of these two forms of cell dropout is reflected by the 
intercapillary distance and, in turn, by microvessel density. Thus, following 
antiangiogenic therapy a regressing tumor may exhibit decreased 
microvessel density, essentially unchanged levels of microvessel density, or 
even increased microvessel density, {taken from  Hlatky et al, 2002)[132]
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Figure 1.6. Quantitative analysis of endothelial cell proliferation and 
pericyte recruitment during pathological tumour angiogenesis and 
physiological ovarian angiogenesis. All data are expressed as mean ± SE. 
{taken from  Eberhard et al, 2000)[ 133]
A. MVD count: colon carcinomas, mammary carcinomas, lung carcinomas, and prostate carcinomas have similarly 
high MVD counts. Glioblastomas and renal cell carcinomas have higher average MVD counts (P < 0.005).
B. Proliferating. Capillary Index. A ranked order o f  the intensity o f  angiogenesis in the different types o f  tumors 
was determined as follows: glioblastomas > renal cell carcinomas > colon carcinomas > mammary carcinomas > 
lung carcinomas > prostate carcinomas. Proliferating. Capillary Index values in malignant human tumours were 
compared with the intensity o f  angiogenesis in the cyclic bovine corpus luteum [C/?; early corpus rubrum 
(angiogenesis)], midstage corpus luteum (CL, maturation), and regressing corpus luteum (REG-CL; regression).
C. Proliferating tumour versus endothelial cell index: A quantitative ratio o f  the total number o f  proliferating 
tumour cells in all tumours: the total number o f  endothelial cells : provides a relative parameter that reflects the per 
tumour cell angiogenic capacity o f  the tumours.
D. Microvessel pericyte coverage index: indices o f  the different types o f  malignant human tumours were compared 
with the values o f  the transient neovasculature during ovarian angiogenesis.
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Figure 1.7. Endothelial cell proliferation and pericyte recruitment in 
individual malignant human tumours (taken from  Eberhard et al, 2000)[ 133]
A. Proliferating Capillary Index (Prol. Cap. Index) in six different tumour types. Prol. Cap. 
Index in glioblastomas, renal cell carcinomas, and colon carcinomas vary over a wide range. 
In contrast, with few exceptions, mammary carcinomas, lung carcinomas, and prostate 
carcinomas have uniformly low Prol. Cap. Index values.
B. Microvessel pericyte coverage index (Peric. Cov. Index) in six different tumour types. 
These varied over a much smaller range than the Prol. Cap. Index
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Figure 1.8. Stylized diagram illustrating classification of signal-intensity 
time curves in breast MRI. Modified from  Schnall MD and Ikeda DM  
(1999) [288]
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Figure 1.9. Converting signal intensity into contrast concentration & model 
fitting. Contrast medium injection (11 ml o f Gd-DTPA) took place after the third data point. 
Quantification o f time signal intensity data (A) from a ROI within the tumour into contrast agent 
concentration (•) is performed first according to the method described by Parker et al.[160]. The 
model fitting procedure (continuous line) is done using the Tofts’ model [164]. Note that model 
fitting to contrast agent concentration data is not perfect. Calculated quantified parameters are 
transfer constant = 0.82 min'1, leakage space 47%, rate constant = 1.74 min*1). Subtraction (100 
seconds), transfer constant (colour scale 0-1 m in 1) and leakage space (colour scale 0-100%) 
images are also shown.
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Figure 1.10. Tissue compartmental model of low molecular weight contrast 
medium kinetics
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Figure 1.11. Carcinoma of unknown primary origin. 70 year old woman 
presenting with metastatic disease in right axillary lymph nodes consistent with breast origin and 
a normal mammogram (not shown). (A) Axial T2-weighted image shows no significant 
abnormality. (B and C) Ti-weighted coronal images o f the right breast before and after 0.2 
mmol/kg Gd-DTPA given intravenously shows 3 focal areas o f enhancement (arrows). (D) 
Subtraction image shows the enhancing lesions well. (E) Signal intensity time curves from 
regions o f interest at the 9 o ’clock (ROI-1) and 1 o’clock (ROI-2) show fast early enhancement 
and plateau and well as wash-out in the delayed phase. (F and G) follow-up examination (3 
months later) following unsuccessful chemotherapy shows deterioration o f appearances with 
widespread areas o f abnormal enhancement.
Ttn» (Mcond*!
89
Figure 1.12. Typical T2 *-weighted DCE-MRI study. 30-year old woman with a 
grade 3 invasive ductal cancer o f the right breast. 22 ml o f IV contrast Gd-DTPA was given after 
the 10th data point (arrow). First pass T2* susceptibility effects cause darkening o f the tumour 
(arrows) (subtle but the effect is better appreciated in the subtraction image (insert)). No 
darkening o f the breast parenchyma is seen. The first pass and recirculation phases are indicated. 
Signal intensity changes for 2 regions o f interest are shown on the subtraction image o f the nadir 
point for ROI corresponding to the tumour.
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Figure 1.13. Model fitting of T2*-weighted data. T2* signal intensity data from the 
tumour ROI are converted into R2* (1/T2*) and then fitted with a gamma variate function. The 
computed values o f  rBV, rBF and MTT for this region o f interest are 265, 10.6 arbitrary units 
and 25.1 seconds. Parametric maps representing blood flow kinetics are shown in figure 1.14.
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Figure 1.14. Parametric T2 *-weighted DCE-MRI images. Parametric images o f 
relative blood volume (rBV), relative blood flow (rBF) and mean transit time (MTT) are derived 
on a pixel-by-pixel basis using gamma variate fitting as shown in figure 1.13. Also shown is the 
T2*-weighted DCE-MRI subtraction image. The graphs show how relative maximum signal 
drop (rMSD) is calculated and that there is a linear correlation between relative blood volume 
and flow at a pixel level within the tumour ROI.
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CHAPTER 2: EVALUATION OF THE EFFECT OF 
NEOADJUVANT CHEMOTHERAPY IN PRIMARY 
BREAST CANCER USING MULTI-PARAMETER 
FUNCTIONAL MRI
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2.1 INTRODUCTION
The ability to identify early during treatment those women with primary breast 
cancer who will fail to respond to neoadjuvant chemotherapy would enable the 
use of alternative therapies that may be more effective [36]. Dynamic contrast 
medium-enhanced MRI (DCE-MRI) using gadolinium chelates provides a 
method for assessing and characterizing tumour microvasculature and provides 
both semi-quantitative and quantitative data which reflect tumour microvessel 
permeability and perfusion [149, 162]. Blood oxygen-level dependant (BOLD) 
MRI potentially provides a means of measuring tumour oxygenation by 
exploiting the different magnetic properties of oxyhaemoglobin and 
deoxyhaemoglobin [280].
This chapter describes the findings from a prospective study assessing multi­
parameter functional MRI (DCE-MRI and BOLD-MRI) of the breasts in women 
receiving neoadjuvant chemotherapy for primary breast cancer (PBC) and 
addresses whether changes in the MRI-derived tumour microvascular 
characteristics and oxygenation, when measured early on in treatment, can 
predict for the final clinical and pathological response.
Thus, the aims of this study were:
• To assess the baseline functional MRI parameters in women with PBC and 
determine whether they correlate with the final clinical and pathological 
response to six cycles of FEC chemotherapy.
• To assess the changes in the functional MRI parameters in women with PBC 
following two cycles of neoadjuvant FEC chemotherapy and determine 
whether these changes correlate with the final clinical and pathological 
response to six cycles of FEC chemotherapy.
• To determine which functional MRI parameters are best able to predict
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pathological non-responsive to treatment
• To determine the reproducibility of each functional MRI parameter and 
determine how much of a change would be statistically significant for an 
individual patient following 2 cycles of chemotherapy
• To consider how DCE-MRI could be used in a neoadjuvant chemotherapy 
paradigm with the aim of improving response rates
2.2 PATIENTS AND METHODS
2.2.1 PATIENTS AND TREATMENT
The study entitled “ Evaluation of MRI during neoadjuvant chemotherapy in 
primary breast cancer” commenced at Mount Vernon Hospital, Northwood, 
Middlesex. U.K., in October 2001 following approval by the local research 
ethics committee (Mount Vernon and Watford Hospitals, protocol number 
EC2001-26). This was a prospective study aimed at evaluating the nature of the 
functional angiogenic response, as determined by Magnetic Reasonance 
Imaging, observed in women receiving neoadjuvant chemotherapy for primary 
breast cancer. Women with newly diagnosed non-metastatic histologically- 
proven breast cancer who were due to receive six cycles of neoadjuvant FEC 
chemotherapy (5-fluorouracil 600mg/m2 intravenously [IV], epirubicin 60mg/m2 
IV and cyclophosphamide 600mg/m IV every 21 days) were eligible for the 
study.
Between October 2001 and June 2003, 37 patients with primary breast cancer 
(T2-4bN0-3cM0 according to the tumour, node metastasis staging system 2002) 
were enrolled onto the study. Inclusion criteria were: (1) Histologically-proven 
primary breast cancer, (2) Age 18-70 years old (3) World Health Organisation 
(WHO) perfomance status 0 or 1 (appendix 2) [289], (4) Not lactating or 
pregnant, (5) No pre-exisiting condition which would deter the delivery of FEC 
chemotherapy (angina, congestive cardiac failure or recent myocardial
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infarction), (6) Absolute neutrophil count >1.5 x 109/1 and platelets >100 x 109/1, 
(7) written informed consent. Exclusion criteria were: (1) MRI scan contra­
indicated (appendix 3) (2) known allergy to gadopentetate dimeglumine (Gd- 
DTPA).
Pre-treatment assessment included full clinical history and physical examination 
(with UICC 2002 TMN staging of the disease [appendix 4]); full blood count; 
urea and electrolytes; liver function tests; bilateral mammography; breast 
ultrasound; core biopsy +/- fine needle aspiration cytology of the primary breast 
tumour.
Prior to commencing FEC NAC, each patient underwent a baseline pre­
treatment multi-parameter functional MRI scan (see section 2.23). Each patient 
then received two cycles of chemotherapy followed by a second MRI 
investigation prior to the third cycle of chemotherapy (estimated 6 weeks apart). 
Patients were assessed clinically prior to each cycle of chemotherapy and 
continued to a total of 6 cycles of FEC chemotherapy provided there was no 
evidence of clinically progressive disease (cPD) as defined by standard 
International Union Against Cancer criteria (see appendix 1). At completion of 
chemotherapy, patients were reassessed clinically and radiologically 
(mammography +/- ultrasound) and further treatment recommended according 
to the response to chemotherapy, the clinician’s discretion and patient choice. 
Further treatment involved surgery to the breast (mastectomy or breast- 
conserving surgery) with or without axillary lymph node surgery, or, in some 
cases where a complete clinical and radiological response had been achieved, 
radiotherapy alone to the breast and ipsilateral axillary and supraclavicular fossa 
(SCF) lymph nodes. In those patients who received surgery, post-operative 
radiotherapy to the breast or chest wall with or without regional nodal irradiation 
was delivered according to the clinical oncologist’s discretion and local 
protocol. Adjuvant hormonal therapy with tamoxifen (20mg daily for five years) 
was recommended for patients with oestrogen or progesterone receptor positive 
breast cancer. A summary of the treatment plan is shown in table 2.1. The 
patient information sheet and consent form are shown in appendices 5 and 6.
96
2.2.2 RESPONSE CRITERIA
2.2.2.1 Clinical response
Clinical response was evaluated from the bidimensional clinical measurements 
of the primary breast tumour prior to and following 6 cycles of FEC 
chemotherapy and was defined according to the UICC/WHO criteria [290, 291] 
as follows:
Complete Response (cCR) Disappearance of all known disease
Partial Response (cPR) Decrease by at least 50% of the sum of the products 
of the largest perpendicular diameters of measurable 
lesions
Stable disease (cSD) Less than 50% decrease and less than 25% increase in 
the sum of the products of the largest perpendicular 
diameters of measurable lesions
Progressive disease (cPD) Increase of more than 25% in the size of a measurable 
lesion or appearance of a new lesion
For the study analysis, clinical responders were defined as those patients with 
cCR or cPR. Clinical non-responders were defined as those patients with cSD or 
cPD. This classification was in accordance with other clinical studies [24, 36]. 
Those patients who progressed during neoadjuvant chemotherapy, such that a 
therapy change was instituted before completing six cycles of FEC 
chemotherapy, were defined as clinical non-responders (n=2).
2 .2 2 2  Pathological response
Pathological response was evaluated by a single consultant pathologist (PIR) 
from a comparison of the pre-treatment core biopsy and the post-chemotherapy 
surgical resected specimen. Response was graded in accordance with previously 
described criteria [292-294]:
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Pathological
response
Description
Grade 1 No residual invasive cancer or DCIS (pathological CR)
Grade 2 Residual DCIS but no invasive cancer
Grade 3 Microscopic residual cancer
Grade 4 Macroscopic residual cancer with chemotherapy-induced 
changes and/or histological tumour response
Grade 5 Macroscopic invasive cancer with no response features
Chemotherapy-induced changes included (1) enlarged cells, (2) finely 
vacuolated “bubbly” voluminous cytoplasm, (3) enlarged vesicular nucleus with 
prominent single eosinophilic nucleolus, (4) occasionally enlarged 
hyperchromatic dense nucleus with an irregular outline, (5) compact hyalinized 
fibrous tissue at the site of good tumour response. Histological tumour response 
was an apparent reduction in tumour cell to stroma ratio. Examples of each 
grade of pathological response are shown in figure 2.1.
For the study analysis, pathological responders were defined as those patients 
with a grade 1, 2, 3 or 4 response. Pathological non-responders were defined as 
those patients with a grade 5 response. Those patients with a clinical & 
radiological CR who did not receive surgery but received radiotherapy alone 
were classified as pathological responders. Those patients with cSD or cPD who 
subsequently received alternative chemotherapy without surgery were classified 
as pathological non-responders.
2.2.3 MULTI-PARAMETER FUNCTIONAL MRI PROTOCOL
All MRI scans were performed at the Paul Strickland Scanner Centre, Mount 
Vernon Hospital, Northwood, Middlesex, UK. All patients were examined on a 
1.5T Siemens Symphony scanner (Siemens AG, Munich, Germany) using a 
dedicated breast coil (figure 2.2). Quality assurance (QA) was performed daily 
on the MRI scanner with recalibration of the breast coil on T1W DCE-MRI
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using the T1 phantom after every change in the system and every machine 
service (breast coil code determined). For the reproducibility cohort, each patient 
was imaged twice within 7 days thus ensuring the same breast coil code and 
minimal magnet changes.
Initial T1 and T2 weighted anatomical scans were performed in the sagittal plane 
to select an imaging plane through the centre of the tumour. For the BOLD- 
MRI, eight spoiled gradient-echo images of the central slice position were 
acquired with a range of different echo times (TE 5-75ms, TR 100ms, flip angle 
40°, slice thickness 8mm, sagittal plane) and the rate of signal decay 
(R2*=l/T2*) was calculated. A proton density weighted (PDW) image was 
acquired (TR 350 ms, TE 4.7 ms, flip angle 6°, central slice position, slice 
thickness 8mm). Dynamic T1-weighted images were acquired at a time 
resolution of 12 seconds for 40 measurements (TR 11 ms, TE 4.7 ms, flip angle 
35°, slice thickness 8mm, sagittal plane, total imaging time 8 minutes 5 seconds) 
from 4 slices (3 through the tumour [middle slice corresponding to central slice 
position] and 1 through the contralateral normal breast). Gadopentetate 
dimeglumine (Gd-DTPA) was injected IV using a power injector (dose
0.1 mmol/kg b.w.) at 4 ml/s during the fifth acquisition. Following this, a T2*- 
weighted DCE-MRI sequence was used to acquire data every 2 seconds over 2 
minutes (TE=20ms, TR=30ms, flip angle=40°, single central slice position, slice 
thickness 8mm, sagittal plane, same slice position) with 0.2mmol/kg b.w. Gd- 
DTPA at 4ml/s after 20s (figure 2.3).
2.2.4 MRI IMAGE ANALYSIS
All calculations were performed pixel-by-pixel using custom analysis software 
called Magnetic Resonance Imaging Workbench (MRIW) which was developed 
at the Institute of Cancer Research, Royal Marsden Hospital, London, UK [295]. 
Analysis of the MRI data for each patient (both scans) was performed at the 
same sitting. For each scan, the tumour region of interest (ROI), defined as the 
contrast-enhancing region on early T1-weighted subtraction images (100 
seconds), was drawn by one investigator (ARP) who was unaware of the 
patient’s clinical and pathological details (figure 2.4). The spoiled gradient-echo
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[f l a s h ] sequences were used to calculate the R2 * measurement using an IDL® 
least-squares fitting routine (figure 2.5).
Signal intensity on the T1-weighted images was converted to T1 relaxation rate 
values using the PDW image, in conjunction with a calibration experiment 
involving phantoms with known T1 relaxation rate values. Gd-DTPA 
concentration was calculated for each pixel during the dynamic acquisition from 
the equation:
Ct(t) = (l/T 1(t)-1 /T 1(0))/R,
where Ct(t) is the tissue Gd-DTPA concentration at time t after injection, Ti(0) is 
the baseline tissue Ti, Ti(t) is the Ti at time t and Ri is the longitudinal 
relaxivity of protons in vivo due to Gd-DTPA. The Gd-DTPA concentration­
time curve was fitted to the Tofts and Kermode model [161] using methods 
previously described [296]. Semi-quantitative (mean gradient [MeanGrad], 
maximum signal amplitude [MaxAmp] and washout [Wt]) and quantitative 
(transfer constant [Ktrans], leakage space [ve], rate constant [keP], and maximum 
Gd-DTPA concentration [MaxGd]) kinetic parameters were calculated on the 
central slice through the tumour (figure 2.6). Using the same technique, data 
from all three slices through the tumour were analyzed and the quantitative T l- 
weighted kinetic parameters for the combined three-slice data (Ktrans, ve, keP and 
MaxGd) kinetic parameters were calculated.
The data from the T2* DCE-MRI (single central slice) were used to calculate 
relative blood volume (rBV), relative blood flow (rBF) and mean transit time 
(MTT) by fitting the time varying R2 * data to a gamma-variate function where, 
by the central volume theorem equation (figure 2.7):
BF = BV/MTT.
i L  i L
Using the single centre-slice data, the median and 5 -95 centile values for each 
parameter were derived from the whole tumour ROI for the pre-treatment and 
post-two cycles of FEC chemotherapy MRI scans, and the treatment changes
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calculated. Using the three-slice data, the median value for the TI W quantitative 
kinetic parameters were derived from the combined whole tumour ROIs for the 
pre-treatment and post-two cycles of FEC chemotherapy MRI scans, and the 
treatment changes calculated.
All calculations were performed pixel-by-pixel within the tumour ROI with the 
exclusion of modelling failures. Modelling failures were either non-enhancing or 
enhancing. Non-enhancing modelling failures were defined as those pixels 
where MaxGad equalled zero. Enhancing modelling failures were defined as 
those pixels where Ktrans was less than O.Olmin'1 or greater than 5m m 1, or when 
the MRIW’s fitting alogorithm was unable to find a solution to the model for the 
data observed.
2.2.5 REPRODUCIBILITY COHORT
The study entitled “ Evaluation of MRI during neoadjuvant chemotherapy in 
primary breast cancer” included a reproducibility arm where patients with 
primary breast cancer were imaged, as described above, twice within one week 
prior to commencing any therapy (either neoadjuvant chemotherapy or primary 
surgery). The data from this cohort were used to calculate the repeatability 
statistic for each parameter using the Bland & Altman methods [297]. 17 
patients in total were recruited to this arm of the study.
2.2.6 NORMAL BREAST DATA
Single-slice dynamic T1W images were acquired from a random slice taken 
through the normal contralateral breast during each MRI scan. Using the 
methods described above, quantitative T1W kinetic parameters (Ktrans, ve, kep 
and MaxGd) were calculated for the pre-treatment and post-two cycles of FEC 
chemotherapy MRI scans from a randomly placed ROI. The treatment changes 
between the two scans were calculated.
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2.3 STATISTICS
Statistical analysis was performed using the StatsDirect statistical software 
package (StatsDirect, Cheshire, UK). Pre-treatment MRI parameter values and 
MRI-derived tumour size were correlated using Spearman’s rank correlation 
coefficient, Rho.
Pre-treatment parameter values and treatment changes were correlated with 
clinical and pathological response following 6 cycles of chemotherapy using the 
Mann-Whitney U-test (MW). The statistical significance was the 2-tailed p- 
value for rejecting the hypothesis of zero correlation.
The repeatability range for each parameter was calculated from the 
reproducibility cohort data using the methods of Bland and Altman [297]. The 
95% confidence interval is the key statistical parameter that is be used to 
determine whether a change in a kinetic parameter following treatment is 
statistically significant or not for one or several patients. For each patient in the 
reproducibility cohort, the difference (d) between the two pre-treatment 
measurements of a parameter was calculated. Data was transformed using 
natural logarithmns if the variability of d was found to depend on its mean value 
( a significant two-tailed Kendall’s tau test). The square root of the mean 
squared difference, dsd, (=V[(£d 2)/n] where n is the number of patients) was 
then calculated. The 95% confidence interval for change for a group of n 
patients is then equal to ±(1.96 x dsd)/Vn). For an individual patient, n=l, so the 
95% confidence interval for change is equal to ±(1.96 x dsd). This is known as 
the repeatability statistic, r, and is expressed as a percentage of the group mean 
pre-treatment value for each parameter. It provides a range within which the 
difference between pre and post-treatment values would be expected to lie for 
95% of observations, assuming that no difference exists between the pre­
treatment and the post-treatment values. Thus, following the application of the 
repeatability statistic to an individual patient’s data, if the difference (d) falls 
outside this range then a significant change is deemed to have occurred. The
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repeatability range for each parameter was calculated to determine how much of 
a change would be statistically significant for a single patient (n=l).
Receiver operating characteristic (ROC) curve analysis was used to determine 
which parameters best predicted for pathological non-response. Area under the 
ROC curve (AUC), sensitivity and specificity for each parameter was calculated.
Spearman’s rank correlation coefficient, Rho, was used to compare the 
parameter values derived using single centre-slice data and three-slice data. 
MedCalc Software (MedCalc, Mariakerke, Belgium) was used to compare ROC 
analysis using single centre-slice data and three-slice data.
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2.4 RESULTS
2.4.1 PATIENT CHARACTERISTICS AND TUMOUR RESPONSE
37 patients were recruited into the study. Nine patients were not evaluable. This 
was a result of either failure to undergo both MRI scans (four patients were 
unable to tolerate the first MRI scan due to discomfort, nausea or 
claustrophobia; one was unable to fit in the scanner due to body habitus) or 
failure to have the second MRI at the specified time point (one patient declined 
the second scan due to a previous experience of nausea and vomiting; one was 
unable to undergo the second scan due to exacerbation of unrelated back pain; 
two patients underwent the second MRI scan following 3 cycles of 
chemotherapy).
Thus there were 28 evaluable patients in total. The 28 evaluable patients 
underwent a multi-parameter functional MRI scan prior to and following two 
cycles of neoadjuvant FEC chemotherapy. The median time between scans was 
42 days (range 34 -  49 days) and the median time from first MRI scan to first 
cycle of FEC chemotherapy was 2 days (range 0-10 days).
The median age of the 28 evaluable patients was 46 years old (range 29-70 
years). The median number of cycles of neoadjuvant FEC chemotherapy 
received was 6 (range 2-7). Seventeen patients were pre-menopausal and 11 
were postmenopausal. Details of the clinical stage of disease at diagnosis, 
tumour pathology, treatment administered and response to treatment (clinical 
and pathological) are shown in table 2.2. In two patients (patient numbers 6 and 
16), chemotherapy was changed prior to surgical assessment and these patients 
were therefore classified as pathological non-responders. Of note, patient 
number 16 was found to have metastatic liver disease following the first MRI 
scan but was included in the analysis. Two patients (patient numbers 28 and 29) 
achieved a clinical and radiological (on mammography and ultrasound) CR and 
received radical radiotherapy to the breast and nodal areas alone (axilla and 
SCF) without surgery. These patients were classified as pathological responders.
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One patient (patient number 11) obtained a clinical CR with a radiological PR 
and received radical radiotherapy to the breast and nodal areas alone. Prior to 
radiotherapy, this patient underwent a post-chemotherapy biopsy of the residual 
radiological abnormality which revealed a grade 3 pathological response. This 
patient was therefore classified as a pathological responder.
Thus, of the 28 evaluable patients, there were 19 clinical responders and 9 
clinical non-responders, giving an overall clinical response rate of 68%. There 
were 11 pathological responders and 17 pathological non-responders giving an 
overall pathological response rate of 39%. Twenty-two patients completed all 
six cycles of FEC chemotherapy and proceeded to surgery. Of these 22, only one 
patient achieved a pathological CR, giving a pCR rate of 4.5%.
2.4.2 SINGLE CENTRE-SLICE DATA
The median values for each MRI-derived kinetic parameter was calculated using 
Microsoft Excel. The 5th-95th centile range was calculated for the T1W 
semiquantitative and quantitative parameters and the T2*W quantitative 
parameters. The parameters evaluated were:
1. T 1W semi-quantitative parameters:
(i) Mean gradient (MeanGrad)(AU)
(ii) Maximum signal amplitude (MaxAmp)(%)
(iii) Washout (Wt)(AU)
2. T 1W quantitative parameters:
(i) Transfer constant (Ktrans)(min'!)
(ii) Leakage space (ve)(%)
(iii) Rate constant ( k e rn in '1)
(iv) Maximum Gd-DTPA concentration (MaxGd)(mmol/kg)
3. T2*W quantitative parameters:
(i) Relative blood volume (rBV)
(ii) Relative blood flow (rBF)
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(iii) Mean transit time (MTT)(sec)
4. BOLD-MRI quantitative parameter, R2 * (sec'1).
The parameter values from the pre-treatment and post-two cycles of FEC 
chemotherapy MRI scans were derived and the treatment changes in the median 
and 5th-95th centile range were calculated. The 5th-95th centile range was the 5th 
centile parameter value subtracted from the 95th centile parameter value. The 
MRI-defined tumour size (product of the bi-dimensional mesurements of the 
contrast-enhancing ROI on early T1W subtraction images [lOOseconds] in the 
sagittal plane) was also determined at each scan and the change in size following 
2 cycles FEC chemotherapy was calculated.
2.4.2.1 Pre-treatment parameter data
No correlation was found between the pre-treatment MRI-defined tumour size 
and the pre-treatment median values for any of the functional MRI parameters: 
MeanGrad, Rho=-0.07, p=0.74; MaxAmp, Rho=0, p=T.OO; Wt, Rho=0.24, 
p=0.22; K1™5, Rho=-0.3, p=0.12; ve, Rho=0.02, p=0.94; keP, Rho=-0.22, p=0.27; 
MaxGd, Rho=0.01, p=0.98; rBV, Rho=-0.06, p=0.76; rBF, Rho=0.01, p=0.97; 
MTT, Rho=-0.09, p=0.65; and R2*, Rho=-0.08, p=0.71.
Primary breast tumours that demonstrated an overall clinical response after 
chemotherapy had the following median pre-treatment parameter values: MRI- 
defined tumour size, 13.2cm2; MeanGrad, 40.7AU; MaxAmp, 81%; Wt, - 
0.24AU; Ktrans, 0.61mm1; ve, 54%; keP, 1.08mm1; MaxGd, 0.41mmol/kg; rBV, 
150; rBF 5.3; MTT, 24.1sec; and R2*, 33.1sec_1. These values were not 
significantly different to those for tumours that did not demonstrate a clinical 
response: MRI-defined tumour size, 17.9cm2; MeanGrad, 29.2AU; MaxAmp, 
92%; Wt, -0.20AU; Ktrans, 0.57mm1; ve, 52%; keP, 1.04mm1; MaxGd, 
0.43mmol/kg; rBV, 191; rBF 8.2; MTT, 23.4sec; and R2*, 31.9SCC'1 (MW, 
p>0.05 for all groups). These values are shown in table 2.3.
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The median pre-treatment parameter values from primary breast tumours that 
demonstrated an overall pathological response were: MRI-defined tumour size, 
13.2cm2; MeanGrad, 40.7AU; MaxAmp, 95%; Wt, -0.24AU; Ktrans, 0.66mm1; 
ve, 57%; kep, 1.19mm1; MaxGd, 0.45mmol/kg; rBV, 177; rBF 6.89; MTT, 
24.5sec; and R2 *, 32.7sec"\ These values did not differ significantly to those 
seen in tumours that failed to demonstrate a pathological response: MRI-defined 
tumour size, 13.1 cm2; MeanGrad, 38.2AU; MaxAmp, 87%; Wt, -0.23AU; 
Ktrans, 0.57mm1; ve, 52%; keP, 1.04mm1; MaxGd, 0.39mmol/kg; rBV, 150; rBF 
5.3; MTT, 23.4sec; and R2 *, 33.7SCC'1 (MW, p>0.05 for all groups). These 
results are shown in table 2.4.
Analysis of the 5th-95th centile range data revealed no significant difference in 
pre-treatment values for clinical or pathological responders and non-responders 
(MW, p>0.05 for all groups). These results are shown in table 2.5 and table 2.6.
th  thThus, pre-treatment median parameter values, 5 -95 centile range and tumour 
size failed to predict for final clinical or pathological response to neoadjuvant 
FEC chemotherapy.
2.4.2.2 Parameter changes compared with tumour response
In general, a reduction in the semi-quantitative and quantitative kinetic 
parameters reflecting tumour vessel permeability and perfusion was seen 
following 2 cycles of NAC in primary breast tumours that subsequently 
demonstrated a clinical or pathological response following completion of NAC. 
Figure 2.8 shows an example of the pre-treatment and post 2 cycles of FEC 
chemotherapy MRI images (anatomical and functional parametric maps) from 
patient number 29 who had a responding tumour.
In general, no significant change or an increase in tumour vessel permeability 
and perfusion kinetic parameters was observed in those tumours that 
subsequently failed to demonstrate a clinical or pathological response to NAC. 
Figure 2.9 shows an example of the pre-treatment and post 2 cycles of FEC
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chemotherapy MRI images (anatomical and functional parametric maps) from 
patient number 20 who had a non-responding tumour.
No trend was seen in the BOLD MRI parameter, R2 *, that predicted for 
response.
Statistical analysis of the 28 patient data revealed that change in median 
MeanGrad, MaxAmp, Ktrans, kep, rBV and rBF significantly correlated with 
clinical response to NAC (MW, p<0.05 for all groups). In responding tumours, 
there was a reduction in the median kinetic parameter values as follows: 
MeanGrad, 47.7%; MaxAmp, 11.5%; Ktrans, 29.6%; keP, 31.2%; rBV, 59.3%; 
and rBF, 56.4%. In non-responding tumours there was an increase in the median 
kinetic parameter values as follows: MeanGrad, 4.9%; MaxAmp, 7.1%; Ktrans, 
16.8%; kep, 5.5%; rBV, 73.4%; and rBF, 70.6%. These results are shown in 
table 2.7 and figure 2.10.
Statistical analysis of the 28 patient data demonstrated that change in median 
MeanGrad, MaxAmp, K*™18, keP, MaxGd, rBV and rBF also significantly 
correlated with final pathological response to NAC (MW, p<0.05 for all 
groups). In those tumours that demonstrated a pathological response, there was a 
reduction in the median kinetic parameter values as follows: MeanGrad, 67.0%; 
MaxAmp, 25.2%; Ktrans, 49.5%; keP, 45.4%; MaxGd, 17.0%; rBV, 61.1%; and 
rBF, 63.4%. In the pathologically non-responding tumours there was a minor 
reduction or an increase in the median kinetic parameter values as follows: 
MeanGrad, -2.4%; MaxAmp, 11.9%; K*™8, 3.5%; keP, -4.8%; MaxGd, 7.8; rBV, 
-2.4%; and rBF, -3.5%. These results are shown in table 2.8 and figure 2.11.
Change in the 5-95th centile range for MeanGrad, Max Amp, Ktrans, keP, 
MaxGad, rBV and rBF significantly correlated with both clinical and 
pathological response to treatment (MW, p<0.05 for all groups). In addition, 
change in the 5-95th centile range for MTT was significant for final pathological 
response to NAC (MW, p<0.05). In the clinically responding tumours, there
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was a reduction in the 5th-95th centile range of the kinetic parameters as follows: 
MeanGrad, 58.1%; MaxAmp, 13.1%; Ktrans, 31.4%; keP, 37.0%; MaxGd, 7.3%; 
rBV, 40.5%; and rBF, 36.7%. In clinically non-responding tumours, there was
th  than increase in the 5 -95 centile range of the kinetic parameters as follows: 
MeanGrad, 14.3%; MaxAmp, 14.1%; Ktram, 19.7%; k^, 12.9%; MaxGd, 13.2%; 
rBV, 53.2%; and rBF, 53.9%. These results are shown in table 2.9 and figure 
2.12. In the pathologically responding tumours, there was a reduction in the 5th- 
95th centile range of the kinetic parameters as follows: MeanGrad, 61.2%; 
MaxAmp, 15.2%; Ktrans, 58.9%; keP, 45.3%; MaxGd, 11.1%; rBV, 62.1%; and
th  thrBF, 57.9%. This was associated with an increase in the 5 -95 centile range of 
MTT of 18.5%. In the pathologically non-responding tumours, there was a 
minor reduction or an increase in the 5th-95th centile range of the kinetic 
parameters as follows: MeanGrad, -7.1%; MaxAmp, 11.9%; Ktrans, 18.7%; keP, 
12.4%; MaxGd, 13.2%; rBV, -0.7%; and rBF, 3.6%. This was associated with a 
reduction in the 5th-95th centile range of MTT of 19.3%. These results are 
shown in table 2.10 and figure 2.13.
Assessment of the change in MRI-derived tumour size following 2 cycles of 
NAC demonstrated a reduction in tumour size in all response groups. In 
clinically responding tumours, there was a reduction of 32.8% compared to a 
reduction of 13% in clinically non-responding tumours. This difference was 
statistically significant (MW, p<0.05). In the tumours than demonstrated a final 
pathological response, there was a reduction in MRI-derived tumours size of 
35.5% compared with 14.8% in pathological non-responders. This difference 
was not statistically significant (MW, p=0.11). These results are shown in table 
2.7 & 2.8 and figures 2.10 & 2.11.
Change in the median Wt, ve, MaxGd and MTT, and change in 5th-95th centile 
range for Wt, ve and MTT did not correlate with final clinical response. Change
th  thin the median Wt, ve and MTT, and change in 5 -95 centile range for Wt and 
ve did not correlate with final pathological response (table 2.9 & 2.10 and 
figures 2.13 & 2.13).
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For the BOLD MRI parameter, R2 *, a 12.9% increase in the median R2 * was 
observed in clinical responders compared to an increase of 0.7% in clinical non­
responders. This difference was not statistically significant (MW, p=0.2). For 
pathological responders, median R2 * increased by 16.3% compared with a 
reduction of 1.5% in pathological non-responders. This difference was not 
statistically significant (MW, p=0.1) (table 2.7 & 2.8 and figures 2.10 & 2.11).
2.4.2.3 Receiver operating characteristic (ROC) curve analysis
ROC curve analysis was used to determine which parameters best predicted for 
pathological non-response. This revealed the best parameters to be: Ktrans, 
AUC=0.83 (sensitivity 100%, specificity 73%); kep, AUC=0.82 (sensitivity 88%, 
specificity 73%); rBF, AUC=0.83 (sensitivity 81%, specificity 80%); and 
MaxAmp, AUC=0.87 (sensitivity 100%, specificity 82%). The results of the 
ROC curve analysis according to the MRI sequence are shown in table 2.11 and 
figure 2.14.
2.4.3 THREE-SLICE T1W QUANTITATIVE DATA
The median values for each parameter from the three-slice analysis was 
calculated using Microsoft Excel. The parameters evaluated were:
(i) Transfer constant (K,,,ns)(min'1)
(ii) Leakage space (ve)(%)
(iii) Rate constant (kepXmin1)
(iv) Maximum Gd-DTPA concentration (MaxGd)(mmol/kg)
The parameter values from the pre-treatment and post-two cycles of FEC 
chemotherapy MRI scans were derived and the treatment changes in the median 
were calculated.
2.4.3.1 Pre-treatment parameter data
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No correlation existed between the pre-treatment MRI-defined tumour size and 
the pre-treatment median values for any of the MRI parameters: Ktrans, Rho=- 
0.16, p=0.41; ve, Rho=0.03, p=0.87; kep, Rho=-0.21, p=0.29; MaxGd, Rho=0.02, 
p=0.93.
Primary breast tumours that demonstrated an overall clinical response after 
chemotherapy had the following median pre-treatment parameter values: Ktrans, 
0.56mm1; ve, 51%; kep, 1.05mm1; MaxGd, 0.41 mmol/kg. These values were not 
significantly different to those for tumours that did not demonstrate a clinical 
response: K1™8, 0.58mm1; ve, 49%; keP, 1.03mm1; MaxGd, 0.40mmol/kg (MW, 
p>0.05 for all groups). These values are shown in table 2.12.
The median pre-treatment parameter values in primary breast tumours that 
demonstrated an overall pathological response were: K1™"8, 0.57mm'1; ve, 54%; 
kep, 1.25mm'1; MaxGd, 0.45mmol/kg. These values did not differ significantly to 
those seen in tumours that failed to demonstrate a pathological response: Ktrans, 
0.55mm'1; ve, 49%; keP, 1.03mm'1; MaxGd, 0.37mmol/kg (MW, p>0.05 for all 
groups). These results are shown in table 2.13.
2.4.3.2 Parameter changes compared with tumour response
Analysis of the 28 patient data revealed that change in median Ktrans, keP and 
MaxGd significantly correlated with clinical response to NAC (MW, p<0.05 for 
all groups). In responding tumours, there was a reduction in the median kinetic 
parameter values as follows: K1™"8, 39.8%; keP, 33.3%; and MaxGd, 0.8%. In 
non-responding tumours there was an increase in the median kinetic parameter 
values as follows: Ktrans, 18.1%; keP, 7.4%; and MaxGd, 8.3%. These results are 
shown in table 2.14 and figure 2.15.
Change in median Ktrans, keP and MaxGd significantly correlated with final 
pathological response to NAC (MW, p<0.005 for all groups). In those tumours 
that demonstrated a pathological response, there was a reduction in the median 
kinetic parameter values as follows: Ktrans, 52.3%; keP, 50.3%; and MaxGad, 
13.0%. In the pathologically non-responding tumours there was a minor
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reduction or an increase in the median kinetic parameter values as follows: 
Ktrans, 16.9%; kep, -8.5%; and MaxGd, 6.3%. Change in median ve did not 
correlate with responsiveness when assessed using 3-slice data. These results are 
shown in table 2.15 and figure 2.16.
2.4.4 COMPARISON OF SINGLE CENTRE-SLICE VERSUS THREE- 
SLICE DATA
The relative utility of multi-slice (three-slice) versus single centre-slice T1W 
DCE-MRI for predicting final pathological response to NAC in patients with 
primary breast cancer was assessed.
Median quantitative parameter values (Ktrans, ve, keP and MaxGd) before and 
after 2 cycles of treatment were compared for the single centre-slice and 3-slice 
analysis using Spearman’s rank correlation coefficient. This revealed a good 
correlation between the values for single centre-slice and 3-slice evaluations for 
all parameters (Rho>0.8, p<0.001 for all groups). The correlation for pre­
treatment median Ktrans is shown in figure 2.17. Median percentage change after 
2 cycles of NAC for single centre-slice and 3-slice evaluations for all parameters 
also demonstrated a good correlation (Rho>0.8, p<0.001 for all groups). The 
correlation for percentage change in median Ktrans is shown in figure 2.18.
Using ROC curve analysis, the predictive performance of the different kinetic 
parameters for determining pathological response from the 3-slice data was 
assessed (figure 2.19). This demonstrated change in median Ktrans to be the best 
parameter for predicting response with an AUC=0.93 (sensitivity 94%, 
specificity 80%). The 3-slice Ktrans demonstrated significantly better test 
performance compared to single centre-slice only evaluation: AUC 0.93 
(sensitivity 88%, specificity 82%) versus AUC 0.83 (sensitivity 100%, 
specificity 73%), p=0.02) (table 2.16).
2.4.5 REPRODUCIBILITY DATA
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The clinical utility of centre-slice versus 3-slice evaluations was further assessed 
by the application of the repeatability range for each parameter to predict 
pathological non-response on an individual basis.
2.4.5.1 Reproducibility cohort
Seventeen patients were recruited into the reproducibility arm of the MRI study. 
Two patients were unable to tolerate the first scan; two patients did not undergo 
the second scan (one declined and one underwent a repeat breast biopsy prior to 
the second scan and was therefore excluded); and one patient had metastatic 
axillary lymph nodes with no primary breast lesion and was therefore excluded. 
Thus, twelve patients with primary breast cancer were imaged twice within one 
week (median 1 day, range 1-7 days) prior to commencement of therapy. Of 
these 12 patients, 9 subsequently received NAC and 3 underwent primary 
surgery. The median age of the reproducibility cohort was 53 years old (range 
37-62 years). The patient characteristics are shown in table 2.17. Histograms 
demonstrating the median values obtained for each parameter for each patient on 
the two reproducibility MRI examinations are shown in figure 2.20.
2.4.5.2 Repeatability Statistics
Using the Bland and Altman methods [297], the repeatability statistics were 
calculated for each parameter for single centre-slice and three-slice analysis 
(table 2.18). The repeatability range represents the range outside which a change 
would be required following an intervention, in this study two cycles of NAC, 
for that change to be deemed a ‘true’ or statistically significant change due to the 
intervention. The repeatability range for each parameter was calculated to 
determine how much of a change would be statistically significant for a single 
patient (n=l).
For the single centre-slice analysis, the repeatability range for each parameter, 
expressed as percentage change of the mean, was as follows: MeanGrad, -62.3 
to 165.0%; MaxAmp, +/- 28.0%; Ktrans, -51.3 to 105.3%; ve, +/- 17.5%; keP, - 
47.8 to 91.7%; MaxGd, +/- 18.7%; rBV, +/- 74.9%; rBF, +/- 63.9%; MTT, +/-
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22.1%; and R2*, +/- 17.5%. The repeatability range for MRI-derived tumour 
size expressed as percentage change of the mean was -26.5 to 36.1% (table 
2.18).
For the three-slice analysis, the repeatability range for each parameter, expressed 
as percentage change of the mean, was as follows: K ^"8, -42.4 to 73.6%; ve, +/- 
29.9%; kep, -57.8 to 136.8%; and MaxGd, +/-18.8% (table 2.18).
Application of the repeatability range to the clinical data revealed change in 
Ktrans as evaluated on the three-slice data was the best predictor of pathological 
response correctly predicting pathological non-response in 16 of 17 patients 
(94%) (figure 2.21) and response in 8 of 11 patients (73%) (figure 2.22). Table 
2.18 shows patient pathological response classification according to functional 
MRI parameters and MRI-derived tumour size.
2.4.6 NORMAL BREAST DATA
For the 28 evaluable patients, the median value for each parameter from the 
single-slice analysis of the normal contralateral breast was calculated using 
Microsoft Excel. The parameters evaluated were:
(i) Transfer constant (Ktrans)(m in1)
(ii) Leakage space (ve)(%)
(iii) Rate constant (kep)(m in1)
(iv) Maximum Gd-DTPA concentration (MaxGd)(mmol/kg)
The parameter values from the pre-treatment and post-two cycles of FEC 
chemotherapy MRI scans were derived and the treatment changes in the median 
were calculated.
The pre-treatment median parameter values were lower in the normal breast 
tissue compared with the tumour ROI (figure 2.23) and there was no correlation 
between the values from the normal breast tissue and the tumour ROI (table 
2.19).
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Neither the pre-treatment parameter values nor the change in median parameter 
values in the normal breast following two cycles of NAC predicted for clinical 
or pathological response to NAC for any of the quantitative parameters assessed 
(tables 2.20,2.21,2.22 and 2.23).
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2.5 DISCUSSION
The ability to identify early during treatment those women with primary breast 
cancer who will fail to respond to neoadjuvant chemotherapy would enable the 
use of alternative therapies that may be more effective [36]. In the clinic, 
response to NAC is currently assessed using the combination of clinical 
examination and conventional imaging techniques, such as mammography and 
breast ultrasound. These methods rely on a change in tumour size for assessing 
response which often becomes apparent only after several cycles of 
chemotherapy. Further, these methods can fail to accurately assess the 
pathological extent of residual tumour [230]. As a result, newer functional 
imaging techniques are being evaluated for their ability to classify tumour 
response earlier on in treatment and hence facilitate the tailoring of treatment to 
individual response. These techniques include PET and multi-parameter 
functional MRI. Other approaches currently under evalution have evolved from 
the recent advances in molecular biology and focus on the identification of 
predictive markers of response. These include the use of immunohistochemistry 
to assess, for example, markers of proliferation, and microarray technology to 
identify chemotherapy response genes.
In this study, we evaluated the role of multi-parameter functional MRI during 
NAC for PBC, using the techniques of:
(1) T1W and T2*W dynamic-contrast enhanced MRI (DCE-MRI), employing 
the low molecular weight contrast agent, Gd-DTPA, and
(2) Blood Oxygen Level Dependant MRI (BOLD MRI), which employs 
dexoyhaemoglobin as an intrinsic contrast agent.
DCE-MRI provides a non-invasive imaging method for assessing the tumour 
microvasculature and in particular, informs upon microvessel permeability and 
perfusion. BOLD-MRI has been shown to inform upon tumour oxygenation by
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exploiting the different magnetic properties of oxyhaemoglobin and 
deoxyhaemoglobin.
The baseline pre-treatment kinetic parameter values did not correlate with the 
pre-treatment MRI-derived tumour size and were therefore not dependent on the 
presenting tumour size. Analysis according to clinical and pathological response 
also demonstrated no relationship between the baseline parameter values and 
tumour response to NAC. Thus, the pre-treatment MRI-derived functional 
vascular characteristics of primary breast cancer are not influenced by tumour 
size and do not inform upon clinico-pathological response to anthracycline- 
based neoadjuvant chemotherapy.
The changes seen in the kinetic parameter values from baseline following 2 
cycles of neoadjuvant FEC chemotherapy did, however, inform upon final 
clinico-pathological response to treatment. Group analysis of the 28 evaluable 
patients demonstrated that the changes seen in the T1W and T2*W DCE-MRI 
parameters reflecting tumour microvessel permeability and perfusion (Mean 
Grad, MaxAmp, Ktrans, keP, rBV and rBF) were significantly different between 
both the clinically and pathologically responding tumours and the non­
responding tumours. In the responding groups, an overall reduction in these 
kinetic parameter values was seen, both in terms of the median values and the 5th 
to 95th centile range, compared with only a minor reduction or an increase the 
non-responding groups.
In terms of tumour size, the early change in MRI-derived tumour size was found 
to correlate with final clinical response but not with final pathological response. 
This is of particular note as the conventional imaging methods currently 
employed for assessing tumour response (mammography and ultrasonography) 
rely on changes in tumour size. Von Minckwitz et al. recently found that clinical 
response after 2 cycles of NAC could predict for pCR [45]. Unfortunately, we 
were unable to assess this finding in our patient cohort due to incomplete clinical 
data following 2 cycles of chemotherapy, however, we did find an appreciable 
discordance between final clinical and final pathological response, with almost a 
third of patients (8/28) failing to obtain a pathological response despite 
achieving a clinical response at the end of treatment. This would suggest that
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clinical response alone does not reliably inform upon final pathological
response.
Complete pathological response to NAC has been shown to predict for improved 
overall survival [24, 30, 83], however, in most trials with anthracycline-based 
chemotherapy only 5-10% of patients achieve a pCR, thereby reducing its 
clinical usefulness as a surrogate marker of outcome. Indeed, in our study, only 
one of the 22 patients who completed the intended 6 cycles of FEC NAC 
achieved a pCR, giving a pCR rate of 4.5%. Therefore, an assessment of 
pathological response, where patients are classified as responders (complete and 
partial pathological response) and non-responders might be a more useful 
surrogate for outcome. The prognostic significance of a partial pathological 
response, however, is largely unknown. In one study of 176 patients with large 
or locally advanced breast cancers receiving NAC, Ogston et al. evaluated lesser 
degrees of pathological response using a new five-point pathological grading 
system where the fundamental feature was a reduction in tumour cellularity 
(Miller/Payne grading system) [294]. They found a significant correlation 
between the new grading system and both DFS and OS at 5 years. Further, in a 
multivariate analysis of prognostic factors, the Miller/Payne grading system was 
shown to be an independent predictor of overall survival. In addition to changes 
in tumour:stromal cellular ratio, other histological features reflecting 
pathological response to NAC have been described [292, 293]. We therefore 
derived a grading system for pathological response, in accordance with the 
Miller/Payne grading system and the other previously described criteria, and 
defined our patients as either pathological responders or non-responders. We, 
thus, used final pathological response as our endpoint measure of the clinical 
effectiveness of NAC and evaluated the MRI data in relation to this measure.
ROC curve analysis was used to compare the predictive performance of the 
different kinetic parameters from the single centre-slice analysis to determine 
pathological response. ROC curves provide a method to compare diagnostic 
examination accuracy and are designed to illustrate the overall information 
yielded by an imaging examination, regardless of the criteria used to interpret 
the images. The curve is a plot of sensitivity (probability of a positive test if the
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condition is present, also known as true-positive fraction) versus [1- 
specificity] (probability of a positive test if the condition is absent, also known as 
false-positive fraction). ROC curve analysis provides a cut-off value for the 
diagnostic test where sensitivity and specificity are at an optimum and yields a 
measure of the area under the ROC curve (AUC) where, in general, the larger 
the AUC, the better the diagnostic examination. Thus, ROC curve analysis 
revealed the best parameters to be change in MaxAmp, Ktrans and rBF (table 
2.11). Although change in MaxAmp appeared the best parameter with an AUC 
0.87, sensitivity 100% and specificity 82%, as a semi-quantitative parameter it is 
less reliable compared with the quantitative parameters. This is because the 
semi-quantitative parameters can be affected by a number of factors including 
machine settings and manufacturer, field strength and contrast dose. Further, the 
signal intensity and the dose of contrast agent were not linearly related in the 
sequence used in this study. The quantitative parameters Ktrans and rBF were 
further evaluated by applying the repeatability range derived from the 
repeatability cohort data, to determine which was the better predictor of 
pathological response on a patient-by-patient basis. The repeatability, derived 
using the Bland and Altman method, determines the range in parameter value 
outside which a change deemed to be significant. Ktrans was found to be the 
better predictor, correctly classifying 100% of pathological non-responders and 
36% of pathological responders. This compared with rBF, which correctly 
classified 88% of pathological non-responders and 20% of pathological 
responders.
Data from the T1W DCE-MRI single-slice (centre-slice) and the multi-slice 
(three-slice) analysis were then compared in order to assess their relative utility 
in predicting final pathological response to NAC. Only the quantitative kinetic 
parameters were assessed. A good correlation was observed between the pre­
treatment and post 2 cycles NAC median values, as well as for the median 
percentage change after 2 cycles of NAC, for the single centre-slice and three- 
slice evaluations for all parameters (r>0.8, p<0.001 for all groups). As with the 
single-slice analysis, the three-slice group analysis demonstrated failure of the 
pre-treatment values to predict for final pathological response to NAC. Change 
in median Ktrans, keP and MaxGd, however, significantly correlated with final
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pathological response. ROC curve analysis revealed change in median Ktrans to 
be the best predictor of response (AUC 0.93, sensitivity 94% and specificity 
82%), with a significantly improved test performance compared to single-slice 
evaluation (p=0.02). Further, application of the 3-slice reproducibility range, 
confirmed change in median Ktrans as the best predictor of pathological response, 
correctly classifying 94% of pathological non-responders (figure 2.21) and 73% 
of pathological responders (figure 2.22 and table 2.18).
The changes observed in the BOLD-MRI parameter, R2 *, did not correlate with 
either the final clinical or pathological response to treatment. This would suggest 
that changes in the oxygenation of breast tumours do not predict for response. 
The effect of scarring and fibrosis on the R2 * within breast tumours remains 
unclear, however, and whether R2 * solely reflects oxygenation or whether it is a 
more complex parameter is remains under investigation. This is discussed 
further in section 4.5.
In summary, the early changes observed in the kinetic MRI parameters reflecting 
tumour microvessel permeability and perfusion can predict for final pathological 
response to neoadjuvant anthracycline-based chemotherapy, with change in 
median Ktrans on multi-slice DCE-MRI examinations being the best predictor of 
response. In light of these findings, multi-slice T1W DCE-MRI could assist in 
tailoring treatment to each individual patient, using change in median Ktrans after 
two cycles of NAC to guide therapy. An example of how multi-slice TI W DCE- 
MRI could be used in the management of patients receiving NAC is illustrated 
in figure 2.24. If the initial NAC regimen is six cycles of FEC then women 
receiving this treatment would undergo a T1W multi-slice DCE-MRI of the 
breasts prior to commencing treatment and then again following 2 cycles of 
chemotherapy. In those women where there was a significant reduction in 
median Ktrans (outside the repeatability range), pathological response could be 
predicted with a positive predictive value (PPV) of 89% and continued treatment 
with FEC would be recommended. In those women where there was a non­
significant reduction (within the reproducibility range), or a significant increase 
in median Ktrans, then pathological non-response could be predicted with a PPV 
of 84%, and treatment would be altered to a non-cross resistant agent, such as
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docetaxel. The aim of such an intervention would be to improve the 
pathological response rate and the individual patient’s long-term outcome in 
non-responding patients, while avoiding the added toxicity and cost of taxane 
chemotherapy in the anthracycline-responding patients.
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Table 2.1. MRI study treatment plan
Diagnosis (core biopsy)
______________________I _____________________
Baseline clinical examination, mammography, 
ultrasound scan breast
I
M RI# 1
I
MRI # 2
2 cycles of FEC chemotherapy
Adjuvant radiotherapy
Adjuvant tamoxifen if 
ER or PgR positive
Reassessment -  
clinical examination, mammograpy
4 further cycles of neoadjuvant 
chemotherapy
Surgery (mastectomy or WLE* & axillary 
surgery)
*WLE=wide local excision
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Table 2.2. MRI study population
Patient N o . A g e M enopausal
Status
T N M  Stage Tum our grade  
& type
N o . FEC  c y c le s  C lin ica l R esp onse  
toFEC
P atholog ica l R esp onse  
(grade)
2 43 Pre T2N1M0 G3IDC 6 PR R (3)
3 56 Post T2N1M0 G2IDC 6 CR R (3)
4 34 Pre T3N0M0 G3IDC 6 PR R (4)
5 34 Pre T3N2M0 G 3IDC 6 SD NR (5)
6 46 Post T4dNlM 0 NOS 5 (changed to docetaxel) SD NR*
7 38 Pre T2N0M0 G 2IDC 6 PR R (4)
10 33 Pre T2N1M0 G 2ID C 6 PR NR (5)
11 45 Pre T4dN3cM0 IDC 6 CR R (3 on bx)
12 59 Post T2N0M0 G 2ID C 6 PR N R  (5)
14 47 Pre T2N0M0 G2IDC 6 CR R (3)
15 51 Post T3N0M0 G3IDC 6 PR NR (5)
16 41 Pre T 4dN lM l NOS 7 ( changed to
paclitaxel/trastuzumab)
PD NR*
18 43 Pre T4aN0M0 IDC 4 (proceeded to surgery) PD NR (5)
20 39 Pre T2N1M0 IDC 6 SD NR (5)
21 39 Pre T2N0M0 G2IDC 6 PR NR (5)
22 51 Post T2N3cM0 Mucinous 6 SD NR (5)
24 29 Pre T2N1M0 G2IDC 2 (proceeded to surgery) PD NR (5)
25 53 Pre T3N0M0 G2 lobular 6 PR NR (5)
27 46 Pre T2N0M0 G2IDC 6 PR NR  (5)
28 50 Post T2N0M0 G3IDC 6 CR R*
29 52 Post T3N0M0 G3IDC 6 CR R*
31 53 Post T2N0M0 G2IDC 5 (due to side-effects) PR R (4)
32 40 Pre T3N1M0 G2IDC 6 PR R (2)
34 70 Post T4bN0M0 G2 lobular 4 (proceeded to surgery) PD NR (5)
36 60 Post T4dN0M0 G3IDC 6 PR NR (5)
39 56 Post T4dNlM 0 G1 lobular 6 SD NR  (5)
40 43 Pre T2N0M0 G 2N O S 6 PR NR (5)
41 47 Pre T3N0M0 G3IDC 6 CR R (3)
ID C - invasive ductal carcinoma; NOS = breast cancer not otherwise specified; *did not receive surgery
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Table 2.3. Pre-treatment median parameter values according to final clinical response
n
Size
(cm2)
T1W  semiquantitadve T1W  quantitative T2*W  quantitative
BOLD
quantitative
M ean Grad
(AU)
MaxAmp
(%)
W t
(AU)
j£tnuu
(min'1)
Ve
(%)
kep
(min*1)
MaxGad
(mmol/kg)
rBV rBF
M TT
(sec)
r 2*
(sec'1)
Clinical Responders
19 13.2 40.7 81 -0.24 0.61 54 1.08 0.41 150 5.30 24.1 33.1
Clinical
Non-Responders
9 17.9 29.2 92 -0.20 0.57 52 1.04 0.43 191 8.20 23.4 31.9
M ann-W hitney U-test p=0.09 p=0.31 p=0.21 p=0.66 p=0.44 p=0.74 p=0.31 p=0.80 p=0.81 p=0.57 p=0.13 p=0.99
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Table 2.4. Pre-treatment median parameter values according to final pathological response
n
Size
(cm2)
T1W  semiquantitative T1W  quantitative T2*W  quantitative
BOLD
quantitative
M ean Grad  
(AU)
M axAmp
(%)
W t
(AU)
j t^ruu
(min'1)
v«
(%) (min'1)
M axGad
(mmol/kg)
rBV rBF
M TT
(sec)
r 2*
(sec'1)
Pathological
Responders
11 13.2 40.7 95 -0.24 0.66 57 1.19 0.45 111 6.89 24.5 32.7
Pathological
Non-Responders
17 17.1 38.2 87 -0.23 0.57 52 1.04 0.39 150 5.30 23.4 33.7
M ann-W hitney
U-test
p=0.68 p=0.31 p=0.89 p>0.99 p=0.16 p=0.46 p=0.16 p=0.10 p=0.48 P=0.36 p=0.24 P=0.79
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Table 2.5. Pre-treatment parameter 5th-95th centile range according to final clinical response
T1W  semiquantitative T1W  quantitative T2*W  quantitative
n
M ean Grad M axAmp W t k*™“ ve l^ ep M axGad rBV rBF M TT
Clinical Responders
19 156 102 1.25 1.11 45 1.95 0.33 383 11.23 11.64
Clinical
Non-Responders
9 126 110 1.19 1.48 40 3.05 0.36 282 11.18 7.75
M ann-W hitney
U-test
p=0.92 p=0.99 p=0.48 p=0.84 p=0.93 p=0.80 p=0.60 p=0.37 p=0.99 p=0.22
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Table 2.6. Pre-treatment parameter 5th-95th centile range according to final pathological response
n
T1W  semiquantitative T1W  quantitative T2*W  quantitative
M ean Grad M axAmp W t k‘™“ Ve k*p MaxGad rBV rBF M TT
Pathological
Responders
11 161 110 1.21 1.72 47 3.63 0.36 446 14.81 11.65
Pathological
Non-Responders
17 114 95 1.34 1.08 40 1.95 0.31 326 9.87 7.75
M ann-W hitney U- 
test
p=0.33 p=0.60 p=0.52 p=0.14 p=0.21 p=0.29 p=0.06 p=0.12 p=0.28 p=0.54
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Table 2.7. Median percentage change in median kinetic parameter values according to clinical response
MRI
sequence
Parameter Clinical 
Responders 
(% change)
Clinical 
Non­
responders 
(% change)
p-value 
(MW test)
T1W
semi-
quantitative
MeanGrad -47.7 4.9 <0.05
MaxAmp -11.5 7.1 <0.05
Wt 0.9 16.9 0.81
T1W
quantitative
j^ trans -29.6 16.8 <0.01
Ve 0 5.2 0.31
kep -31.2 5.5 <0.005
MaxGd -3.0 7.8 0.14
T2*W
quantitative
rBV -59.3 73.4 <0.001
rBF -56.4 70.6 =0.001
MTT -4.8 1.15 0.29
BOLD r 2* 12.9 0.7 0.72
Tumour size -32.8 -13.0 <0.05
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Table 2.8. Median percentage change in median kinetic parameter values 
according to pathological response
MR1
sequence
Parameter Pathological 
Responders 
(% change)
Pathological 
Non-responders 
(% change)
p-value 
(MW test)
T1W semi- 
quantitative
MeanGrad -67.0 -2.4 <0.05
MaxAmp -25.2 5.4 <0.001
Wt 20.2 5.3 0.64
T1W
quantitative
l^ -trans -49.5 3.5 <0.005
Ve -2.0 3.7 0.23
-45.4 -4.8 <0.005
MaxGd -17.0 7.8 <0.05
T2*W
quantitative
rBV -61.1 -2.4 <0.01
rBF -63.4 -3.5 =0.005
MTT -4.2 0.5 0.87
BOLD R2* 16.3 -1.5 0.10
Tumour size -35.5 -14.8 0.11
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Table 2.9. Median percentage change in 5th-95th centile range for kinetic
parameter values according to clinical response
MRI
sequence
Parameter
5th-95th
centile
range
Clinical 
Responders 
(% change)
Clinical 
Non­
responders 
(% change)
p-value 
(MW test)
T1W
semi-
quantitative
MeanGrad -58.1 14.3 <0.01
MaxAmp -13.1 14.1 <0.001
Wt 7.7 9.2 >0.99
T1W
quantitative
l^ trans -31.4 19.7 <0.05
Ve -4.2 13.2 0.17
k«p -37.0 12.9 <0.05
MaxGd -7.3 13.2 <0.05
T2*W
quantitative
rBV -40.5 53.2 <0.0005
rBF -36.7 53.9 <0.005
MTT 4.8 -16.6 0.54
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Table 2.10. Median percentage change in 5th-95th centile range for kinetic
parameter values according to pathological response
MRI
sequence
Parameter 
5tb-95th 
centile range
Pathological 
Responders 
(% change)
Pathological 
Non-responders 
(% change)
p-value 
(MW test)
T1W semi- 
quantitative
MeanGrad -61.2 -7.1 <0.05
MaxAmp i to 11.9 <0.05
Wt 16.9 4.6 0.34
T1W
quantitative
j^ t r a n s -58.9 18.7 <0.005
Ve -2.1 9.1 0.67
k e p -45.3 12.4 <0.01
MaxGd -11.1 13.2 <0.001
T2*W
quantitative
rBV -62.0 ■ o <0.05
rBF -57.9 3.6 <0.01
MTT 18.5 -19.3 <0.05
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Table 2.11. ROC curve analysis on change in median parameter values for 
predicting pathological non-response (single-slice analysis)
Test Parameter
Optimal 
cut-off 
(% change)
AUC
Sensitivity
( % )
Specificity
( % )
M orphology Size -30.9 0.68 71 72
T1W  semi- 
quantitative
M eanG rad -47.6 0.76 88 73
M axAm p -12.5 0.87 100 82
W t 83.1 0.56 94 27
T1W
quantitative
l t^rans -45.1 0.83 100 73
ve -1.9 0.64 82 55
i^ ep -24.7 0.82 88 73
M axG ad -6.6 0.73 94 63
T2*W
quantitative
rBV -34.5 0.81 69 90
rB F -55.6 0.83 81 80
M TT -24.4 0.48 13 100
BOLD r 2* 11.6 0.70 75 70
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Table 2.12. Three-slice analysis pre-treatment median parameter values
according to final clinical response
n
T1W  quan tita tive
l t^rans
(m in 1)
ve
(% )
hep
(m in-1)
M axG ad
(mmol/kg)
Clinical Responders
19 0.56 51 1.05 0.41
Clinical
N on-Responders
9 0.58 49 1.03 0.40
p-value
(M ann-W hitney U-test)
p=0.74 p=0.88 p=0.40 p=0.92
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Table 2.13. Three-slice analysis pre-treatment median parameter values
according to final pathological response
n
T1W  quantitative
j^trans
(m in '1)
Ve
(% )
hep
(min*1)
M axGad
(mmol/kg)
Pathological
Responders
11 0.57 54 1.25 0.45
Pathological
N on-Responders
17 0.55 49 1.03 0.37
p-value
(M ann-W hitney U-test)
p=0.19 p=0.61 p=0.18 p=0.13
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Table 2.14. Three-slice analysis of median percentage change in median
T1W quantitative kinetic parameter values according to clinical response
M R I sequence P aram eter
Clinical Responders 
(%  change)
Clinical 
N on-responders 
(%  change)
p-value 
(M W  test)
T1W
quantitative
j t^rans -39.8 18.1 =0.002
Ve 2.0 9.6 0.16
K? -33.3 7.4 =0.0005
M axGd -0.81 8.3 <0.05
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Table 2.15. Three-slice analysis of median percentage change in median
T1W quantitative kinetic parameter values according to pathological
response
M R I sequence P aram eter
Pathological 
Responders 
(%  change)
Pathological 
N on-responders 
(%  change)
p-value 
(M W  test)
T1W
quantitative
l^trans -52.9 16.9 <0.0001
Ve 2.3 7.0 0.16
-50.3 -8.5 <0.005
M axGd -13.0 6.3 <0.005
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ITable 2.16. ROC curve analysis on change in median T1W quantitative 
parameter values to predict pathological response comparing single-slice 
and three-slice analysis
Test P aram eter
O ptim al 
cut-off 
(%  change)
AUC
Sensitivity
(% )
Specificity
(% )
M orphology Size -30.9 0.68 71 72
T1W  
quantitative: 
SINGLE - 
SLICE
l t^rans -45.1 0.83 100 73
Ve -1.9 0.64 82 55
-24.7 0.82 88 73
M axGd -6.6 0.73 94 63
T1W
quantitative:
TH REE-
SLICE
j t^rans -32.5 0.93 94 82
Ve -4.3 0.66 94 45
kep -19.7 0.85 82 91
M axGd -1.9 0.81 94 64
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Table 2.17. MRI reproducibility cohort characteristics
Patient
No.
Age Menopausal
Status
TNM Stage Tumour grade 
& type
Treatment
received
Rp 1 52 Post T3N0M0 G3IDC NAC
Rp 2 58 Post T2N0M0 G2IDC NAC
Rp 4 38 Pre T2N0M0 G1 IDC NAC
Rp 6 58 Post T1N0M0 G1 IDC BCS
Rp 7 47 Pre T3N0M0 G3IDC NAC
Rp9 56 Post T2N0M0 Lobular NAC
Rp 10 56 Post T1N0M0 G1 IDC BCS
Rp 11 41 Pre T1N0M0 G2IDC BCS
Rp 12 54 Post T2N0M0 G2IDC NAC
Rp 15 37 Pre T4dN0M0 G2IDC NAC
Rp 16 48 Pre T3N0M0 G3IDC NAC
Rp 17 62 Post T2N1M0 G2IDC NAC
NAC = neoadjuvant chemotherapy 
BCS = primary breast conserving surgery
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Table 2.18. Patient pathological response as classified by functional MRI 
parameters (single-slice and three-slice) and repeatability range
M R I
Sequence
P aram eter Non-resDonders
correctly
classified
(patient numbers)
Resoonders
correctly
classified
(patient numbers)
R epeatability 
range 
(%  change in 
individual patient 
m edian required  
for significance a t 
95%  confidence)
T1W
sem iquantitative
M eanG rad 100% (17/17) 55% (6/11) -62.3 to +165.0
M axAm p 100% (17/17) 45% (5/11) -28.0 to +28.0
T1W
quantitative
(single-slice)
l t^rans 100% (17/17) 36% (4/11) -51.3 t o +105.3
Ve 100% (17/17) 27% (3/11) -17.5 t o +17.5
Kn 94% (16/17) 45% (5/11) -47.8 to +91.7
M axGd 94% (16/17) 45% (5/11) -18.7 t o +18.7
T2*W
quantitative
rBV 88% (14/16) 20% (2/10) -74.9 to +74.9
rBF 88% (14/16) 20% (2/10) -63.9 to +63.9
M TT 88% (14/16) 0% (0/10) -22.1 t o +22.1
BOLD R2* 81% (13/16) 40% (4/10) -17.5 t o +17.5
T1W
quantitative
(3-slice)
j t^rans 94% (16/17) 73% (8/11) -42.4 to +73.6
Ve 100% (17/17) 9% (1/11) -29.9 to +29.9
Ko 88% (15/17) 36% (4/11) -57.8 to + 136.8
M axGd 100% (17/17) 36% (4/11) -18.8 t o +18.8
T um our size 59% (10/17) 73% (8/11) -26.5 to 36.1
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Table 2.19. Correlation between pre-treatment T1W quantitative kinetic 
parameter values from the tumour ROI and the normal contralateral 
breast tissue
M R I sequence M R I param eter
T um our R O I vs. norm al contrala teral breast 
tissue
S pearm an’s R ank  C orrelation Coefficient, Rho 
(p-value)
T1W
Q uantitative
(single-slice)
l^trans 0.08 (0.70)
Ve -0.01 (0.96)
kep -0.002 (0.94)
M axG d -0.19(0.32)
140
Table 2.20. Pre-treatment median kinetic parameter values according to 
clinical response in the normal contralateral breast tissue
M RI sequence
P aram eter
(m edian)
Clinical
Responders
Clinical
Non­
responders
p-value 
(MW  test)
T1W
quantitative
j t^rans 0.06 0.05 0.56
Ve 0.18 0.18 0.38
k«p 0.36 0.30 0.88
M axGd 0.12 0.11 0.77
Table 2.21. Pre-treatment median kinetic parameter values according to 
pathological response in the normal contralateral breast tissue
M RI sequence
P aram eter
(m edian)
Pathological
Responders
Pathological
Non­
responders
p-value 
(M W  test)
K4™"* (m in '1) 0.06 0.05 0.49
T1W ve (% ) 0.22 0.18 0.15
quantitative keP (m in '1) 0.29 0.35 0.85
M axGd (mmol/kg) 0.12 0.11 0.96
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Table 2.22. Median percentage change in median kinetic parameter values 
according to clinical response in the normal contralateral breast tissue
MRI sequence
Parameter
(median)
Clinical 
Responders 
(% change)
Clinical 
Non­
responders 
(% change)
p-value 
(MW test)
T1W
quantitative
l^ trans -16.6 -0.4 0.85
Ve -4.9 -16.0 0.53
^ep -1.9 -11.2 0.77
MaxGd -10.9 -17.1 0.47
Table 2.23. Median percentage change in median kinetic parameter values 
according to pathological response in the normal contralateral breast tissue
MRI sequence
Parameter
(median)
Pathological 
Responders 
(% change)
Pathological 
Non­
responders 
(% change)
p-value 
(MW test)
T1W
quantitative
j^ trans -24.0 1.4 0.38
Ve -22.9 -0.11 0.15
hep -1.88 -11.15 0.96
MaxGd -21.2 0 0.19
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Figure 2.1.1. Example of pathological response grade 1
(i) pre-treatment core biopsy histology (invasive ductal carcinoma, not graded)
(ii) post-chemotherapy histology (pathological complete response)
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Figure 2.1.2. Example of pathological response grade 2
(i) pre-treatment core biopsy histology (grade 2 invasive ductal carcinoma)
(ii) post-chemotherapy histology (residual DCIS, no tumour cells)
200|im ► y  *-• y  •• ? - ..
(ii)
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Figure 2.1.3. Example of pathological response grade 3
(i) pre-treatment core biopsy histology (grade 3 invasive ductal carcinoma)
(ii) post-chemotherapy histology (microscopic residual cancer cells)
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Figure 2.1.4. Example of pathological response grade 4
(i) pre-treatment core biopsy histology (grade 3 invasive ductal carcinoma)
(ii) post-chemotherapy histology (macroscopic residual cancer with 
chemotherapy-induced changes &/or histological tumour response)
(i)
(ii)
h
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Figure 2.1.5. Example of pathological response grade 5
(i) pre-treatment core biopsy histology (grade 3 invasive ductal carcinoma)
(ii) post-chemotherapy histology (macroscopic invasive cancer with no response 
features)
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Figure 2.2. 1.5T Siemens symphony scanner
(i) with patient in position for MRI scan o f  breasts
(ii) breast coil with phantom in place for calibration
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Figure 2.3. MRI study patient example of
(a) T1W image pre-contrast (b) T1W image post contrast (subtraction image) 
(c) T2*W image pre-contrast (d) T2*W image post contrast (subtraction image) 
(e) Proton density image (f) R2* decay image
Figure 2.4. Example of tumour ROI
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Figure 2.5. R2* signal intensity time decay curve
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Figure 2.6. Gd-DTPA concentration-time curve data fitted to Tofts and 
Kermode model -  data from patient showing change in Gd-DTPA uptake 
within tumour ROI over time and overlying model fit. T1W images from the 
central slice are shown at four time points and the associated Ktrans parametric 
map.
o 0.3
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Figure 2.7. Fitting of T2* time series data to a gamma variate function
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G am m a Variate
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Figure 2.8. Pre-treatment and post-2 cycles of neoadjuvant FEC 
chemotherapy DCE-MRI images in a responding patient (patient number 29)
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Figure 2.9. Pre-treatment and post-2 cycles of neoadjuvant FEC 
chemotherapy DCE-MRI images in a non-responding patient (patient 
number 20)
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Figure 2.10. Median percentage change in median kinetic parameter values
according to clinical response
Clinical responders
Clinical non-responders
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Figure 2.11. Median percentage change in median kinetic parameter values
according to pathological response
Q,
2 0 - *3o
§
<L)
m ■
r r
1
>
<a
u. HH
• ■ ‘■ ■ ' a —
- 2 0 -
- 4 0 -
- 6 0 -
Pathological responders 
Pathological non-responders
157
Tu
m
ou
r 
siz
e
%
 c
ha
ng
e 
in 
5th
 -
95
th 
ce
nt
ile
 
ra
ng
e
Figure 2.12. Median percentage change in 5th -9 5 th centile range for
kinetic parameters according to clinical response
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Figure 2.13. Median percentage change in 5th -9 5 th centile range for kinetic
parameters according to final pathological response
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Figure 2.14. ROC curve analysis of MRI-derived tumour size change and 
percentage change in median for predicting pathological non-response
(single-slice analysis)
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Figure 2.15. Three-slice analysis of median percentage change in median T1W
quantitative kinetic parameter values according to pathological response
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Figure 2.16. Three-slice analysis of median percentage change in median T1W
quantitative kinetic parameter values according to pathological response
Pathological responders
Pathological non-responders
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Figure 2.17. Correlation of pre-treatment median Ktrans 3-slices (y-axis) 
versus single centre-slice (x-axis)
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Figure 2.18. Correlation of percentage change in median Kfrans 3-slices (y 
axis) versus centre-slice (x-axis)
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Figure 2.19 ROC curve analysis (3-slice data) comparing diagnostic
performance of T1W quantitative kinetic parameter values and lesion size
changes to predict pathological response
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Figure 2.20. Median param eter values obtained for each patient on the two 
reproducibility MRI examinations (Spearman’s rank correlation 
coefficient, Rho, and p-value shown in table at end)
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(iii) single-slice Ktrans
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(v) single-slice kep
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(xiii) three-slice MaxGd
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Kinetic Parameter
Spearman’s Rank 
Correlation 
Coefficient, Rho
p-value
MeanGrad 0.27 0.38
MaxAmp 0.97 <0.0001
Ktrans (single-slice) 0.36 0.25
Ve(single-slice) 0.90 <0.0001
kep (single-slice) 0.62 =0.03
MaxGd 0.80 =0.002
rBV 0.23 0.46
rBF 0.26 0.40
R2* 0.79 =0.003
K*” 8 (three-slice) 0.46 0.13
ve (three-slice) 0.93 <0.0001
kep (three-slice) 0.50 0.09
MaxGd (three-slice) 0.92 <0.0001
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Figure 2.21. Three-slice Ktrans repeatability range applied to pathological non- responders (arrow indicates
single incorrectly classified patient)
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Figure 2.22. Three-slice Ktrans repeatability range applied to pathological responders (arrows indicate
correctly classified patients)
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Figure 2.23 Box and Whisker plots of pre-treatment median values for
(i) Ktrans (ii) ve (iii) kep and (iv) MaxGd in the tumour ROI and the 
normal contralateral breast tissue.
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Figure 2.24. Multi-slice T1W DCE-MRI treatment intervention pathway
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CHAPTER 3: IMMUNOHISTOCHEMICAL 
ASSESSMENT OF THE EFFECTS OF 
NEOADJUVANT CHEMOTHERAPY ON 
TUMOUR ANGIOGENESIS IN PRIMARY 
BREAST CANCER
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3.1 INTRODUCTION
Angiogenesis is known to be a prerequiste for both tumour growth and 
metastases [93]. Angiogenesis is regulated by multiple stimulatory (pro- 
angiogenic) and inhibitory angiogenic factors or chemokines. In normal 
physiological angiogenesis there is a balance between these factors, however, in 
tumours it is postulated that an “angiogenic switch” leads to an imbalance of 
chemokines favouring angiogenesis. In breast tumours, the most potent pro- 
angiogenic factor is VEGF and tumour expression of VEGF has been shown to 
be of prognostic value [97,100,101,103].
Microvessel density (MVD) is currently the best recognised method for 
assessing the intensity of tumour angiogenesis and the majority of studies with 
MVD have shown it to be an independent prognostic factor for both relapse-free 
and overall survival in patients with breast cancer [117, 120, 298]. A smaller 
number of studies have failed to demonstrate this association and possible 
explanations for this include type of endothelial antibody employed, the 
counting technique used and the region of tumour assessed [122]. A further 
explanation, however, may be that MVD provides only a static measure of the 
tumour vascular status rather than a measure of functional vascularity. Eberhard 
et al. addressed this issue of the “functional” status of tumour vessels and 
demonstrated that pericyte recruitment, as assessed by alpha-smooth muscle 
actin (a-SMA, indicates a difference in the functional status of the tumour 
vasculature which may reflect varying degrees of maturation of the tumour 
vascular bed [133].
This chapter describes a study evaluating the effect of neoadjuvant 
anthracycline-based chemotherapy on tumour angiogenesis through the 
assessment of tumour MVD, microvessel pericyte recruitment (pericyte 
coverage index, PCI) and the expression of VEGF in primary breast tumours.
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The aims o f the study were:
• To determine whether the angiogenesis-related parameters of tumour MVD, 
PCI and VEGF expression in diagnostic breast cancer core-biopsy specimens 
predict for clinical or pathological response to neoadjuvant 5-fluorouracil, 
epirubicin and cyclophosphamide (FEC) chemotherapy.
• To determine the changes in tumour MVD, PCI and VEGF expression 
following neoadjuvant FEC chemotherapy as assessed on surgical excision 
specimens and whether any changes relate to final clinical or pathological 
response.
• To assess the interrelationships between tumour MVD, PCI and VEGF 
expression in primary breast cancer before and after neoadjuvant FEC 
chemotherapy.
3.2 PATIENTS
Eligible patients for this study were those who had presented with primary breast 
cancer and had received neoadjuvant FEC chemotherapy prior to definitive 
surgery. Samples of the formalin-fixed paraffin-embedded pre-treatment 
diagnostic core biopsy and the post-chemotherapy resected tumour specimen 
were required for analysis. The study included patients recruited to the 
“Evaluation of MRI during neoadjuvant chemotherapy in primary breast cancer” 
study.
Pre-treatment diagnostic core biopsy specimens were available from 90 patients 
for CD34/a-SMA analysis. Of these patients, 62 also had samples available for 
VEGF analysis. The patient demographics are shown in table 3.1. Pre-treatment 
samples from an additional 9 patients who had received non-FEC neoadjuvant 
chemotherapy (n=6) or who had undergone primary surgery (n=3) were included 
in the comparison of pre-treatment VEGF with pre-treatment MVD and PCI.
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Eighty paired pre- and post-neoadjuvant FEC chemotherapy breast specimens 
(diagnostic core biopsy and definitive surgical specimen respectively) were 
available for the assessment of MVD and PCI using CD34/a-SMA 
immunohistochemical doublestaining. The patient demographics are shown in 
table 3.2. Of these, 48 paired samples were available for VEGF assessment.
3.2.1 RESPONSE CRITERIA
3.2.1.1 Clinical response
Clinical response was evaluated from the bidimensional clinical measurements 
of the primary breast tumour prior to and following 6 cycles of FEC 
chemotherapy and was defined according to the UICC/WHO criteria (appendix 
1) [290,291] as follows:
Complete Response (cCR) Disappearance of all known disease
Partial Response (cPR) Decrease by at least 50% of the sum of the products 
of the largest perpendicular diameters of measurable 
lesions
Stable disease (cSD) Less than 50% decrease and less than 25% increase in 
the sum of the products of the largest perpendicular 
diameters of measurable lesions
Progressive disease (cPD) Increase of more than 25% in the size of a measurable 
lesion or appearance of a new lesion
For the study analysis, clinical responders were defined as those patients with 
cCR or cPR. Clinical non-responders were defined as those patients with cSD or 
cPD. This classification was in accordance with other clinical studies [24, 36]. 
Those patients who progressed during neoadjuvant chemotherapy, such that a
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therapy change was instituted before completing six cycles of FEC 
chemotherapy, were defined as clinical non-responders (n=l).
3.2.1.2 Pathological response
Pathological response was evaluated by a single consultant pathologist (PIR) 
from a comparison of the pre-treatment core biopsy and the post-chemotherapy 
surgical resected specimen. Response was graded in accordance with previously 
described criteria [292-294]:
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Pathological
response
Description
Grade 1 No residual invasive cancer or DCIS (pathological CR)
Grade 2 Residual DCIS but no invasive cancer
Grade 3 Microscopic residual cancer
Grade 4 Macroscopic residual cancer with chemotherapy-induced 
changes and/or histological tumour response
Grade 5 Macroscopic invasive cancer with no response features
Chemotherapy-induced changes included (1) enlarged cells, (2) finely 
vacuolated “bubbly” voluminous cytoplasm, (3) enlarged vesicular nucleus with 
prominent single eosinophilic nucleolus, (4) occasionally enlarged 
hyperchromatic dense nucleus with an irregular outline, (5) compact hyalinized 
fibrous tissue at the site of good tumour response. Histological tumour response 
was an apparent reduction in tumour cell to stroma ratio. Examples of each 
grade of pathological response are shown in figure 2.1.
For the study analysis, pathological responders were defined as those patients 
with a grade 1, 2, 3 or 4 response. Pathological non-responders were defined as 
those patients with a grade 5 response.
3.3 MATERIALS AND METHODS
3.3.1 IMMUNOHISTOCHEMISTRY
3.3.1.1 Principle of the Avidin-Biotin Complex (ABC) method
Immunohistochemical staining was performed using the avidin-biotin complex 
(ABC) method. This method depends on the high affinity of avidin 
(streptavadin) for biotin via four binding site (dissociation constant 10'19M). A 
biotinylated immunoglobulin is used as a link antibody. Biotinylation is a mild 
process where biotin molecules are covalently bound to the constant regions of
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the heavy chain. Open sites on avidin on a separate pre-formed avidin-biotin 
enzyme complex bind to the biotin on the link antibody. Horseradish peroxidase 
(HRP) and alkaline phosphatase are commonly used as the enzyme labels within 
the pre-formed avidin-biotin enzyme complex. The sequence of reagent 
application is: primary antibody followed by biotinylated secondary antibody 
followed by pre-formed avidin-biotin enzyme complex.
3.3.1.2 Horseradish peroxidase (HRP)
In the presence of an electron donor, HRP activity results in the formation of an 
enzyme-substrate complex followed by oxidation of the electron donor. The 
electron donor provides the driving force in continuing catalysis of peroxidase, 
while its absence stops the reaction. There are several electron donors that 
become coloured insoluble products upon oxidation and these are known as 
chromogens. Diaminobenzine tetrahydrochloride (DAB) is a commonly used 
chromogen in peroxidase based immunohistochemistry and produces a brown 
insoluble end product on oxidation. When using HRP, endogenous cellular 
peroxidases must be blocked to ensure the stain is specific to bound antibody. 
This is done by bathing the samples in hydrogen peroxide before adding the 
primary antibody. HRP was used for CD34 staining in the CD34/a-SMA 
doublestaining technique and for the VEGF immunohistochemical staining.
3.3.1.3 Alkaline phosphatase
In the alkaline phosphatase immunostaining method, alkaline phosphatase 
hydrolyses naphthol phosphate esters (substrate) to phenolic compounds and 
phosphates. The phenols couple to colourless diazonium salts (chromogen) to 
product insoluble, coloured azo dyes. The Fast Red substrate-chromogen 
solution was used for a-SMA staining in the CD34/a-SMA doublestaining 
technique.
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3.3.1.4 Doublestain immunohistochemistry for CD34 and a-SMA
The pre- and post-treatment pathological specimens for each patient were 
stained simultaneously. Paraffin-embedded sections, 4pm thick, were cut from 
tumour blocks and mounted onto microscope slides (Surgipath Europe Ltd, X- 
tra slides™). Slides were dewaxed in xylene for 5 minutes prior to rehydration 
through graded alcohols (100, 90, 70%) to water and then washed in tris buffer 
saline (50mmol tris-HCL)(TBS). Each section was encircled with a resin pen. 
The DAKO EnVision™ doublestain system (DakoCytochromation Ltd, UK, 
K1395) was used to perform the staining. The slides were incubated with 0.03% 
hydrogen peroxidase for 5 minutes to block endogenous peroxidase activity, 
then washed in water followed by TBS. Anti-CD34 mouse monoclonal 
antibody, QBend/10 (Novocastra Labs Ltd, UK, NCL-L-END™) diluted 1/50 in 
antibody diluent (DakoCytochromation Ltd, UK, S3022) was applied and the 
slides incubated for 30 minutes. The slides were washed with TBS and then 
labelled polymer, horseradish peroxidase (secondary antibody [mixed anti­
mouse Ig and anti-rabbit Ig]) was applied for 30minutes. The slides were washed 
with TBS and then substrate-chromogen solution, liquid diaminobenzidine 
(DAB+), was applied for 3 minutes. The slides were washed with TBS and then 
incubated with a doublestain blocking reagent. Following washing with TBS, 
mouse monoclonal anti-actin, a - smooth muscle antibody (Sigma-Aldrich, UK, 
A 2547™) (anti-a-sm-1 or a-SMA) diluted 1/20 000 in antibody diluent 
(DakoCytochromation Ltd, UK, S3022) was applied for 60 minutes. The slides 
were washed in TBS and then incubated with labelled polymer, alkaline 
phosphatase (secondary antibody [mixed anti-mouse Ig and anti-rabbit Ig]) for 
30 minutes. The slides were washed with TBS and then substrate-chromogen 
solution, Fast Red, was applied for 5 minutes. The slides were rinsed with water, 
counterstained with Gills haematoxylin (Surgipath Europe Ltd, 01500E) and 
coverslips were mounted using aqueous mounting medium (DakoCytomation 
Ltd, UK, Faramount Mounting Medium, S3025™). This process is demonstrated 
in figure 3.1.a. All immunohistochemical runs included a positive control slide 
(breast carcinoma).
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3.3.1.5 Quantification of MVD and PCI
Vessel counting was performed at x 200 magnification. For each specimen, 
random fields were counted with a median number of 10 fields (range 4-30) in 
the core biopsy specimens and 8 fields (range 2-16) in the post-treatment tumour 
specimens. In the case of small core biopsies (n=20), vessel counting was 
performed on all fields (median 6.5; range 1-21). Five post-treatment specimens 
had minimal residual tumour and only a single field was assessable. Post­
treatment specimens with a pathological CR (grade 1 pathological response) or 
only residual DCIS (grade 2 pathological response) were not included in the 
analysis as MVD and PCI were only assessed in areas with tumour cells.
For MVD, the number of microvessels (CD34 positive) per field were counted 
& expressed per mm2 (1 field = 0.18mm2). Single endothelial cells, endothelial 
cell clusters and microvessels within the tumour, clearly separated from adjacent 
microvessels, were counted. Areas adjacent to DCIS were not counted. For PCI, 
the number of CD34 & a-SMA positive vessels (or endothelial cell(s)) were 
counted per field and expressed as a percentage of all CD34 positive vessels 
within that field. The median MVD and PCI for each specimen was used in the 
analysis. Examples of CD34/a-SMA doublestaining of breast tumour specimens 
are shown in figure 3.1.
3.3.1.6 Immunohistochemistry for VEGF
The pre- and post-treatment pathological specimens for each patient were 
stained simultaneously. Formalin-fixed paraffin-embedded sections, 4pm thick, 
were cut from tumour blocks and mounted onto microscope slides (Surgipath 
Europe Ltd, X-tra slides™). Slides were dewaxed in xylene for 5 minutes prior 
to rehydration through graded alcohols (100, 90, 70%) to water. Each section 
was encircled with a resin pen. Antigen retrieval was performed on the slides by 
placing them in a bath of TBS and boiling for 12 minutes in a 800W microwave 
oven (2450 MHz Panasonic NN-6453BBPQ). The volume of fluid was topped 
up to its original level and the slides were then left to stand for 10 minutes at
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room temperature before being washed well in running tap water. Slides were 
then transferred to the Dako Autostaining machine (DakoCytochromation Ltd, 
UK) containing peroxidase block (DakoCytochromation Ltd, UK, S2023), the 
detection reagents (ChemMate™ HRP, DakoCytochromation Ltd, UK, K5001) 
and anti-human VEGF mouse monoclonal antibody (VEGF AB-7, NeoMarkers 
Inc., Fremont, USA) diluted 1/100 in antibody diluent (DakoCytochromation 
Ltd, UK, S3022). The autostainer programme included 5 minutes in peroxidase 
block, 1 hour incubation in primary antibody (anti-VEGF antibody), 30 minutes 
incubation in ChemMate™ secondary and tertiary reagents and 5 minutes in 
DAB substrate. When the programme was completed, stained slides were 
removed from the machine, washed with water and counterstained with Gills 
haematoxylin (Surgipath Europe Ltd, 01500E). The slides were then washed in 
water, dehydrated in graded alcohols (70, 90, 100%) and mounted in DPX 
(Surgipath Europe Ltd, 08600E). All immunohistochemical runs included a 
positive control slide (breast carcinoma).
3.3.1.7 Quantification of VEGF staining
Quantification of VEGF staining was performed by two observers at one sitting. 
A VEGF immunoreactive score (IRS) was devised to quantify the degree of 
VEGF staining in a similar manner to described elsewhere[174]. The VEGF IRS 
was calculated as the product of the intensity of VEGF scoring and the 
percentage of cells staining. The intensity of VEGF staining was scored as: 
negative=0, weak=l, moderate=2, strong=3. The percentage of cells staining 
was scored as: 0% = 0, <5% = 1, 5-20% = 2, 20-50% = 3, >50% = 4. Thus the 
possible range of VEGF IRS was from 0 to 12 (figure 3.2). Examples of tumour 
specimens with different VEGF IRS are shown in figure 3.3.
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3.4 STATISTICAL AN A LY SIS
Statistical analysis was performed using the StatsDirect statistical package 
(StatsDirect, Cheshire, UK). The relationship between MVD count, PCI and 
VEGF expression was quantified using Spearman’s rank correlation coefficient, 
Rho. Pre-treatment and change in MVD, PCI and VEGF according to clinical & 
pathological response to 6 cycles of neoadjuvant FEC was assessed using the 
Mann-Whitney U-test (MW). Change in MVD, PCI and VEGF following 
chemotherapy in the whole group was evaluated using the Wilcoxon’s signed 
ranks test. Pre-treatment MVD, PCI and VEGF according to clinical and 
pathological subgroups was evaluated using the Kruskal-Wallis test (KW). A p- 
value <0.05 was required for statistical significance.
3.5 RESULTS
3.5.1 PRE-TREATMENT ANGIOGENESIS-RELATED PARAMETERS 
TO PREDICT RESPONSE
3.5.1.1 Pre-treatment microvessel density and pericyte coverage index
Ninety pre-treatment (diagnostic) core-biopsy breast tumour samples taken from 
patients prior to receiving neoadjuvant FEC chemotherapy were available for 
intratumoural MVD and PCI assessment. The median MVD was 76.9/mm2 
(range 6.25 -  493.8/mm2; interquartile range 47.8 -  107.6/mm2) and the median 
PCI was 18.7% (range 0 - 66.7%; interquartile range 6.7 -  31.3%). No 
correlation was found between the pre-treatment MVD and pre-treatment PCI 
(Rho = -0.12, p = 0.27).
3.5.1.2 Pre-treatment MVD and PCI according to clinical response
Of the 90 patients, there were 71 clinical responders and 19 clinical non­
responders. The median MVD in the clinically responding patient group (n = 71)
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was 75/mm2 (range 9.26 -  493.8/mm2; interquartile range 44.4 -  108.3/mm2) 
and in the clinically non-responding group (n = 19) was 86.1/mm2 (range 6.3 -  
242.6/mm2; interquartile range 58.3 -  116.7/mm2). This difference was not 
statistically significant (MW, p = 0.49). The median PCI in the clinically 
responding group (n = 71) was 18.3% (range 0 -  66.7%; interquartile range 6.7 
-  31.7%) and in the clinically non-responding group (n = 19) was 21.5% (range 
0 -  40%; interquartile range 3.2 -  33.3%). This difference was not statistically 
significant (MW, p = 0.98). These results are shown in table 3.3 and illustrated 
using Box and Whisker plots in figure 3.4. No association was found between 
the pre-treatment MVD or PCI and the clinical response subgroups CR, PR, PD 
or SD (KW, p=0.45 and p= 0.61 respectively) (figure 3.5).
3.5.1.3 Pre-treatment MVD and PCI according to pathological response
Of the 90 patients, 86 underwent surgery following neoadjuvant chemotherapy. 
There were 27 pathological responders and 59 pathological non-responders. The 
median MVD in the pathologically responding patient group (n = 27) was 
77.8/mm2 (range 9.26 -  242.6/mm2; interquartile range 41.7 -  122.8/mm2) and 
in the pathologically non-responding group (n = 59) was 75/mm (range 6.3 -  
493.8/mm2; interquartile range 50 -  105.6/mm2). This difference was not 
statistically significant (MW, p = 0.87). The median PCI in the pathologically 
responding group (n = 27) was 13.6% (range 0 -  66.7%; interquartile range 7.8 -  
29.8%) and in the pathologically non-responding group (n = 59) was 21.4% 
(range 0 -  54.5%; interquartile range 3.2 -  33.3%). Again, this difference was 
not statistically significant (MW, p = 0.84). These results are shown in table 3.4 
and illustrated using Box and Whisker plots in figure 3.6. No association was 
found between the pre-treatment MVD or PCI and the pathological response 
subgroups 1 to 5 (KW, p=0.36 and p=0.92 respectively) (figure 3.7).
3.5.1.4 Pre-treatment Tissue Vascular Endothelial Growth Factor
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Sixty-two pre-treatment (diagnostic) core-biopsy breast tumour samples taken 
from patients prior to receiving neoadjuvant FEC chemotherapy were available 
for vascular endothelial growth factor (VEGF) assessment. Tissue VEGF was 
scored using the VEGF immunoreactive score (IRS) as described in section
3.3.1.7 and illustrated in figure 3.2. The median VEGF IRS was 6 (range 0 -  12; 
interquartile range 4 - 9).
3.5.1.5 Pre-treatment tissue VEGF according to clinical response
Of the 62 patients, there were 50 clinical responders and 12 clinical non­
responders. The median VEGF IRS in the clinically responding patient group (n 
= 50) was 6 (range 0 - 1 2 ;  interquartile range 4 - 9 )  and in the clinically non­
responding group (n = 12) was also 6 (range 3 - 1 2 ;  interquartile range 4 - 9). 
There was no significant difference between the clinical responders and non­
responders (MW, p = 0.87) (table 3.5 and figure 3.8). No association was found 
between the pre-treatment VEGF and the clinical response subgroups CR, PR, 
PD or SD (KW, p=0.78) (figure 3.9).
3.5.1.6 Pre-treatment tissue VEGF according to pathological response
Of the 62 patients, 59 underwent surgery following neoadjuvant chemotherapy. 
There were 19 pathological responders and 40 pathological non-responders. The 
median VEGF IRS in the pathologically responding patient group (n = 19) was 8 
(range 2 - 1 2 ;  interquartile range 4 - 1 2 )  and in the pathologically non­
responding group (n = 40) was 4 (range 0 - 1 2 ;  interquartile range 4 - 8). This 
difference was not statistically significant (MW, p = 0.32). These results are 
shown in table 3.6 and illustrated using Box and Whisker plots in figure 3.10. 
No association was found between the pre-treatment VEGF and the pathological 
response subgroups 1 to 5 (KW, p=0.73) (figure 3.9).
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3.5.1.7 Correlation of pre-treatment tissue VEGF, MVD and PCI
Seventy-one pre-treatment core-biopsy breast tumour samples taken from 
patients prior to receiving either NAC (n = 68) or primary surgery (n = 3), were 
assessed for the relationship between tumour VEGF and both MVD and PCI. 
The median values (range; interquartile range) were: VEGF IRS, 8 (0 -  12; 4 - 
12); MVD, 75/mm2 (6.3 -  400/mm2; 45.4 -  105.2/mm2); and PCI, 18.3% (0 -  
66.7%; 6.7 -  31.6%). There was a trend towards a positive correlation between 
VEGF and MVD (Rho= 0.22, p = 0.06) (figure 3.11). No correlation was seen 
between VEGF and PCI (Rho= -0.09, p = 0.45) (figure 3.12).
3.5.2 CHANGES IN ANGIOGENESIS-RELATED PARAMETERS 
FOLLOWING NAC
3.5.2.1 Changes in MVD and PCI following NAC
Eighty paired pre- and post-neoadjuvant FEC chemotherapy breast specimens 
(diagnostic core biopsy with corresponding surgical resection specimen) were 
available for assessment of MVD and PCI. The median (range; interquartile 
range) pre-treatment MVD and PCI values were 76.4/mm2 (6.25 -  493.8/mm2;
46.5 -  106.6/mm2) and 17.3% (0 -  66.7%; 6.6 -  30.4%) respectively. The 
median (range; interquartile range) post-treatment MVD and PCI values were 
72.2/mm2 (25 -  261.1/mm2; 50 -  100/mm2) and 25.5% (0 -  100%; 18.2 -  
43.3%) respectively. There was no significant difference between the pre- and 
post-treatment MVD values (Wilcoxon’s signed rank test, p = 0.48). However, 
there was a statistically significant difference between the pre- and post­
treatment PCI values (Wilcoxon’s signed rank test, p<0.0001) with a significant 
increase in PCI following chemotherapy. These results are shown in table 3.7 
and illustrated using Box and Whisker plots and Ladder plots in figures 3.13 
and 3.14.
3.5.2.2 Change in MVD and PCI according to response
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3.5.2.2.1 Clinical response
Of the 80 patients with pre- and post-treatment evaluations, there were 62 
clinical responders and 18 clinical non-responders. The median change in MVD 
following chemotherapy was 0 (range -393.8 to 138.9; interquartile range -25 to 
23.4) in the clinical responders and -19.4 (range -129.6 to 172.2; interquartile 
range -50.9 to 16.7) in the clinical non-responders. This difference was not 
statistically significant (MW, p = 0.18). The median change in PCI following 
chemotherapy was 11.1 (range -34.0 to 88.2; interquartile range -1.7 to 28.6) in 
the clinical responders and -1.1 (range -33.3 to 37.5; interquartile range -7.5 to 
12.2) in the clinical non-responders. This difference tended towards statistical 
significant (MW, p = 0.052). These results are summarised in table 3.8 and 
illustrated using Box and Whisker plots in figure 3.15.
3.5.2.2.2 Pathological response
Of the 80 patients with pre- and post-treatment evaluations, there were 24 
pathological responders and 56 pathological non-responders. The median change 
in MVD following chemotherapy was -1.1 (range -163.9 to 113.9; interquartile 
range -29.9 to 33.1) in the pathological responders and -4.2 (range -393.8 to 
172.2; interquartile range -34.0 to 22.2) in the pathological non-responders. This 
difference was not statistically significant (MW, p = 0.61). The median change 
in PCI following chemotherapy was 12.9 (range -34.0 to 88.2; interquartile 
range -0.2 to 35.5) in the pathological responders and 7.9 (range -33.3 to 77.1; 
interquartile range -6.4 to 22.7) in the pathological non-responders. This 
difference was not statistically significant (MW, p = 0.14). These results are 
summarised in table 3.9 and illustrated using Box and Whisker plots in figure 
3.16.
3.5.2.3 Changes in VEGF following NAC
Forty-eight paired pre- and post-neoadjuvant FEC chemotherapy breast 
specimens (diagnostic core biopsy with corresponding surgical resection 
specimen) were available for assessment of tissue VEGF. The median pre- and
192
post-treatment VEGF IRS was 6 (range 0 - 1 2 ;  interquartile range 4 - 9 )  and 4 
(range 0 - 1 2 ;  interquartile range3 - 6) respectively. This difference between the 
pre- and post-treatment VEGF IRS was found to be statistically significant 
(MW, p = 0.002) (table 3.10 and figure 3.17).
3.5.2.4 Change in VEGF according to response
3.5.2.4.1 Clinical Response
Of the 48 patients, there were 39 clinical responders and 9 clinical non­
responders. The median change in VEGF IRS following chemotherapy was -2 
(range -10 to 6; interquartile range -4 to 0) in the clinical responders and -2 
(range -8 to 5; interquartile range -3 to 0) in the clinical non-responders. There 
was no significant difference in the two groups (p = 0.78) (table 3.11 and figure 
3.18).
3.5.2.4.2 Pathological Response
Of the 48 patients, there were 14 pathological responders and 34 pathological 
non-responders. The median change (range; interquartile range) in VEGF IRS 
following chemotherapy was -3 (-9 to +1; -5 to 0) in the pathological responders 
and —1(-10 to +6; -4 to 0) in the pathological non-responders. This difference 
was not statistically significant (p = 0.32) (table 3.12 and figure 3.19).
3.6 DISCUSSION
Angiogenesis is critical for the growth and metastasis of solid tumours. Novel 
therapies under investigation for the treatment of cancer have included those that 
specifically target the tumour vasculature. These have been divided into two 
main groups: the vascular targeting agents, which work by directly damaging the 
existing tumour vasculature; and the antiangiogenic agents, which inhibit the 
process of neovascularisation. These new treatments differ from the 
conventional cytotoxic chemotherapeutic agents which act directly on the
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tumour cells inducing DNA damage and hence cell death. It is anticipated that 
future anticancer therapies involving antivascular agents will involve a 
combination of these agents with conventional chemotherapy. As a result, 
knowledge of the vascular effects of conventional chemotherapeutic agents is 
important and might help, for example, in the design of rational drug 
combinations and sequencing.
The treatment of primary breast cancer with neoadjuvant chemotherapy, prior to 
definitive surgery, provides an ideal in vivo model for assessing the effects of 
treatment with tumours in situ. Using this treatment model, Makris et al. 
previously demonstrated a significant reduction in MVD, as assessed by 
Chalkley point counting, following neoadjuvant chemotherapy [128]. In absolute 
terms, however, the difference in median scores on the Chalkley count between 
tumours treated with neoadjuvant chemotherapy and those not treated was only 
0.6 (median score 5.7 and 6.3 respectively). This small difference may reflect 
the fact that MVD can only provide a static quantitative measure of tumour 
vascularity and fails to provide a qualitative measure of vascular function, that 
is, the extent of actively proliferating angiogenic vessels. Indeed, it may be that 
the functional vascular status of a tumour, in terms of the proportion of actively 
proliferating (“immature”) to non-proliferating (“mature”) vessels is more 
important for predicting both response to treatment and long-term outcome than 
the total number of vessels alone. Bottini et al. also demonstrated a modest but 
significant reduction in MVD following NAC (pre-treatment median 51.26/mm2 
and post-treatment median 44.27/mm2) but this change did not correlate with 
tumour response [129]. In both series, MVD was counted in the area of highest 
vascular density, the so-called “vascular hotspot”.
The aim of this study was to evaluate the effect of neoadjuvant chemotherapy on 
tumour vascularity in primary breast cancers in a group of women treated 
uniformly with conventional anthracycline-based chemotherapy (5-fluorouracil, 
epirubicin and cyclophosphamide [FEC]). In particular, an assessment of the 
effect on both quantitative and qualitative vascular measures was performed 
using the parameters MVD and PCI. In physiological angiogenesis, the 
acquisition of pericyte coverage on endothelial tubes leads to vessel
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remodelling, maturation and stabilisation [299]. The relationship between 
pericytes and endothelial cells in tumour microvessels remains unclear [98], 
however, pericyte recruitment to tumour vessels does still appear to reflect 
vessel maturation [133, 137]. Therefore, for this study, the functional vascular 
status of the breast tumours was assessed using the CD34/a-SMA 
doublestaining immunohistochemical technique, where mature vessels were 
defined as those staining with antibodies to both CD34 and a-SMA, and 
immature vessels as those staining only for CD34. The pericyte coverage index 
(PCI), defined as the fraction of mature vessels to the total number of vessels 
(expressed as a percentage), was used as the measure of the functional vascular 
status. Thus, a low PCI represented a more actively proliferating vascular bed 
compared with a high PCI. Unlike the previous studies [128, 129], MVD and 
PCI were calculated from random (or total) fields for each pathological sample 
rather that from hotspots, in order to inform upon the global effect of NAC on 
tumour vascularity. The effect of NAC on the expression of the pro-angiogenic 
factor VEGF was also assessed.
Evaluation of the pre-treatment diagnostic core biopsy specimens revealed that 
neither MVD, PCI nor VEGF expression predicted for clinico-pathological 
response to NAC. Further, no correlation was found between MVD and PCI. 
There was a non-significant trend towards a positive correlation between MVD 
and VEGF expression (p=0.06) which may reflect the significant role VEGF 
plays in driving tumour angiogenesis within breast tumours. No correlation was 
found between PCI and VEGF expression.
Following neoadjuvant FEC chemotherapy, no significant change was seen in 
MVD however, a significant increase in the PCI was observed from 17.3% to 
25.5% (p<0.0001). This would suggest that despite no apparent alteration in the 
total number of tumour microvessels following NAC, the quality of the 
microvessels does change. NAC appears to have a “pruning” effect on immature 
proliferating vessels resulting in an increase in the proportion of mature, 
stabilised vessels. Following NAC, a significant reduction in VEGF expression 
was also observed, with the median VEGF IRS falling from 6 to 4 (p=0.002).
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The mechanism of action producing this vascular effect is unclear but two 
possibilities exist:
(1) a direct anti-angiogenic effect of chemotherapy on proliferating 
microvessels, or
(2) an indirect effect of chemotherapy via tumour cell death, leading to a 
reduction in the production of the pro-angiogenic cytokines, such a VEGF, 
that support tumour angiogenesis.
This “pruning” effect on immature proliferating vessels has been observed in 
studies using antiangiogenic agents, in particular the anti-VEGF agents [300- 
303], and has been termed vascular “normalisation” [304]. The immature, 
functionally abnormal tumour blood vessels are cut back through the elimination 
of endothelial cells, resulting in a more “normal” and hence more efficient 
vasculature. The “normalised” vasculature remains functionally less effective 
than its normal counterpart but the change does lead to in an improvement in 
nutrient and drug delivery to the tumour bed. The changes observed in PCI in 
this study therefore suggest that anthracycline-based NAC may be inducing a 
similar effect and that this effect may be mediated through a reduction in VEGF 
production subsequent to tumour cell death.
When change in MVD and PCI was assessed according to final clinical response 
to NAC, no difference in MVD was observed, however, a non-significant trend 
was seen towards an increase in PCI in the clinically responding group 
compared with the clinically non-responding group (median change in PCI 
11.1% and -1.1% respectively, MW, p=0.052). No significant difference was 
seen when change in either MVD or PCI was assessed according to final 
pathological response to NAC. Similarly, change in VEGF expression did not 
correlate with final clinical or pathological response to NAC. These findings 
suggest that the vascular changes observed in this patient cohort, were not 
directly contributing to tumour shrinkage with the possible exception of clinical 
tumour response. This corresponds to the findings from Bottini et al. [129] 
where the reduction in MVD did not correlate with tumour response but is at 
odds with findings from Marson et al. [131], where a significant correlation was 
found between percentage change in MVD and percentage reduction in tumour 
volume, however, this was in response to tamoxifen therapy.
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In summary, therefore, this study demonstrated that neoadjuvant anthracycline- 
based chemotherapy leads to an alteration in the functional quality o f the 
vascular bed in primary breast cancers with an increase in the proportion of 
mature microvessels but with no significant effect on the total number of 
microvessels. An associated reduction in tumour VEGF expression was also 
observed and may reflect the possible mechanism of action for these vascular 
changes. No correlation was found between the change in MVD, PCI or VEGF 
and final clinico-pathological response to NAC suggesting that these vascular 
changes do not impact directly on tumour shrinkage. In addition, none of the 
pre-treatment parameter values were able to predict for final clinico-pathological 
response. The implications of these findings, in particular for combination 
therapy with antiangiogenic agents are addressed in the final discussion (chapter
5).
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Table 3.1. Demographics of the patients with pre-treatment diagnostic core
biopsy specimens available for CD34/a-SMA analysis
No. o f pa tien ts 90
M edian  age (range) 48 Y EA RS (25 -  70)
M enopausal s ta tu s PR E  51 
P E R I 12 
PO ST  27
S tage II 68
III 22
G R A D E 1 6
2 33
3 39 
UNK N O W N  12
ER sta tu s P O SIT IV E  64 
N E G A T IV E  23 
N O T K N O W N  3
PgR  s ta tu s P O SIT IV E  45 
N E G A T IV E  27 
N O T  K N O W N  18
C lin ical response C R  18 
P R  53 
SD 14 
PD  5
O verall clinical response R ESPO N D E R S 71 
N O N -R ESPO N D ER S 19
Pathological response G R A D E 1 1 
G R A D E 2 1 
G R A D E 3 16 
G R A D E 4 9 
G R A D E 5 59 
NO SU RG ERY  4
O verall patho log ical response 
(n=86)
R E SPO N D ER S 27 
N O N -R ESPO N D ER S 59
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Table 3.2. Demographics of the patients with paired pre- and post­
treatment specimens available for CD34/a-SMA analysis
No. o f  p a tien ts 80
M edian  age (range) 47 Y EA RS (29 -  70)
M enopausal s ta tu s PR E  46 
P E R I 12 
PO ST  22
S tage II 59
III  21
G R A D E 1 6
2 29
3 37 
U NK N O W N  8
E R  s ta tu s P O SIT IV E  58 
N E G A T IV E  19 
N O T  K N O W N  3
PgR  s ta tu s P O SIT IV E  41 
N E G A T IV E  23 
N O T  K N O W N  16
C lin ical response C R  14 
P R  48 
SD 14 
PD  4
O verall clinical response R ESPO N D E R S 62 
N O N -R ESPO N D ER S 18
P atho log ical response G R A D E 1 0 
G R A D E 2 0 
G R A D E 3 15 
G R A D E 4 9 
G R A D E 5 55
O verall pa tho logical response R E SPO N D ER S 24 
N O N -R ESPO N D ER S 56
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Table 3.3. Pre-treatment MVD and PCI according to clinical response
M VD 
(in te rq u a rtile  range)
P C I
(in te rq u a rtile  range)
C lin ical responders 
(n=71)
75/mm2 
(4 4 .4 -  108.3)
18.3%
(6 .7 -3 1 .7 )
C lin ical non -responders 
(n=19)
86.1 /mm2 
(5 8 .3 -1 1 6 .7 )
21.5%
(3 .2 -3 3 .3 )
p-value (M ann-W hitney) 0.49 0.98
Table 3.4. Pre-treatment MVD and PCI according to pathological response
M VD 
(in te rq u a rtile  range)
P C I
(in te rq u artile  range)
Pathological responders 
(n=27)
77.8/mm2
(4 1 .7 -1 2 2 .8 )
13.6%
(7 .8 -2 9 .8 )
Pathological non -responders 
(n=59)
75/mm2
(5 0 -1 0 5 .6 )
21.4%
(3 .2 -3 3 .3 )
p-value (M ann-W hitney) 0.87 0.84
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Table 3.5. Pre-treatment tissue VEGF IRS according to clinical response
M edian V EG F IR S (range)
Clinical responders 
(n=50)
6 (0 - 1 2 )
Clinical non-responders 
(n=12)
6 (3 -  12)
p-value (M ann-W hitney) 0.87
Table 3.6. Pre-treatment tissue VEGF IRS according to pathological 
response
M edian V EG F IRS (range)
Pathological responders 
(n=19)
8 ( 2 - 1 2 )
Pathological non-responders 
(n=40)
4 ( 0 - 1 2 )
p-value (M ann-W hitney) 0.32
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Table 3.7. Pre- and post-treatment MVD and PCI
M edian MVD (range) M edian P C I (range)
P re-trea tm en t 76.4/mm2 17.3%
(n=80) (6 .2 5 -4 9 3 .8 ) (0 -6 6 .7 )
Post-treatm ent 72.2/mm2 25.5%
(n=80) (2 5 -2 6 1 .1 ) (0 -1 0 0 )
p-value
(W ilcoxon’s signed ranks p = 0.48 p <  0.0001
test)
Table 3.8. Change in MVD and PCI following neoadjuvant chemotherapy 
according to clinical response
M edian change in MVD 
(range)
M edian change in PC I 
(range)
Clinical R esponders 
(n=62)
0
(-393.8 to 138.9)
11.1 
(-34.0 to 88.2)
Clinical N on-responders 
(n=18)
-19.4 
(-129.6 to 172.2)
-1.1 
(-33.3 to 37.5)
p-value (M ann-W hitney U-test) 0.18 =0.052
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Table 3.9. Change in MVD and PCI following neoadjuvant chemotherapy
according to pathological response
M edian change in MVD 
(range)
M edian change in PC I 
(range)
Pathological R esponders 
(n=24)
-1.1
(-163.9 to 113.9)
12.9 
(-34.0 to 88.2)
Pathological N on-responders 
(n=56)
-4.2
(-393.8 to 172.2)
7.9
(-33.3 to 77.1)
p-value (M ann-W hitney U-test) 0.61 0.14
Table 3.10. Pre- and post-treatment VEGF IRS
M edian V EGF IRS 
(range; in terquartile  range)
P re-treatm en t 6
(n=48) ( 0 -  12; 4 - 9 )
Post-treatm ent 4
(n=48) ( 0 - 1 2 ;  3 - 6 )
p-value
(W ilcoxon’s signed ranks test)
p = 0.002
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Table 3.11. Change in VEGF IRS following neoadjuvant chemotherapy
according to clinical response
M edian change in V EGF 
IRS (range)
C linical R esponders -2
(n=39) (-10 to 6)
Clinical N on-responders -2
(n=9) (-8 to 5)
p-value 
(M ann-W hitney U-test)
0.78
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Table 3.12. Change in VEGF IRS following neoadjuvant chemotherapy
according to pathological response
M edian change in V EGF 
IRS (range)
Pathological Responders -3
(n=14) (-9 to 1)
Pathological N on-responders -1
(n=34) (-10 to 6)
p-value 
(M ann-W hitney U-test)
0.32
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Figure 3.1.a. Diagram of Avidin-Biotin Complex (ABC) method
Step 1. Application o f primary antibody
Step 2. Application o f biotinylated 
secondary antibody
AA
Step 3. Application o f pre-formed 
avidin-biotin enzyme complex (e.g. 
horseradish peroxidase enzyme)
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Figure 3.1.b. Diagram of DAKO EnVision™ Doublestain method
Step 1. Application o f primary antibody Step 2. Application o f HRP labelled 
(anti-CD34) polymer (secondary antibody)
Step 3. Application o f DAB chromogen
X
M  AA
Step 4. Application of Double Stain block
A AA
Step 5. Application o f (second) primary 
antibody (a-SMA)
AA •
Step 6. Application o f AP labelled polymer 
(secondary antibody)
Step 7. Application o f Fast Red Chromogen
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Figure 3.1 Examples of CD34/a-SMA double staining of breast cancer 
specimens
(i) Breast tumour with MVD 66.7/mm2 and PCI 0%. Arrow indicates immature 
vessel with CD34 staining only.
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(ii) Breast tumour with MVD 127.8/mm2 and PCI 39%. Arrow indicates mature 
vessel with CD34 and a-SM A  staining .
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Figure 3.2 VEGF immunoreactive score (VEGF IRS)
Intensity
0 negative
1 weak
2 moderate
3 strong
X
Cells staining %
0 0%
1 <5%
2 5-20%
3 20-50%
4 >50%
IRS
0-12
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Figure 3.3 Examples of VEGF staining in breast tum our
(i) Breast carcinoma with weak VEGF staining in 20-50% o f tumour cells 
(VEGF IRS 3)
(ii) Breast carcinoma with moderate VEGF staining in >50% of tumour 
cells (VEGF IRS 8)
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(iii) Breast carcinoma with strong VEGF staining in >50% o f  tumour cells 
(VEGF IRS 12)
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Figure 3.4 Box and Whisker plots of pre-treatment (i) MVD and (ii) PCI
according to clinical response
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Figure 3.5. Box and Whisker plot of pre-treatm ent (i) microvessel density 
and (ii) pericyte coverage index according to clinical response subgroups 
(CR=complete response, PR=partial response, SD=stable disease, 
PD=progressive disease)
(i) 5 0 0 . ,
CR
n=18
PR 
n=53
SD
n=14
PD
n=5
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Figure 3.6. Box and Whisker plots of pre-treatment (i) MVD and (ii) PCI
according to pathological response
(i)
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Figure 3.7. Box and Whisker plots of pre-treatment (i) microvessel density 
(MVD) and (ii) pericyte coverage index (PCI) according to pathological 
response grade subgroups
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Figure 3.8. Box and Whisker plot of tissue VEGF immunoreactive score 
(IRS) according to clinical response
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Figure 3.9. Box and Whisker plot of pre-treatment VEGF according to (i) 
clinical response subgroups (CR=complete response, PR=partial response, 
SD=stable disease, PD=progressive disease) and (ii) pathological response 
grade subgroups (grade 1 to 5)
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Figure 3.10. Box and Whisker plot of tissue VEGF IRS according to
pathological response
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Figure 3.11 Correlation of pre-treatment biopsy MVD versus tissue VEGF 
IRS
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Figure 3.12 Correlation of pre-treatment biopsy PCI versus tissue VEGF 
IRS
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Figure 3.13. Pre- and post-treatment MVD illustrated using (i) Box and
Whisker plot and (ii) Ladder plot
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Figure 3.14. Pre- and post-treatment PCI illustrated using (i) Box and
Whisker plot and (ii) Ladder plot
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Figure 3.15. Box and Whisker plots of absolute change in (i) MVD and
(ii) PCI according to clinical response
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Figure 3.16. Box and Whisker plots of absolute change in (i) MVD and (ii)
PCI according to pathological response
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Figure 3.17. Box and Whisker plot of pre- and post-treatment VEGF IRS
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Figure 3.18. Box and Whisker plot of absolutebchange in VEGF IRS
according to clinical response
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Figure 3.19. Box and Whisker plot of absolute change in VEGF IRS 
according to pathological response
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CHAPTER 4: EVALUATION OF THE 
PATHOPHYSIOLOGICAL CORRELATES OF 
MULTI-PARAMETER FUNCTIONAL MM
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4.1 INTRODUCTION
In primary breast cancer, the relationship between functional MRI-derived 
vascular parameters and immunohistochemically-derived measures of tumour 
angiogenic status remain unclear. Broad correlations between T1-weighted 
(T1W) kinetic parameters and MVD have been shown by some studies [305- 
307] while others have found no correlation [174, 308]. Similarly, confliciting 
results have been found with tumour VEGF expression and tissue enhancement 
in T1W DCE-MRI [174, 308].
Functional DCE-MRI provides ‘real-time’ information regarding the functional 
vascular status of the tumour, however, the underlying pathophysiology of DCE- 
MRI, in terms of angiogenic activity, is not yet fully understood. A comparison 
of the DCE-MRI kinetic parameters with immunohistochemical-derived 
qualitative measures o f angiogenic activity, such as pericyte coverage index, 
rather than the conventional quantitative measure of MVD has not been 
performed. Further, to date, the histological and immunohistochemical correlates 
of T2*-weighted (T2*W) DCE-MRI and BOLD MRI have not been assessed 
and neither have the relationship between the different functional MRI kinetic 
parameters. Further, BOLD MRI is a non-enhanced MRI techniques that uses 
deoxyhaemoglobin as an “intrinsic” contrast medium and, as such, provides a 
potential non-invasive method for assessing the tissue oxygenation. BOLD MRI 
has not been validated in PBC. Carbonic anhydrase IX (CA IX) is a 
transmembrane enzyme involved in the regulation of tissue pH and is one of the 
most strongly hypoxia-inducible proteins. CA IX tissue staining has been shown 
to correlate with direct measurement of oxygen tension [309]. An assessment of 
the relationship between tissue CA IX staining and BOLD MRI, together with 
DCE-MRI, might further our understanding of the effect of hypoxia on the 
functional MRI parameters
The aims of this study were:
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1. To assess the relationship between the T1W DCE-MRI, T2*W DCE-MRI 
and BOLD MRI kinetic parameters.
2. To assess the relationship between functional MRI kinetic parameters (T1W 
and T2*W DCE-MRI and BOLD MRI) and histological features of primary 
breast cancer.
3. To assess the relationship between functional MRI kinetic parameters (T1W 
and T2*W DCE-MRI and BOLD MRI) and immunohistochemically-derived 
angiogenesis-related features of primary breast cancer.
4. To assess the relationship between functional MRI kinetic parameters (T1W 
and T2*W DCE-MRI and BOLD MRI) and the immunohistochemical 
hypoxia-related parameter, carbonic anhydrase IX (CA IX).
5. To assess the relationship between the hypoxia-related parameter, CA IX, 
tumour histology and the angiogenesis-related parameters of primary breast 
cancer.
4.2 PATIENTS AND METHODS
Patients recruited to the “ Evaluation of MRI during neoadjuvant chemotherapy 
in primary breast cancer” (treatment or reproducibility arm) who had 
successfully undergone a multi-functional dynamic MRI scan prior to treatment 
(either neoadjuvant chemotherapy or primary surgery) were eligible for this part 
of the study. Ethical approval was obtained from the local research ethics 
committee as part of the “ Evaluation o f MRI during neoadjuvant chemotherapy 
in primary breast cancer” study (Mount Vernon and Watford Hospitals, protocol 
number EC2001-26). A pre-treatment formalin-fixed paraffin-embedded 
diagnostic core biopsy was required for analysis.
A total of 46 patients successfully completed a pre-treatment MRI scan. This 
included patients from the treatment and the reproducibility arm of the 
“Evaluation of MRI during neoadjuvant chemotherapy in primary breast cancer” 
study together with a number of patients who underwent a pre-treatment MRI
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scan but then received an alternative chemotherapy regimen to FEC. A pre­
treatment diagnostic core biopsy was available on 41 patients. The patient 
demographics are shown in table 4.1. 40 pre-treatment diagnostic core biopsy 
samples were available for carbonic anhydrase IX analysis; 39 samples were 
available for CD34/a-SMA analysis; and 38 samples were available for VEGF 
analysis.
4.2.1 MRI PROTOCOL
All MRI scans were performed at the Paul Strickland Scanner Centre, Mount 
Vernon Hospital, Northwood, Middlesex, UK. The MRI protocol employed was 
as described in sections 2.2.3 and 2.2.4, For each patient, the median value of 
each of the following parameters was calculated:
A. Single-slice analysis:
5. T 1W semi-quantitative parameters:
(iv) Mean gradient (MeanGrad)(AU)
(v) Maximum signal amplitude (MaxAmp)(%)
(vi) Washout (Wt)(AU)
6. T1W quantitative parameters:
(v) Transfer constant (Ktrans)(min'1)
(vi) Leakage space (ve)(%)
(vii) Rate constant (keP)(min_1)
(viii) Maximum Gd-DTPA concentration (MaxGd)(mmol/kg)
7. T2*W quantitative parameters:
(iv) Relative blood volume (rBV)
(v) Relative blood volume (rBF)
(vi) Mean transit time (MTT)(sec)
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8. BOLD-MRI quantitative parameter, R2* (sec'1)
B. Three-slice analysis:
T1W quantitative parameters:
(i) Transfer constant (K ^^X m in'1)
(ii) Leakage space (ve)(%)
(iii) Rate constant (kepXmin'1)
(vii) Maximum Gd-DTPA concentration (MaxGd)(mmol/kg)
4.2.2 PRIMARY BREAST CANCER HISTOLOGY
Tumour histological subtype, oestrogen receptor status and tumour grade were 
assigned according to the pre-treatment diagnostic core-biopsy and/or post­
treatment surgical specimen analysis and were obtained from the formal 
pathological reports. The histological tumour types were: invasive ductal 
carcinoma (n=35), invasive lobular carcinoma (n=5), mixed invasive ductal and 
lobular carcinoma (n=4), mucinous carcinoma (n=l) and carcinoma, NOS (not 
otherwise specified) (n=l).
Oestrogen receptor status was scored as positive or negative. Tumours were 
scored as oestrogen receptor positive if  either the diagnostic core-biopsy or post­
treatment surgical specimen demonstrated oestrogen receptor staining.
Tumour grade was assigned according to the Bloom-Richardson system. Where 
there was a discrepancy between the grade assigned to the pre-treatment 
diagnostic core biopsy sample and the post-treatment surgical specimen, the 
highest grade was taken.
Tumour necrosis was scored from the pre-treatment diagnostic core biopsy 
sample by a single independent pathologist (PIR). Tumour necrosis was scored 
as present or absent.
4.2.3 IMMUNOHISTOCHEMISTRY
231
Immunohistochemical staining for CD34/a-SMA (double-staining), VEGF and 
carbonic anhydrase IX (CA-IX) was performed on pre-treatment diagnostic 
breast cancer core biopsy specimens. The staining techniques employed for 
CD34/a-SMA and VEGF are described in section 3.3.1.4 and 3.3.1.6 
respectively. Microvessel density (MVD) and pericyte coverage index (PCI) 
were quantified as described in section 3.3.I.5. MVD was expressed as the 
number of vessels per mm . PCI was the number of CD34 & a-SMA positive 
vessels (or endothelial cell(s)) per high power field (x 200 magnification) 
expressed as a percentage of all CD34 positive vessels within that field. VEGF 
expression was quantified using the VEGF immunoreactive score (VEGF IRS). 
The VEGF IRS is described in section 3.3.I.7.
4.2.3.1 Immunohistochemistry for CA-IX
Paraffin-embedded sections, 4pm thick, were cut from tumour blocks and 
mounted onto microscope slides (Surgipath Europe Ltd, X-tra slides™). Slides 
were dewaxed in xylene for 5 minutes prior to rehydration through graded 
alcohols (100, 90, 70%) to water and then washed in tris buffer saline (50mmol 
tris-HCL)(TBS). Each section was encircled with a resin pen. The slides were 
incubated with Dako peroxidase block (DakoCytochromation Ltd, UK, 
EnVision™ kit, K4006) for 5 minutes to block endogenous peroxidase activity, 
then washed in water and rinsed in TBS. The slides were then incubated with 
protein block (DakoCytochromation Ltd, UK, X0909) for 5 minutes to reduce 
non-specific secondary antibody staining. Carbonic anhydrase-IX (CA-IX) 
mouse monoclonal antibody (supplied by Professor Adrian Harris, Weatherall 
Institute of Molecular Medicine, John Radcliffe Hospital, Oxford) diluted 1/50 
in antibody diluent (DakoCytochromation Ltd, UK, S3022) was applied and the 
slides incubated for 1 hour at room temperature. The slides were washed in TBS 
and then Envision Horseradish peroxidase mouse polymer 
(DakoCytochromation Ltd, UK, EnVision™ kit, K4006) was applied for 30 
minutes. The slides were washed with TBS and then incubated with 
diaminobenzidine (DAB) substrate (DakoCytochromation Ltd, UK, EnVision™ 
kit, K4006) for 5 minutes. Slides were rinsed in TBS, washed in water and then
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counterstained with Gills haematoxylin (Surgipath Europe Ltd, 01500E). The 
slides were washed in water, dehydrated in graded alcohols (70, 90, 100%) and 
mounted in DPX (Surgipath Europe Ltd, 08600E). All runs included a positive 
control slide (breast carcinoma).
4.2.3.2 Quantification of CA-IX staining
CA-IX immunostaining was quantified in carcinoma cells as positive or 
negative.
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4.3 STA TISTIC A L A N A L Y SIS
Statistical analysis was performed using the StatsDirect statistical package. 
Spearman’s rank correlation coefficient, Rho, was used to analyse the 
relationship between continuous variables. The Mann-Whitney U-test (MW) 
was used to assess the relationship between two independent subgroups for 
continuous variables. The Kruskal-Wallis test (KW) was used to assess the 
relationship between more than two independent subgroups for continuous 
variables. The Fisher’s exact test was used to assess the statistical relationship 
between two dichotomous variables. A p-value <0.05 was required for statistical 
significance.
4.4 RESULTS
4.4.1 FUNCTIONAL M RI KINETIC PARAMETERS
Semi-quantitative and quantitative T1W DCE-MRI kinetic parameter data was 
available on all of the 46 patients who underwent a pre-treatment functional 
MRI scan o f the breasts. Quantitative T2*W DCE-MRI kinetic parameter data 
was available on 42 patients and the BOLD MRI parameter data, R2*, was 
available on 44 patients.
4.4.1.1 T1W (single-slice) and T2*W DCE-MRI
A significant positive correlation existed between the median values of the 
T2*W quantitative kinetic parameters, rBV and rBF, and the median values of 
the T1W semiquantitative parameters MeanGrad (Rho=0.40, p<0.01 and 
Rho=0.38, p<0.05 respectively), MaxAmp (Rho=0.62, p<0.001 and Rho=0.66, 
p<0.001 respectively) and Wt (Rho=0.63, p<0.0001 and Rho=0.65, p<0.0001 
respectively). No correlation was found between MTT and the T1W 
semiquantitative parameters (MeanGrad, Rho=0.08, p=0.69; MaxAmp, 
Rho=0.30, p=0.06; Wt, Rho=0.01, p=0.93) (table 4.2).
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A significant positive correlation existed between the median values of the 
T2*W quantitative kinetic parameters, rBV and rBF, and the median values of 
the T1W quantitative parameters, Ktrans (Rho=0.47, p=0.002 and Rho=0.46, 
p=0.003 respectively) and kep (Rho=0.47, p=0.002 and Rho=0.48, p<0.002 
respectively). There was no correlation between rBV or rBF and the remaining 
T1W quantitative parameters, ve (Rho=0.10, p=0.55; Rho=0.12, p=0.46, 
respectively) or MaxGd (Rho=0.23, p=0.14; Rho=0.28, p=0.07, respectively). A 
significant correlation existed between MTT and ve (Rho=0.33, p<0.05) but 
there was no correlation between MTT and the other T1W quantitative 
parameters (Ktrans, Rho=-0.003, p=0.98; keP, Rho=-0.18, p=0.24; MaxGd, 
Rho=0.25, p=0.11) (table 4.2).
4.4.1.2 T1W (three-slice) and T2*W DCE-MRI
A significant positive correlation existed between the median values of the 
T2*W quantitative kinetic parameters, rBV and rBF, and the median values of 
the T1W quantitative parameters (three-slice analysis), Ktrans (Rho=0.51, 
p<0.001 and Rho=0.54, p<0.0005 respectively), keP (Rho=0.49, p=0.001 and 
Rho=0.51, p<0.001 respectively) (figure 4.1) and MaxGd (Rho=0.31, p<0.05 
and Rho=0.50, p<0.001 respectively). There was no correlation between ve and 
rBV or rBF (Rho=0.16, p=0.32; r=0.18, p=0.27, respectively) but a significant 
correlation existed with MTT (Rho=0.38, p<0.05). There was no correlation 
between MTT and Ktrans, keP or MaxGd (Rho=-0.10, p=0.52; Rho=-0.23, p=0.15; 
Rho=0.27, p=0.09, respectively) (table 4.2).
4.4.1.3 DCE-MRI and BOLD MRI
There was a significant inverse correlation between the BOLD MRI parameter, 
R2*, and the T1W semiquantitative parameters MaxAmp (Rho=-0.65, 
p<0.0001) and Wt (Rho=-0.61, p<0.0001), and the T2*W quantitative 
parameters rBV (Rho=-0.73, p<0.0001) and rBF (Rho=-0.71, p<0.0001). There 
was no correlation between R2 * and any o f the remaining DCE-MRI kinetic 
parameters (table 4.3 and figure 4.2)
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4.4.2 FUNCTIONAL MRI PARAMETERS AND PRIMARY BREAST 
CANCER HISTOLOGICAL FEATURES
4.4.2.1 Histological tumour type
The histological tumour types were: invasive ductal carcinoma (n=35); invasive 
lobular carcinoma (n=5); mixed invasive ductal and lobular carcinoma (n=4); 
mucinous carcinoma (n=l); and carcinoma, NOS (not otherwise specified)(n=l). 
Correlations between the functional MRI parameters and the histological tumour 
type were assessed according to the three commonest histological sub-types only 
i.e. invasive ductal carcinoma, invasive lobular carcinoma and mixed invasive 
ductal and lobular carcinoma.
There was a significant difference in the median values for R2 * according to 
histological subtype (KW, p<0.04) with lower median R2 * values seen in the 
invasive ductal carcinomas (median 32.2SCC'1) compared with the invasive 
lobular (median 38.9SCC*1) and mixed invasive ductal and lobular carcinomas 
(median 39.8sec_1) (table 4.4 and figure 4.3). There was also a significant 
difference in the median values for Wt according to histological subtype (KW, 
p<0.02) with lower median Wt values seen in the mixed invasive ductal and 
lobular carcinomas (median -0.60AU) compared with the invasive ductal 
(median -0.23AU) and invasive lobular carcinomas (median -0.24AU) (table 4.4 
and figure 4.4). No significant difference was seen for the remaining MRI 
parameters according to histological subtype (table 4.4).
4.4.2.2 Tumour grade
Tumour grade was assessable in 43 of the 46 patients who underwent a pre­
treatment function MRI of the breasts. Where there was a discrepancy between 
the grade assigned to the pre-treatment diagnostic core biopsy sample and the 
post-treatment surgical specimen, the highest grade was taken. Thus, three
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tumours were graded as grade 1, twenty tumours were graded as grade 2 and 
twenty tumours were graded as grade 3.
There was a significant difference in the median values for Ktrans, keP, rBV, rBF, 
MeanGrad and Wt according to tumour grade (KW, p<0.05 for all groups) with 
higher median values generally being associated with a higher tumour grade 
(table 4.5). In light of the small number of low grade tumours (n=3), a further 
analysis was performed with the division of tumour grade into 2 clinically 
relevant groups: high grade (i.e. grade 3 tumours, n=20) and non-high grade (i.e. 
grade 1 and 2 tumours, n=23). This demonstrated a significant difference in the 
median values for rBV, rBF, MaxAmp and MeanGrad according to grade (MW, 
P<0.05 for all groups) with high grade tumours displaying higher kinetic values 
(table 4.6). For the remaining MRI parameters, no difference was found in the 
median values according to tumour grade (table 4.5 and 4.6).
4.4.2.3 Oestrogen-receptor status
Of the 46 patients who underwent a pre-treatment functional MRI of the breasts, 
35 had oestrogen-receptor positive tumours and 11 had oestrogen-receptor 
negative tumours (table 4.1). The oestrogen-receptor positive tumours 
demonstrated a significantly higher median R2 * compared with the oestrogen- 
receptor negative tumours (median R2 * 37sec_1 and 22.2 sec'1 respectively; MW, 
p<0.0005) (table 4.7 and figure 4.5). The oestrogen-receptor positive tumours 
also demonstrated a significantly lower median keP (three-slice analysis), rBV, 
rBF and Wt compared with the oestrogen-receptor negative tumours (MW, 
p<0.05 all groups) (table 4.7 and figure 4.6). No significant difference was 
found for the remaining MRI parameters according to oestrogen-receptor status. 
These results are shown in table 4.7.
4.4.2.4 Tumour necrosis
Tumour necrosis was scored on the pre-treatment diagnostic core-biopsy 
samples from 40 patients. Tumour necrosis was present in 13 tumour samples 
and absent in 27 tumour samples. Those tumours with necrosis demonstrated a
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significantly lower median R2* compared with those tumours with no necrosis 
(median R2* 27.5SCC1 and 35.6 sec-1 respectively; MW, p<0.05) (figure 4.7). 
Those tumours with necrosis also demonstrated a significantly higher median kep 
(single-slice and three-slice analysis, MW, p<0.05 for both), Ktrans (single-slice 
analysis, MW, p<0.05) rBV (MW, p=0.0005) and rBF (MW, p<0.001) 
compared with those tumours with no necrosis (figure 4.8). No significant 
difference was found for the other remaining MRI parameters according to 
tumour necrosis. These results are shown in table 4.8.
4.4.3 FUNCTIONAL M RI PARAMETERS AND
IMMUNOHISTOCHEMICAL ANGIOGENESIS-RELATED 
PARAMETERS
4.4.3.1 Microvessel density and Pericyte coverage index
Microvessel density (MVD) and pericyte coverage index (PCI) values were 
available on 39 diagnostic core-biopsy breast tumour samples taken from 
patients who had undergone a functional MRI scan prior to treatment.
The relationship between MVD and PCI and the T1W semi-quantitative (single­
slice) and quantitative DCE-MRI parameters (single-slice and three-slice 
analysis) were assessable on 39 patients. No significant correlation was found 
between MVD or PCI and any of the T1W kinetic parameters (Spearman’s rank 
correlation, p>0.05 for all). These results are shown in table 4.9.
The relationship between MVD and PCI and the T2*W DCE-MRI quantitative 
parameters (single-slice analysis) was assessable on 36 patients. No significant 
correlation was found between MVD or PCI and any of the T2*W kinetic 
parameters (Spearman’s rank correlation, p>0.05 for all). These results are 
shown in table 4.9.
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The relationship between MVD and PCI and the BOLD MRI parameter, R2*, 
was assessable on 37 patients. A significant positive correlation was found 
between MVD and R2 * (Rho=0.35, p=0.035). No significant correlation was 
found between PCI and R2 * (Rho=0.02, p=0.9) table 4.9.
4.4.3.2 Vascular endothelial growth factor
The VEGF IRS was available on 38 (diagnostic) core-biopsy breast tumour 
samples taken from patients who had undergone a functional MRI scan prior to 
treatment.
The relationship between VEGF IRS and the T1W semi-quantitative (single­
slice) and quantitative DCE-MRI parameters (single-slice and three-slice 
analysis) was assessable on 38 patients. No significant correlation was found 
between VEGF IRS and any of the T1W kinetic parameters (Spearman’s rank 
correlation, p>0.05 for all groups). These results are shown in table 4.9.
The relationship between VEGF IRS and the T2*W DCE-MRI quantitative 
parameters (single-slice analysis) was assessable on 35 patients. No significant 
correlation was found between VEGF IRS and any of the T2*W kinetic 
parameters (Spearman’s rank correlation, p>0.05 for all groups). These results 
are shown in table 4.9.
The relationship between VEGF IRS and the BOLD MRI parameter, R2 *, was 
assessable on 36 patients. No significant correlation was found between VEGF 
IRS and R2* (Rho=0.07, p=0.67) table 4.9.
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4.4.4 FUNCTIONAL MRI PARAMETERS AND THE HYPOXIA- 
RELATED PARAMETER, CA-IX
Carbonic-anhydrase IX (CA-IX) staining was performed on the pre-treatment 
diagnostic core-biopsy samples of 40 patients. CA-IX staining was negative in 
25 samples and positive in 15 samples.
The relationship between CA-IX staining and the T1W semi-quantitative 
(single-slice) and quantitative DCE-MRI parameters (single-slice and three-slice 
analysis) was assessable on 40 patients. CA-IX positive tumours had a 
significantly higher median Wt compared with CA-IX negative tumours (- 
0.17AU) and -0.25AU respectively, MW, p<0.05) (figure 4.9). There was no 
significant difference between the CA-IX positive or negative tumours for the 
remaining T1W kinetic parameters (MW, p>0.05 for all). These results are 
shown in table 4.10.
The relationship between CA-IX staining and the T2*W quantitative DCE-MRI 
parameters (single-slice analysis) was assessable on 37 patients. CA-IX positive 
tumours had significantly higher rBV and rBF values compared with CA-IX 
negative tumours (rBV 211.6 and 125.2 respectively, MW, p<0.005; rBF 8.1 and 
5.0 respectively, MW, p<0.005) (figure 4.9). No significant correlation was 
found between CA-IX staining and MTT (MW, p=0.32). These results are 
shown in table 4.10.
The relationship between CA-IX staining and the BOLD MRI parameter, R2 *, 
was assessable on 38 patients. CA-IX positive tumours had a significantly lower 
R2 * compared with CA-IX negative tumour (28.9sec_1 and 36.0SCC'1 
respectively, MW, p<0.05) (table 4.10 and figure 4.10).
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4.4.5 CA-IX, HISTOLOGICAL TUMOUR FEATURES AND THE 
ANGIOGENESIS-RELATED PARAMETERS OF PRIMARY 
BREAST CANCER
4.4.5.1 Histological tumour features
The relationship between the individual histological tumour features was 
assessable on up to 45 patients. Tumour grade was divided into two groups for 
the analysis: high grade (i.e. grade 3 tumours, n=20) and non-high grade (i.e. 
grade 1 and grade 2 tumours, n=23). There was a significant association between 
tumour grade and both oestrogen-receptor (ER) status (Fisher’s exact, p<0.005) 
and histological tumour type (Fisher’s exact, p<0.0001), with high grade 
tumours tending to be ER negative invasive ductal carcinomas (IDC). Further, 
there was a significant association between ER status and histological tumour 
type (Fisher’s exact, p<0.05) with all of the non-IDC tumours being ER positive. 
ER status was also associated with pathological tumour necrosis (Fisher’s exact, 
p<0.05), with no necrosis in the majority of ER positive tumours. These results 
are shown in table 4.11.
4.4.5.2 CA-IX and histological tumour features
The relationship between tumour CA-IX status and tumour grade was assessable 
in 39 patients. Tumour grade was divided into two groups for the analysis: high 
grade (i.e. grade 3 tumours, n=18) and non-high grade (i.e. grade 1 and grade 2 
tumours, n=21). There was a significant association between tumour grade and 
CA-IX status (Fisher’s exact, p<0.01), with negative CA-IX status being 
associated with non-high grade tumours (table 4.12).
The relationship between tumour CA-IX status and oestrogen receptor status 
was assessable in 40 patients. There was a significant association between 
oestrogen receptor status and CA-IX status (Fisher’s exact, p<0.05), with 
negative CA-IX status being associated with positive oestrogen receptor status 
(table 4.12).
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The relationship between tumour CA-IX status and tumour necrosis on the 
diagnostic core-biopsy samples was assessable in 40 patients. There was a 
significant association between tumour necrosis and CA-IX status (Fisher’s 
exact, p<0.001), with tumour necrosis being associated with positive CA-IX 
status (table 4.12).
4.4.5.3 CA-IX and Angiogenesis-related param eters
The relationship between tumour CA-IX status and MVD and PCI was 
assessable in 38 patients. There was a non-significant trend towards a lower 
MVD in CA-IX positive tumours compared with CA-IX negative tumours 
(55.6/mm2 and 88.9/mm2 respectively, MW, p=0.06) (table 4.13 and figure 
4.11). There was no significant difference in PCI between CA-IX positive and 
negative tumours (12.5% and 9.8% respectively, MW, p=0.59) (table 4.13).
The relationship between tumour CA-IX status and VEGF IRS was assessable in 
37 patients. There was no significant difference in VEGF IRS between CA-IX 
positive and negative tumours (9 and 8 respectively, MW, p=0.58) (table 4.13).
4.4.5.4 Tum our histological features and Angiogenesis-related param eters
The relationships between tumour histology parameters (tumour grade, 
histological subtype, oestrogen receptor status and tumour necrosis) and the 
angiogenesis-related parameters (MVD, PCI and VEGF IRS) were assessed. 
Tumour grade was divided into two groups for the analysis: high grade (n=20) 
and non-high grade (n=23). No significant correlation was found between any of 
the individual histological parameters and any of the individual angiogenesis- 
related parameters. These results are shown in table 4.14.
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4.5 DISCUSSION
Multi-parameter functional DCE-MRI provides ‘real-time’ information 
regarding the tumour microvasculature. The underlying pathophysiological 
correlates of functional MRI are not yet fully understood. The aim of this study 
was to assess the relationship between the 3 functional MRI techniques, namely, 
T1W-DCE-MRI, T2*W DCE-MRI and BOLD, and to assess the relationship 
between the MRI-derived kinetic parameters and both conventional histological 
features of breast cancers and immunohistochemically-derived measures of 
tumour angiogenesis and oxygenation.
Analysis of the T1W and T2*W DCE-MRI kinetic parameters revealed a 
significant correlation between the T2*W perfusion-related parameters, rBV and 
rBF, and the T1W semi-quantitative parameters MeanGrad, MaxAmp and Wt, 
and the T1W quantitative parameters Ktrans, keP and MaxGd (MaxGd on three- 
slice analysis only). While the semi-quantitative parameters describe the tumour 
signal intensity enhancement following the administration of GdDTPA, the 
T1W quantitative parameters provide a more accurate measure of the change in 
contrast medium concentration at the tumour tissue level. Both the T1W semi­
quantitative and quantitative parameters are dependant upon microvessel 
permeability, surface area and tumour blood flow. K*13"8 describes the 
transendothelial transport o f GdDTPA by diffusion from the intravascular space 
to the extravascular extracellular space (EES) within the tumour (figure 1.10). In 
tissues where vascular permeability is greater than vascular inflow, the delivery 
of contrast to the EES becomes dependent on the delivery o f the contrast 
medium to the tissue as a whole, that is the blood perfusion. This is termed a 
“flow-limited” situation and blood perfusion becomes the dominant factor 
determining contrast agent kinetics. In a “flow-limited” situation, Ktrans 
approximates to tissue blood flow per unit volume. If tissue perfusion is 
sufficient and transport out of the vasculature does not deplete the intravascular 
contrast medium concentration, then transport across the vessel wall is the major 
factor determining contrast medium kinetics. This is termed a “non-flow 
limited” situation and here Ktrans approximates to the vessel permeability-surface
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area product. In breast tumours, vascular permeability tends to outstrip the 
vascular in flow (flow-limitation) and hence we would expect the Ktrans values to 
be dominated by blood perfusion. The rate constant, kep, which describes the 
diffusion of contrast agent back into the vasculature from the EES is similarly 
affected. Thus, the significant correlation observed between the T1W kinetic 
parameters, in particular, Ktrans and keP, and the T2*W perfusion-related 
parameters, rBV and rBF, is what would be expected and confirms a “flow- 
limited” situation in primary breast tumours.
The non-enhanced MRI technique of BOLD MRI uses deoxyhaemoglobin as an 
“intrinsic” contrast medium and, as such, provides a potential method for 
assessing tissue oxygenation using the parameter R2*. A high R2* value reflects 
an increased deoxyhaemoglobin concentration and hence a relatively low tissue 
oxygenation while a low R2* value reflects a decreased deoxyhaemoglobin level 
and hence a relatively higher tissue oxygenation. Analysis of the BOLD MRI 
parameter, R2* with both the T1W and T2*W DCE-MRI parameters, revealed a 
significant inverse correlation between R2* and the T1W semi-quantitative 
parameters MaxAmp and Wt, and the T2*W perfusion-related parameters rBV 
and rBF. These inverse correlations appear to demonstrate what one would 
expect, that is, tumours with low blood perfusion would exhibit a relatively 
lower level of oxygenation compared with those with high blood perfusion.
In order to assess the pathophysiological correlates of the functional MRI 
parameters, the kinetic parameters were analysed according to both conventional 
histological features o f primary breast tumours and immunohistochemically- 
derived measures of tumour angiogenesis and oxygenation.
Analysis o f the functional MRI parameters according to conventional 
histological tumour features revealed significant differences in kinetic parameter 
values according to histological tumour type, histological tumour grade, 
oestrogen-receptor status and pathological tumour necrosis. Invasive ductal 
carcinomas were found to have significantly lower median R2* values compared 
with invasive lobular or mixed ductal/lobular carcinomas, however, further
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distinction of the invasive ductal carcinoma subgroup was not seen. This may 
have been a result o f the small patient numbers within the two other histological 
tumour subtypes (lobular carcinomas, n=5; mixed ductal/lobular, n=4).
Histological tumour grade is known to be an important prognostic feature in 
primary breast cancer, in particular, grade 3 tumours are associated with a worse 
prognosis [9]. Analysis of the functional MRI parameters according to grade 
(high grade (i.e. grade 3) versus non-high grade (i.e. grade 1 and 2)) revealed a 
significant difference in the T1W semi-quantitative parameter values, MaxAmp 
and MeanGrad, and the T2*W perfusion-related parameters, rBV and rBF 
according to tumour grade. This suggested a strong relationship between breast 
cancer blood perfusion/permeability and histological tumour grade, with high 
grade tumours demonstrating higher perfusion/permeability. This would be in 
accordance with the finding by others of a positive correlation between tumour 
grade and angiogenesis [121]. This greater blood perfusion and vessel 
permeability may result in an increased risk of micrometastic disease and hence, 
in part, explain the adverse prognostic significance of high tumour grade. In this 
study, no association was found between the immunohistochemically-derived 
angiogenesis-related parameters MVD, PCI and VEGF expression and any of 
the T1W or T2*W DCE-MRI parameters, however, a positive correlation was 
found between MVD and the BOLD MRI parameter, R2*. This may, in part, 
reflect hypoxia-driven angiogenesis, however, no association was found between 
MVD and tumour hypoxia as assessed by CA-IX expression. Further, a 
paradoxical association was noted between R2* and CA-IX expression, with 
lower R2* median values associating with CA-IX expression. This is in direct 
contrast to findings in human prostate cancer, where a significant positive 
correlation was found between R2* and tumour hypoxia, as assessed by 
pimonidazole [310]. This would suggest that within primary breast cancers, R2* 
may not be informing upon the tumour cellular oxygenation state, but rather 
simply reflecting the oxygenation level within the tumour vessels. This would be 
supported by the significant inverse correlation seen between R2* and the 
perfusion-related parameters, rBV and rBF, suggesting that R2* contrast within 
breast tumours in dominated by blood flow and volume. As such, tumour
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cellular hypoxia may be stimulating angiogenesis and this would explain the 
higher rBV and rBF values associated with CA-IX positive tumours, with low 
levels of intravascular deoxyhaemoglobin resulting in a low R2* value. This 
paradox of a large blood volume and concomitant tumour hypoxia has been 
observed in vitro [311]. In a similar fashion, pathological tumour necrosis may 
be a driving force for angiogenesis, resulting in the higher Ktrans, keP, rBV and 
rBV and lower R2* values that are seen to be associated with tumour necrosis.
Evaluation of the functional MRI parameters according to oestrogen-receptor 
(ER) status demonstrated significantly lower median keP, rBV, rBF and Wt in 
ER positive tumours compared with ER negative tumours, suggesting a lower 
blood perfusion in ER positive tumours. A significantly higher median R2* was 
also seen with ER positive tumours. ER status has been shown to be an 
important prognostic factor in early breast cancer [312, 313], with positive ER 
status being associated with improved outcome. This may be an indirect effect 
due to the additional treatment option adjuvant endocrine therapy that is 
available to patients with ER positive tumours, however, it may also be a direct 
effect of a biologically less aggressive tumour type. Indeed, as was demonstrated 
in this study, ER status has been correlated with lower tumour grade [313]. It 
may be that the biologically less aggressive nature of ER positive tumours may 
be a result o f their lower blood perfusion.
Correlation of CA-IX staining with histological tumour features revealed a 
significant association between CA-IX staining and tumour grade, ER status and 
tumour necrosis. Positive CA-IX staining tended to associate with the aggressive 
tumour features of high grade, ER negative status and necrosis. No association 
was found between either CA-IX staining or the histological tumour features and 
any of the immunohistochemically-derived angiogenesis-related parameters.
In summary, therefore, significant positive correlations were found between 
T1W and T2*W DCE-MRI kinetic parameters suggesting high microvessel 
permeability within breast tumours and “flow-limited” GdDTPA contrast
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kinetics. In addition, a significant inverse correlation was observed between the 
BOLD MRI parameter, R2*, and the T2*W perfusion-related parameters, rBV 
and rBF, suggesting the R2* contrast in breast cancers is dominated by blood 
volume and flow. The apparent paradoxical association between R2* and the 
immunohistochemically-derived measure of tumour hypoxia (CA-IX staining), 
suggests that, unlike human prostate cancers, R2* may not reflect the tumour 
intracellular oxygenation level but rather reflect intravascular oxygenation. 
Further, the high perfusion-related parameters associated with CA-IX staining 
may reflect hypoxia driven angiogenesis.
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Table 4.1. Demographics of those patients who underwent a pre-treatment
multi-parameter functional MRI scan
No. o f patien ts 46
M edian age (range) 48 years (29 -  70)
M enopausal sta tu s
P re  26 
Post 20
Stage
I 3
II 31
III  11
IV  1
G rad e
1 3
2 20 
3 20 
U nknow n 3
E R  sta tus
Positive 35 
Negative 11
Histological type
Invasive ductal 35 
L obu lar 5 
M ixed 4 
O th e r 2
T u m o u r necrosis 
(n=40)
A bsent 27 
P resen t 13
CA -IX  stain ing  
(n=40)
Negative 25 
Positive 15
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Table 4.2. Spearman’s rank correlation coefficients showing the 
relationship between the T1W and T2*W DCE-MRI kinetic parameters
T1W  M R I 
sequence
M R I
p a ram e te r
S p earm an ’s R an k  C orre la tion  Coefficient 
R ho (p-value)
T2*W  param eters
rBV rB F M TT
Semi-
quan tita tive
M eanG rad 0.40 (<0.01) 0.38 (<0.05) 0.08 (0.62)
M axA m p 0.62 (<0.0001) 0.66 (<0.000l) 0.30 (0.06)
W t 0.63 (<0.0001) 0.65 (<0.0001) 0.01 (0.94)
Q uan tita tive
(single-slice)
Intrant 0.47 (=0.002) 0.46 (<0.005) -0.003 (0.98)
ve 0.10(0 .55) 0.12 (0.46) 0.33 (<0.05)
k«P 0.47 (<0.002) 0.48 (<0.002) -0.18(0.24)
M axG d 0.23 (0.14) 0.28 (0.07) 0.25 (0.11)
Q uan tita tive
(three-slice)
Intrant 0.51 (<0.0001) 0.54 (<0.0005) -0.10(0.52)
Ve 0.16(0.32) 0.18(0.27) 0.38 (<0.05)
K 0.49 (=0.001) 0.51 (<0.001) -0.22 (0.16)
M axG d 0.31 (<0.05) 0.34 (<0.05) 0.27 (0.09)
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Table 4.3. Spearman Rank correlation coefficients showing the relationship 
between the T1W and T2*W DCE-MRI kinetic parameters and the BOLD 
MRI parameter, R2*.
D C E-M R I
Sequence
M R I
P aram e te r
S p earm an ’s R an k  C orre la tion  Coefficient 
R ho (p-value)
BOLD M R I param eter, R2*
T1W
semi-
quan tita tive
M eanG rad -0.14(0.39)
M axA m p -0.65 (<0.0001)
W t -0.61 (<0.0001)
T1W
quantita tive
(single-slice)
j^ tran s -0.06 (0.70)
Ve 0.04 (0.80)
K -0.15 (0.32)
M axG ad -0.02 (0.90)
T1W
quan tita tive
(three-slice)
l^ tran s -0 .18(0.24)
Ve -0.11 (0.49)
K -0 .14(0.36)
M axG ad -0.16(0.29)
T2*W
quan tita tive
rBV -0.73 (<0.0001)
rB F -0.71 (<0.0001)
M T T -0.19(0.24)
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Table 4.4. Pre-treatment median functional MRI parameter values
according to tumour histological subtype
M R I sequence
M R I p a ram e te r 
(m edian)
T u m o u r histology
p-value 
(K ruskal- 
W allis test)
Invasive
ductal
(n=35)
Invasive
lobu lar
(n=5)
M ixed 
ductal & 
lobu lar 
(n=4)
T1W
Semi-
quan tita tive
M eanG rad  (AU) 39.7 42.6 42.6 0.89
M axA m p (% ) 92 77 86 0.67
W t (AU) -0.23 -0.24 -0.60 =0.02
T1W
Q uantita tive
(single-slice)
K tr““  (min*1) 0.58 0.57 0.68 0.60
Ve(%) 54 50 70 0.07
k ^ m in * 1) 1.14 0.80 0.97 0.63
M axG d
(m m ol/kg)
0.41 0.37 0.53 0.06
T1W
Q uantita tive
(three-slice)
( m in 1) 0.56 0.55 0.54 1.00
Ve(%) 49 48 59 0.21
k ^ m i n 1) 1.05 0.83 0.91 0.55
M axG d
(m m ol/kg)
0.40 0.42 0.45 0.31
T2*W
Q uantita tive
rBV 161.3 95.5 94.0 0.41
rB F 6.40 4.14 4.23 0.49
M T T  (sec) 23.89 23.20 23.83 0.81
BOLD M R I R2* (s e c 1) 32.2 38.9 39.8 =0.04
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Table 4.5. Pre-treatment median functional MRI parameter values
according to tumour grade
M R I sequence
M R I p a ram ete r 
(m edian)
T u m o u r grade p-value
(K ruskal-W allis
test)
1
(n=3)
2
(n=20) s II 
w
N> 
^
 
O
T1W
Semi-
quan tita tive
M eanG rad  (AU) 20.51 41.64 41.85 =0.04
M axA m p (% ) 85 86 101 0.11
W t (AU) -0.24 -0.25 -0.18 =0.04
T1W
Q uantita tive
(single-slice)
Ktr*"‘ (m in 1) 0.32 0.64 0.58 =0.04
v«(%) 50 57 51 0.19
k e r n i n ') 0.60 1.05 1.14 =0.04
M axG d
(m m ol/kg)
0.37 0.46 0.40 0.10
T1W
Q uantita tive
(three-slice)
Ktr*“  (min*1) 0.30 0.56 0.55 =0.04
ve(%) 48 53 48 0.23
k e r n i n ' ) 0.58 0.98 1.08 =0.02
M axG d
(m m ol/kg)
0.35 0.42 0.36 0.19
T2*W
Q uantita tive
rBV 66.3 128.1 176.6 =0.04
rB F 2.69 5.21 7.13 =0.03
M T T  (sec) 23.8 23.8 23.8 0.81
BOLD M R I R 2* (se c 1) 37.3 33.9 30.5 0.06
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Table 4.6. Evaluation of pre-treatment median functional MRI parameter
values according to high grade versus non-high grade tumours
M R I sequence
M R I p a ram e te r 
(m edian)
T um our grade
p-value 
(M ann-W hitney U- 
test)
High
G rade
(n=20)
N on-high
grade
(n=23)
T1W
Semi-
quan tita tive
M eanG rad  (AU) 41.8 38.5 0.28
M axA m p (% ) 101 86 <0.05
W t (AU) -0.18 -0.24 <0.05
T1W
Q uantita tive
(single-slice)
K e r n i n ' 1) 0.58 0.58 0.60
Ve(%) 51 55 0.13
kepOnin'1) 1.14 1.00 0.43
M axG d
(m m ol/kg)
0.40 0.43 0.22
T1W
Q uantita tive
(three-slice)
Ktr,M ( m in 1) 0.55 0.55 0.93
Ve(%) 48 53 0.23
kepCmin'1) 1.08 0.90 0.20
M axG d
(m m ol/kg)
0.36 0.42 0.28
T2*W
Q uantita tive
rBV 176.6 127.3 <0.05
rB F 7.13 5 <0.01
M T T  (sec) 23.8 23.8 0.88
BOLD M R I R 2* (se c 1) 30.5 34.4 0.06
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Table 4.7. Pre-treatment median functional MRI parameter values
according to tumour oestrogen-receptor status
M R I sequence
M R I p a ram ete r 
(m edian)
O estrogen-
recep to r
positive
O estrogen-
recep to r
negative
p-value 
(M ann- 
W hitney U-test)
T1W
Semi-
quan tita tive
M eanG rad  (AU) 42.4 39.4 0.86
M axA m p (% ) 87 100 0.28
W t (AU) -0.24 -0.16 =0.03
T1W
Q uantita tive
(single-slice)
Klr*"8 (m in '1) 0.58 0.58 0.60
Ve(%) 54 54 0.72
keP (m in '1) 0.98 1.21 0.13
M axG d
(m m ol/kg)
0.41 0.45 0.83
T1W
Q uantita tive
(three-slice)
K‘r*D* (m in '1) 0.53 0.61 0.11
Ve(% ) 49 50 0.98
keP (m in’1) 0.93 1.22 =0.04
M axG d
(m m ol/kg)
0.40 0.41 0.53
T2*W
Q uantita tive
rBV 127 191 =0.01
rB F 5.4 8.1 =0.007
M T T  (sec) 24.1 23.6 0.19
BOLD M R I R2* (se c 1) 37 22.2 =0.0004
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Table 4.8. Pre-treatment median parameter values according to tumour
necrosis status
M R I sequence
M R I pa ram ete r 
(m edian)
T um our
necrosis
presen t
T um our
necrosis
absent
p-value 
(M ann- 
W hitney U-test)
T1W
Semi-
quantita tive
M eanG rad  (AU) 40.7 39.7 0.31
M axA m p (% ) 92 91 0.55
W t (AU) -0.20 -0.25 0.06
T1W
Q uantita tive
(single-slice)
K trM*(min 4 ) 0.71 0.58 =0.02
ve(% ) 57 53 0.81
kep(m in '1) 1.34 0.93 =0.02
M axG d
(m m ol/kg)
0.46 0.41 0.20
T1W
Q uantita tive
(three-slice)
Ktr*M (m in '1) 0.62 0.55 0.052
v*(% ) 54 48 0.98
k e p fm in 1) 0.93 1.22 =0.035
M axG d
(m m ol/kg)
0.44 0.40 0.06
T2*W
Q uantita tive
rBV 218.4 126.6 =0.0005
rB F 8.5 5.4 =0.0008
M T T  (sec) 24.0 23.7 0.51
BOLD M R I R2* (se c 1) 27.5 35.6 =0.02
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Table 4.9. Correlations between the functional MRI parameters and 
immunohistochemical angiogenesis-related parameters
M R I sequence
M R I
p aram e te r
S p earm an ’s R an k  C orre la tion  Coefficient, 
R ho 
(p-value)
MVD PC I
V EG F
IRS
T1W
Semi-
quan tita tive
M eanG rad 0.15(0.37) 0.08 (0.61) 0.10(0.55)
M axA m p -0.22 (0.18) 0.10(0.55) 0.12(0.49)
W t -0.26 (0.11) -0.15(0.35) 0.11 (0.50)
T1W
Q uantita tive
(single-slice)
l^trans 0.07 (0.69) 0.01 (0.96) 0.29 (0.08)
Ve 0.02 (0.89) 0.14(0.39) 0.28 (0.09)
k«P 0.02 (0.91) 0.001 (0.99) 0.15(0.38)
M axG d -0.02 (0.92) 0.09 (0.60) 0.29 (0.08)
T1W
Q uantitative
(three-slice)
l t^rans 0.11 (0.51) 0.08 (0.62) 0.12(0.46)
Ve -0.08 (0.64) 0.24 (0.15) 0.19(0.25)
Kp 0.03 (0.85) -0.01 (0.94) 0.07 (0.66)
M axG d -0.17(0.30) 0.22 (0.19) 0.21 (0.20)
T2*W
Q uantita tive
rBV -0.21 (0.21) -0.10(0.54) 0.14(0.41)
rB F -0.25 (0.14) -0.06 (0.72) 0.15(0.39)
M TT -0.15 (0.39) -0.04(0.81) 0.03 (0.84)
BOLD M R I R2* 0.35 (=0.035) 0.02 (0.90) 0.07 (0.67)
256
Table 4.10. Pre-treatment median parameter values according to carbonic
anhydrase-lX status
M R I sequence
M R I p a ram e te r 
(m edian)
CA-IX
positive
CA-IX
negative
p-value 
(M ann-W hitney 
U-test)
T1W
Semi-
quan tita tive
M eanG rad  (AU) 44.7 38.5 0.14
M axA m p (% ) 102 87 0.08
W t (AU) -0.17 -0.25 =0.02
T1W
Q uantita tive
(single-slice)
KtrM,(m in *) 0.70 0.58 0.07
Ve (% ) 55 53 0.86
kep(m in '1) 1.34 0.98 0.06
M axG d
(m m ol/kg)
0.45 0.41 0.49
T1W
Q uantita tive
(three-slice)
K ^ m i n 1) 0.60 0.53 0.11
Ve(%) 54 48 0.29
k ^ m i n 1) 1.25 0.98 0.09
M axG d
(m m ol/kg)
0.44 0.40 0.19
T2*W
Q uantita tive
rBV 211.6 125.2 =0.0015
rB F 8.1 5.0 =0.0011
M T T  (sec) 24.0 23.4 0.32
BOLD M R I R 2* (se c 1) 28.9 36.0 =0.01
257
Table 4.11. Relationship between the individual histological tumour 
features of primary breast cancer
p-value 
(Fisher’s exact test)
Grade 
(high vs. non-high)
ER status 
(positive vs. negative)
Necrosis 
(present vs. absent)
Histology 
(IDC vs. non-IDC)
<0.0001 =0.04 =0.30
Grade
(high vs. non-high)
- =0.003 =0.052
ER status
(positive vs. negative)
- - =0.02
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Table 4.12. Relationship between CA-IX status and histological parameters
of primary breast cancer
H istological
fea tu res
CA-IX status 
(positive vs. negative)
p-value (F isher’s exact test)
T u m o u r g rad e  
(high g rade  vs. non-high grade)
<0.001
O estrogen-recep to r sta tus 
(positive vs. negative)
<0.05
T um our necrosis 
(presen t vs. absent)
<0.001
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Table 4.13. Pre-treatment median MVD, PCI and VEGF IRS according to
carbonic anhydrase-IX status
A ngiogenesis-related
p aram ete r
CA-IX
positive
CA-IX
negative
p-value 
(M ann-W hitney U-test)
M VD 55.6/m m2 88.9/mm2 0.06
PC I 12.5% 9.8% 0.59
V EG F IRS 9 8 0.58
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Table 4.14. Relationship between the pre-treatment angiogenesis-related
parameters and tumour histology
Angiogenesis-
related
p a ram e te r
Histological subtype T um our grade
Invasive
ductal
L obu lar
M ixed
ducta l/lobu lar
p-value 
(K ruskal- 
W allis test)
H igh
grade
Non-high
grade
p-value 
(M ann- 
W hitney U- 
test)
M VD 75.0/mm2 125.0/mm2 61.1/mm2 0.14 66.7/mm2 80.6/mm2 0.28
PC I 11.6% 20.8% 22.3% 0.90 11.6% 14.9% 0.93
V E G F IRS 8 9 6 0.27 9 8 0.79
Angiogenesis-
related
p aram ete r
O estrogen recep to r sta tus T um our necrosis
Positive Negative
p-value 
(M ann- 
W hitney U- 
test)
P resen t A bsent
p-value 
(M ann- 
W hitney U- 
test)
MVD 80.6/mm2 66.7/mm2 0.25 55.6/mm2 80.6/mm2 0.15
PC I 15.5% 10.3% 0.30 12.5% 9.8% 0.83
V EG F IRS 8 10 0.49 9 8 0.41
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Figure 4.1 Scatter plot demonstrating correlation between T1W (three- 
slice) and T2*W DCE-MRI parameters
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Figure 4.2 Scatter plot demonstrating correlation between BOLD MRI 
parameter, R2*, and T2*W DCE-MRI parameters
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Figure 4.3. Box and Whisker plot of median R2* according to histological 
sub-type
5 0 -,
4 0 -
J8 3 0 -
2 0 -
1 0 -
invasive
ductal
carcinoma
invasive
lobular
carcinoma
mixed invasive 
ductal and lobular
Figure 4.4. Box and Whisker plot of median Wt according to histological 
sub-type
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Figure 4.5. Box and Whisker plot of median R2* according to oestrogen-receptor
status
1
I
Ii
ER
positive
ER
n e g a t iv e
266
Median rBF
min -[ lower quartile - median - upper quartile ]- max
h
OS<1
Median Wt (AU) 
min -[ lower quartile - median - upper quartile ]- max
£  6  jb
8 -
Median kep (mirr‘)  
min -[ lower quartile - median - upper quartile ]- max
F  2 =
■o S  
^  £  »  
=: 2 
ora os
5  3 CO
Ci « * —. n m
s
■t «■*H ©
«b
»
a
3CT
5*
7?
Median rBV
min -[ lower quartile - median - upper quartile ]- max
h
(TO
S
5
«88
0nm1
2
2
13
8
8
3
«
fD
2
8rs
«o
a
3*
era
Figure 4.7. Box and Whisker plot of median R2* according to tumour necrosis
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Figure 4.11. Box and Whisker plot of MVD according to CA-IX staining
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CHAPTER 5: CONCLUDING DISCUSSION
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The principal aim of this thesis was to evaluate the vascular response to 
conventional anthracycline-based cytotoxic chemotherapy in primary breast 
cancer, using the neoadjuvant treatment setting as an in vivo research platform. 
With the primary tumour in situ, the neoadjuvant treatment setting enables a 
direct assessment of tumour chemo-responsiveness and permits an evaluation of 
the possible underlying biological mechanisms of response. In addition, 
response in the primary tumour may act as a surrogate marker of response in 
occult micrometastatic disease and hence enable the tailoring of treatment 
according to the individual patient response.
Conventional cytotoxic chemotherapy drugs produce their effect by damaging 
the reproductive integrity o f cancer cells, either through damage to the DNA or 
damage to the mitotic machinery. With increased understanding of the critical 
dependence of cancers on angiogenesis for growth and survival, novel therapies 
that target the tumour vasculature have evolved. These novel treatments can be 
divided into those that directly damage the tumour vessels (vascular targeting 
agents) and those that impede the formation of new blood vessels (anti- 
angiogenic agents). It is proposed that these novel agents will be used in 
combination with conventional cytotoxic agents, and therefore, it is important to 
understand the effects of conventional chemotherapy on the tumour vasculature. 
This may enable the rational design o f future treatment regimens.
Advances in radiological technology have lead to the development of functional 
imaging techniques that provide a non-invasive method for assessing the tumour 
microvasculature and these techniques have an increasing role in the evaluation 
of the effects of novel anti-angiogenic and vascular targeting agents. Multi­
parameter functional MRI is one such technique and was used to evaluate the 
vascular response to neoadjuvant FEC chemotherapy in 28 patients with primary 
breast cancer in the study described in Chapter 2. Vascular kinetic parameters 
derived from T1W DCE-MRI, T2*W DCE-MRI and BOLD MRI were 
measured from within primary breast tumours prior to treatment and then again 
following two cycles o f FEC chemotherapy. The whole tumour ROI was 
assessed rather than the tumour hotspot as this enables an appreciation of the
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degree of enhancement heterogeneity across the tumour and removes potential 
observer bias related to hotspot selection. Further, pixel mapping of the ROI 
allows spatial matching of the different tumour vascular characteristics. In 
addition, although Hayes et al. did demonstrate a greater reduction in kinetic 
parameter values at the tumour hotspot following NAC in PBC, hotspot analysis 
was not shown to be superior to ROI analysis for predicting response to 
treatment [314] and a recent consensus guideline has confirmed whole tumour 
ROI assessment as the technique of choice [315].
In relation to the timing of the second MRI scan, the time-point following two 
cycles of NAC was selected following data from a pilot study of T1W DCE- 
MRI in patients receiving a variety o f NAC regimens for PBC [316]. This study 
demonstrated that, although changes in the DCE-MRI kinetic parameter values 
were seen following a single cycle of NAC, the changes were unable to predict 
for final clinico-pathological outcome. Following two cycles of NAC, however, 
changes in the T1W DCE-MRI parameter, K1™8, could predict for final 
pathological response with an accuracy equivalent to change in MRI-derived 
tumour size. Hence, the baseline parameter values and the changes seen after 
two cycles of treatment were correlated with final clinical and pathological 
response to six cycles of treatment in order to determine whether the vascular 
changes could predict for treatment response.
The UICC/WHO criteria for clinical response [290, 291] was used in this study 
rather than the RECIST criteria [317] in order to allow a comparison of the 
results with that of other imaging studies of NAC in primary breast cancer [84, 
91, 316]. In addition, the relationship between clinical response and long term 
outcome has been demonstrated in NAC studies where the UICC/WHO response 
criteria was used [24] and validation of the RECIST response criteria in this 
setting remains to be fully assessed [318]. In relation to the pathological tumour 
response, this was scored by a single experienced pathologist and graded 1 to 5 
according to defined criteria as described in chapter 2. Patients with a 
pathological response grade from 1 to 4 were defined as pathological responders,
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while those patients with a grade 5 pathological response were defined as 
pathological non-responders. This classification was used for a number of 
reasons. Firstly, although complete pathological response (pCR) has been shown 
to predict for improved overall survival [24, 30, 83], its clinical usefulness is 
limited by the small number of patients (5-10%) who achieve such a response 
following anthracycline-based NAC. Thus, a system that groups patients with a 
complete or partial pathological response together may be clinically more 
relevant. Secondly, despite the presence of macroscopic residual tumour 
following NAC, those patients with a grade 4 pathological response were 
defined as “pathological responders” as the presence of chemotherapy-induced 
response features and a reduction in the tumour cell to stromal ratio has been 
shown to predict for an improved outsome when compared with residual 
macroscopic disease in the absence of any response features [294, 319, 320]. 
This may be a reflection of adequate cell kill at the level of systemic tumour 
micrometastases. Finally, the significance of residual DCIS when there has been 
a pathological complete response in the invasive cancer component following 
NAC remains unclear. Some pathological grading systems include residual 
DCIS within the pCR subgroup [294] while others do not [320]. Although NAC 
has no effect on DCIS, it remains to be clarified as to whether residual DCIS 
following NAC has an impact on longterm outcome [321] and hence residual 
DCIS alone was graded seperately to pCR for the purposes of this study.
Analysis o f the data demonstrated that none of the baseline (pre-treatment) MRI- 
derived kinetic parameters were able to predict for final clinico-pathological 
response to NAC, however, the early changes in the microvessel permeability 
and perfusion-related kinetic parameters (MeanGrad, MaxAmp, Ktrans, keP, rBV 
and rBF) following two cycles of treatment did predict for final clinico- 
pathological response. A reduction in these parameters correlated with treatment 
response. Using ROC curve analysis, the transfer constant, Ktrans, a T1W DCE- 
MRI kinetic parameter that describes the transendothelial diffusion of low 
molecular weight contrast medium from the intravascular space into the 
extravascular extracellular space, was shown to be the best predictor of 
pathological treatment response when evaluated using three-slice imaging data,
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with an AUC of 0.93 (sensitivity 94%, specificity 82%). There was, however, a 
trade-off between the identification of pathological non-responders and the 
misclassification of pathological responders (3 responding patients misclassified 
as non-responders). An evaluation of parameter combinations may lead to an 
improvement in the test specificity. Following the application of repeatability 
data from a reproducibility cohort of 12 patients, a failure of Ktrans to drop 
significantly following two cycles of FEC NAC was able to predict for 
pathological non-response at an individual patient level with a positive 
predictive value (PPV) of 84% on the three-slice analysis. The improved 
accuracy for predicting pathological response with the three-slice data set over 
the single central-slice data suggests that further improvements in the technique 
might be possible with greater spatial resolution. This would be at the expense of 
temporal resolution (a doubling of the tumour slice numbers would require a 
halving of the data points collected for each slice), however kinetic modelling of 
the data would still be possible and might lead to an increase in the test’s PPV.
Change in K1™"8 was also shown to be superior to change in MRI-derived tumour 
size for predicting response both on the group analysis and following the 
application of the reproducibility data. This is important as the conventional 
imaging techniques, namely X-ray mammography and ultrasonography, 
principally rely on changes in tumour size for evaluating tumour response to 
NAC. Calculation of the T1W DCE-MRI quantitative kinetic parameter values, 
however, relies on the pharmacokinetic modelling technique used to assess the 
Gd-DTPA concentration-time curve and the assumptions inherent to each model 
[163]. The Tofts and Kermode model was used in this study [161] and assumes 
that the vascular volume is negligible and that there is no dilution of contrast 
medium by the time it reaches the venous end of the capillary bed. Both of these 
assumptions are probably incorrect for tumours and more sophisticated models 
that are able to provide insights into tissue comparment behaviour are needed 
[322]. In general, however, if  the contrast agent concentration can be measured 
accurately and the type, volume and method of administration are consistent, 
then it is possible to directly compare pharmacokinetic parameters between 
patients at different scanning sites despite these caveats.
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Unfortunately, the effect of chemotherapy on menses and the changes in DCE- 
MRI kinetic parameter values was not assessed in this study. There is no data on 
the effects of the menstrual cycle on breast tumour kinetics, however, hormone 
replacement therapy has been shown to increase normal breast tissue perfusion 
as assessed by MRI in postmenopausal women [323]. Change in Ktrans following 
2 cycles of NAC, however, did predict for pathological response irrespective of 
menopausal status. An analysis of the normal breast tissue according to 
menopausal status may provide further insights into the hormonal effects on 
breast tissue permeability and perfusion.
Thus, this study demonstrated that conventional anthracycline-based 
chemotherapy has an effect on the tumour vascularity of primary breast cancers, 
in particular on microvessel permeability and perfusion, and that the early 
changes seen in these parameters following two cycles of treatment correlate 
with final clinico-pathological response. This study also demonstrated that the 
T1W DCE-MRI parameter, Ktrans, is able predict for pathological tumour 
response at the individual patient level with a PPV for non-response of 84%. 
This might enable the tailoring o f treatment according to individual tumour 
response and as such, prompt a therapy change that would hopefully improve 
patient outcome. This could be explored in an intervention study where the 
degree of change in K*™18 on T1W DCE-MRI following two cycles of FEC NAC 
would determine whether treatment was continued with FEC chemotherapy or 
whether a treatment change was instituted, for example, a change to a taxane 
drug.
What remains unclear from this study is whether FEC chemotherapy is having a 
direct anti-angiogenic effect on the primary breast cancer microvasulature or 
whether the chemotherapy is acting indirectly via an effect on the balance of 
pro-angiogenic and anti-angiogenic factors subsequent to tumour cell death. This 
could be further explored in vitro, for example, by evaluating the effect of 
anthracyclines directly on proliferating endothelial cells or by measuring the
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changes in angiogenic factor levels and angiogenic activity subsequent to 
tumour cell death and the effect of angiogenic factor re-exposure. In addition, 
the changes seen in the MRI-derived kinetic parameters in this study may be 
specific for FEC chemotherapy and as such, an evaluation of the effects of 
different chemotherapy agents, such as the taxanes, on the functional MRI 
parameters warrants investigation.
To further evaluate the vascular response to FEC chemotherapy in primary 
breast cancer, changes in angiogenesis as assessed at the histological tumour 
level was assessed and this study was described in Chapter 3. Using 
immunohistochemical staining techniques, a quantitative and a qualitative 
(functional) measure of tumour angiogenesis were evaluated in paired pre- and 
post-NAC pathological tumour specimens. Microvessel density (MVD) is a 
measure of the total number of microvessels seen within a high power field (x 
200 magnification) and informs upon the net effect of tumour angiogenesis and 
angio-regression. A monoclonal antibody against one of the pan-endothelial cell 
antigens is used to highlight the tumour vasculature and in this study, the anti- 
CD34 antibody was used. MVD, however, fails to inform upon the quality, or 
functional status, of the tumour vasculature. An assessment of the functional 
status of vessels may provide a better measure of the tumour angiogenic activity 
and may be more informative in terms of prognosis or predicting response to 
treatment. Pericyte recriutment to microvessels is thought to reflect vessel 
maturation, and therefore, pericyte coverage was used as a measure of the 
functional vascular status in this study. Using immunohistochemical double- 
staining with the pan-endothelial marker, anti-CD34, and the mural cell marker, 
alpha-smooth muscle actin (a-SMA), the pericyte coverage index (PCI) was 
defined as the number o f CD-34 and a-SMA positive vessels per high power 
field, expressed as a percentage of all CD-34 positive vessels within that field. 
Thus, a low PCI was reflective of an immature, proliferating tumour vasculature, 
while a high PCI represented a mature, more stabilised vasculature.
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Evaluation of the MVD and PCI in the pre-treatment diagnostic core-biopsy 
breast tumour specimens demonstrated a median MVD of 76.4/mm2 and a 
median PCI of 17.3%. Although continuous, the variables did not exhibit a 
normal distribution and hence non-parameteric statistical testing was used as a 
more robust method. This demonstrated that neither baseline MVD nor PCI 
correlated with the clinico-pathological response to treatment. Following 6 
cycles of neoadjuvant FEC chemotherapy, the median MVD and PCI values in 
the definitive surgical specimens were 72.2/mm2 and 25.5% respectively and the 
rise in PCI was found to be strongly significant (Wilcoxon’s signed ranks test, 
p<0.0001). Thus, despite no apparent change in the total number of tumour 
microvessels following NAC, the quality or functional status of the vessels does 
appear to change. NAC appears to have a “pruning” effect on the immature 
proliferating vessels resulting in an increase in the proportion of mature, 
stabilised vessels. A similar “pruning” effect on tumour vasculature has been 
observed in studies using anti-angiogenic agents, in particular the anti-VEGF 
agents [300-303], and has been termed vascular “normalisation” [304, 324]. This 
pruning effect results in a more “normal” and hence more efficient vasculature, 
with improvements in nutrient and drug delivery to the tumour bed. Further, 
there appears to be a “normalisation window” period during which combination 
therapy, for example, the anti-angiogenic agents and radiotherapy or cytotoxic 
chemotherapy, might work best.
The changes observed in PCI in this study would suggest anthracycline-based 
chemotherapy induces a similar effect. Further, the evaluation o f tumour VEGF 
expression prior to and following NAC within tumour specimens demonstrated a 
significant reduction in VEGF following chemotherapy. This reduction in VEGF 
production may, in part, represent the mechanism via which the chemotherapy is 
mediating its effect and may be a direct response to chemotherapy-induced cell 
death. The role of other angiogenic factors in this process, however, warrants 
further evaluation. For example, upregulation of the angiogenic factor, ang-1, 
has been shown in solid brain tumours following blockage of the VEGF-receptor 
2 and is thought to mediate the increase in vessel pericyte coverage and vascular 
normalisation [302].
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The results from the study described in Chapter 3 may assist in the development 
of rational drug combinations of cytotoxic chemotherapy and novel anti- 
angiogenic agents in the treatment of breast cancer. For example, if 
anthracycline-based chemotherapy is inducing a reduction in the immature 
proliferating vessels but failing to have an impact on the mature, more stabilised 
tumour vessels, then combination therapy with a novel agent that preferentially 
targets the mature blood vessels would be most appropriate. Further, if 
anthracycline-based chemotherapy is having its effect via a reduction in VEGF 
expression then further VEGF blockage may not necessarily improve tumour 
response, and the targeting alternative angiogenic factors might be more 
appropriate.
Change in MVD, PCI and VEGF expression failed to predict for clinico- 
pathological response to NAC, although a non-significant trend was observed 
towards an increase in PCI in the clinically responding group compared with the 
clinically non-responding. Failure of the baseline and changes in MVD to 
predict for response to NAC has been demonstrated by others [128-130] and 
Hlatky et al. have proposed that MVD cannot be used as a marker of response to 
treatment as it does not provide a direct measure of the angiogenic activity or the 
angiogenic dependence of a tumour [132]. PCI was assessed as a measure of 
“functional” vascular status, however, also failed to predict for response and it 
may be that more specific measures of activated endothelium need to be 
measured to predict for treatment response, for example, endoglin (CD 105) 
[142]. The evaluation of other markers reflecting endothelial actvitiy and 
functional vascular status is suggested. An alternative explanation for these 
negative results may be sampling error. Breast tumours are known to be 
heterogenous and the pre-treatment diagnostic core biopsy may not provide an 
accurate representation of the whole tumour. Indeed, consistency in terms of the 
tumour histological grade between the diagnostic core biopsy and the subsequent 
whole breast tumour following primary surgery varies between 76-90% [325, 
326].
281
The apparent vascular “normalisation” observed following NAC might in part 
explain the reduction in the permeability and perfusion-related DCE-MRI 
parameters observed in responding patients following two cycles of neoadjuvant 
chemotherapy. An assessment of the tumour MVD and PCI at this time-point 
might have determined whether this was the case or not. To further explore the 
pathophysiological correlates of the functional MRI kinetic parameters, the 
relationship between the MRI parameters and primary breast cancer features was 
evaluated and this study was described in Chapter 4.
The relationship between the functional MRI parameters and the conventional 
tumour histological features was assessed, as was the relationship with tumour 
MVD, PCI, VEGF expression and CA-IX staining (hypoxia-related marker) as 
evaluated from the pre-treatment diagnostic core biopsy specimens. Again non- 
parameteric statistical testing was used as a more robust method in the absence 
of a normal distribution of the data. This revealed a significant correlation 
between the permeability and perfusion-related DCE-MRI parameters and the 
aggressive tumour features of high grade and ER negative status. The increased 
vascularity of these tumours might explain, in part, their aggressive nature via an 
increased route of access for micrometastases into the peripheral circulation. No 
correlation was found, however, between the anigogenesis-related parameters 
(MVD, PCI and VEGF) and tumour grade or ER status, or any of the T1W or 
T2*W DCE-MRI parameters. A positive correlation was found between MVD 
and the BOLD MRI parameter, R2*, possibly reflecting hypoxia-driven 
angiogenesis, however, given the multiple testing this positive correltation may 
have occurred by chance. Doubt was cast over the role of R2* as a potential 
measure of the intra-tumour oxygenation level when CA-IX expression 
(hypoxia-related marker) within the tumour was found to be associated with a 
lower median R2*. A low R2* is thought to reflect low deoxyhaemoglobin and 
high oxygen levels, while a high R2* reflects the reverse and, as such, a positive 
association between CA IX staining and high R2* had been expected. It would 
appear, however, that R2* does not inform upon the tumour cellular oxygenation 
status in PBC but rather reflects the oxygenation level within the tumour vessels.
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Thus, a high R2* might be the result of high oxygen extraction by active tumour 
cells leading to a high intravascular deoxyhaemoglobin level in the absence of 
tumour hypoxia. The dominant effect of tumour blood flow and volume on R2* 
was further supported by the significant inverse correlation between R2* and 
both rBV and rBF. CA-IX staining was found to associate with higher rBV and 
rBF values and this may reflect hypoxia-induced angiogenesis. In addition, CA- 
IX was associated with the aggressive tumour features of high grade, ER 
negative status and necrosis.
Failure to demonstrate a positive correlation between the angiogenesis-related 
parameters and the functional MRI parameters measuring microvascular 
permeability and perfusion may reflect sampling differences between the MRI- 
defined tumour regions of interest (ROI) and the pathological specimens. The 
functional MRI parameter values were the median values measured from the 
whole tumour ROI, whereas MVD, PCI, VEGF and CA-IX were evaluated from 
a single random core-biopsy sample. However, others have attempted to make a 
comparison between T1W DCE-MRI kinetic parameters and tumour MVD 
(“hotspot” counting) using larger primary surgical breast cancer specimens with 
mixed results [174, 305, 307, 308]. It may be that failure to consistently 
demonstrate a correlation between these measures is a reflection of the disparity 
between the visible microvasculature as evaluated from a single “snap-shot” in 
time (i.e. pathological specimen) & the “real-time” functional microvasculature 
as measured by functional imaging.
In summary, this research has demonstrated a vascular response to neoadjuvant 
conventional anthracycline-based chemotherapy in primary breast cancer as 
assessed both by functional MRI and by immunohistochemical evaluation of 
pathological tumour specimens. The early vascular changes observed on DCE- 
MRI during treatment are able to predict for final clinico-pathological response 
and may enable more accurate tailoring of treatment to the individual with the 
aim of improving outcome. The pathophysiological correlates of functional MRI 
have also been explored. Further, FEC neoadjuvant chemotherapy appears to
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cause vascular “normalisation” and this process may be mediated through a 
reduction in VEGF expression. These findings should help in the rational design 
of future cytotoxic and anti-angiogenic combination therapies.
284
REFERENCES
1. National Statistics, Health, breast cancer. 2004, www.statistics.gov.uk.
2. Fisher, B., et al., Twenty-year follow-up o f a randomized trial comparing total 
mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment o f invasive 
breast cancer. N Engl J Med, 2002. 347(16): p. 1233-41.
3. EBCTCG, Poly chemotherapy for early breast cancer: an overview o f the randomised 
trials. Early Breast Cancer Trialists' Collaborative Group. Lancet, 1998.352(9132): p. 
930-42.
4. EBCTCG, Tamoxifen for early breast cancer: an overview o f the randomised trials. 
Early Breast Cancer Trialists' Collaborative Group. Lancet, 1998. 351(9114): p. 1451-
67.
5. EBCTCG, Effects o f chemotherapy and hormonal therapy for early breast cancer on 
recurrence and 15-year survival: an overview o f the randomised trials. Lancet, 2005. 
365(9472): p. 1687-717.
6. Kaufmann, M., et al., International expert panel on the use o f primary (preoperative) 
systemic treatment o f operable breast cancer: review and recommendations. J Clin 
Oncol, 2003.21(13): p. 2600-8.
7. Carter, C.L., C. Allen, and D.E. Henson, Relation o f tumor size, lymph node status, and 
survival in 24,740 breast cancer cases. Cancer, 1989. 63(1): p. 181-7.
8. Hopton, D.S., et al., Histological grading o f breast cancer; significance o f grade on 
recurrence and mortality. Eur J Surg Oncol, 1989.15(1): p. 25-31.
9. Elston, C. W. and I.O. Ellis, Pathological prognostic factors in breast cancer. I. The 
value o f histological grade in breast cancer: experience from a large study with long­
term follow-up. Histopathology, 1991.19(5): p. 403-10.
10. Ellis, I.O., et al., Pathological prognostic factors in breast cancer. II. Histological type. 
Relationship with survival in a large study with long-term follow-up. Histopathology, 
1992. 20(6): p. 479-89.
11. Collett, K., R. Skjaerven, and B.O. Maehle, The prognostic contribution o f estrogen 
and progesterone receptor status to a modified version o f the Nottingham Prognostic 
Index. Breast Cancer Res Treat, 1998. 48(1): p. 1-9.
12. Haybittle, J.L., et al., A prognostic index in primary breast cancer. Br J Cancer, 1982. 
45(3): p. 361-6.
13. Galea, M.H., et al., The Nottingham Prognostic Index in primary breast cancer. Breast 
Cancer Res Treat, 1992.22(3): p. 207-19.
14. Gunduz, N., B. Fisher, and E.A. Saffer, Effect o f surgical removal on the growth and 
kinetics o f residual tumor. Cancer Res, 1979. 39(10): p. 3861-5.
15. Fisher, B., et al., Presence o f a growth-stimulating factor in serum following primary 
tumor removal in mice. Cancer Res, 1989. 49(8): p. 1996-2001.
16. Fisher, B., et al., Effect o f local or systemic treatment prior to primary tumor removal 
on the production and response to a serum growth-stimulating factor in mice. Cancer 
Res, 1989. 49(8): p. 2002-4.
17. Bonadonna, G., et al., Primary chemotherapy to avoid mastectomy in tumors with 
diameters o f three centimeters or more. J Natl Cancer Inst, 1990. 82(19): p. 1539-45.
18. Hortobagyi, G.N., et al., Management o f stage III primary breast cancer with primary 
chemotherapy, surgery, and radiation therapy. Cancer, 1988. 62(12): p. 2507-16.
19. Gardin, G., et al., Locally advanced non-metastatic breast cancer: analysis o f 
prognostic factors in 125 patients homogeneously treated with a combined modality 
approach. Eur J Cancer, 1995.31A(9): p. 1428-33.
20. Smith, I.E., et al., High complete remission rates with primary neoadjuvant infusional 
chemotherapy for large early breast cancer. J Clin Oncol, 1995.13(2): p. 424-9.
21. Chollet, P., et al., Clinical and pathological response to primary chemotherapy in 
operable breast cancer. Eur J Cancer, 1997. 33(6): p. 862-6.
22. Kuerer, H.M., et al., Pathologic tumor response in the breast following neoadjuvant 
chemotherapy predicts axillary lymph node status. Cancer J Sci Am, 1998. 4(4): p. 230- 
6.
23. Fisher, B., et al., Effect ofpreoperative chemotherapy on the outcome o f women with 
operable breast cancer. J Clin Oncol, 1998.16(8): p. 2672-85.
285
24. Wolmark, N., et al., Preoperative chemotherapy in patients with operable breast 
cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-
18. J Natl Cancer Inst Monogr, 2001(30): p. 96-102.
25. Mauriac, L., et al., Neoadjuvant chemotherapy for operable breast carcinoma larger 
than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut 
Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol, 1999.10(1): p. 47-52.
26. Semiglazov, V.F., et al., Primary (neoadjuvant) chemotherapy and radiotherapy 
compared with primary radiotherapy alone in stage Ilb-IIIa breast cancer. Ann Oncol, 
1994. 5(7): p. 591-5.
27. Scholl, S.M., et al., Neoadjuvant versus adjuvant chemotherapy in premenopausal 
patients with tumours considered too large for breast conserving surgery: preliminary 
results of a randomised trial: S6. Eur J Cancer, 1994.30A(5): p. 645-52.
28. Powles, T.J., et al., Randomized trial o f chemoendocrine therapy started before or after 
surgery for treatment o f primary breast cancer. J Clin Oncol, 1995.13(3): p. 547-52.
29. Makris, A., et al., A reduction in the requirements for mastectomy in a randomized trial 
of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol, 1998. 
9(11): p. 1179-84.
30. van der Hage, J.A., et al., Preoperative chemotherapy in primary operable breast 
cancer: results from the European Organization for Research and Treatment o f Cancer 
trial 10902. J Clin Oncol, 2001.19(22): p. 4224-37.
31. Reichman, B.S., et al., Taxol and recombinant human granulocyte colony-stimulating 
factor, an active regimen as initial therapy for metastatic breast cancer. A preliminary 
report. Ann N Y Acad Sci, 1993. 698: p. 398-402.
32. Holmes, F.A., et al., Phase 11 trial o f taxol, an active drug in the treatment o f metastatic 
breast cancer. J Natl Cancer Inst, 1991. 83(24): p. 1797-805.
33. Chan, S., et al., Prospective randomized trial o f docetaxel versus doxorubicin in 
patients with metastatic breast cancer. J Clin Oncol, 1999.17(8): p. 2341-54.
34. Seidman, A.D., et al., Paclitaxel as second and subsequent therapy for metastatic 
breast cancer: activity independent o f prior anthracycline response. J Clin Oncol,
1995.13(5): p. 1152-9.
35. Nabholtz, J.M., et al., Prospective randomized trial o f docetaxel versus mitomycin plus 
vinblastine in patients with metastatic breast cancer progressing despite previous 
anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol, 1999.17(5): 
p. 1413-24.
36. Smith, I.C., et al., Neoadjuvant chemotherapy in breast cancer: significantly enhanced 
response with docetaxel. J Clin Oncol, 2002. 20(6): p. 1456-66.
37. Hutcheon, A.W., Heys, S.W., Sarkar, T.K., Eremin, O., Walker, L.G., Miller, I.D., 
Docetaxel primary chemotherapy in breast cancer: a five year update o f the Aberdeen 
trial. Breast Cancer Res Treat, 2003. 82: p. S9 ( supplement 1, abstract 11).
38. Bear, H.D., et al., The effect on tumor response of adding sequential preoperative 
docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from 
National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol, 
2003. 21(22): p. 4165-74.
39. Bear, H.D. A randomized trial comparingpreooperative (preop) 
doxorubicin/cyclophosphamide (AC) to preop AC followed by preop docetaxel (T) and 
to preop AC followed by postoperative (postop) T in patients (pts) with operable 
carcinoma o f the breast: results o f the NSABP B-27. in San Antonio Breast Cancer 
Symposium. 2004. San Antonio, Texas, USA.
40. Buzdar, A.U., et al., Prospective evaluation o f paclitaxel versus combination 
chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant 
therapy in patients with operable breast cancer. J Clin Oncol, 1999.17(11): p. 3412-7.
41. Gianni, L., Baselga, J., Eiermann, N. et al., First report of the European Cooperative 
Trial in operable breast cancer (ECTO): Effects o f primary systemic therapy (PST) on 
locoregional disease. Proc Am Soc Clin Oncol, 2002.21: p. 34a (abstract 132).
42. Green, M.C., Budzar, A.U., Smith, T., Ibrahim, N.K., Valero, V., Rosales, M., 
Crostofanilli, M., Booser, D.J., Pusztai, L., Rivera, E., Theriault, R., Carter, C., 
Singletary, S.E., Kuerer, H.M., Hunt, K., Strom, E., Hortobagyi, G.N., Weekly 
paclitaxel followed by FAC as primary systemic chemotherapy o f operable breast 
cancer improves pathologic complete remission rates when compared to every 3 week
286
paclitaxel therapy followed by FAC - final results o f a prospective randomised trial 
Proc Am Soc Clin Oncol, 2002. 21: p. 35a (abstract 135).
43. Jackisch, C., et al., Dose-dense biweekly doxorubicin/docetaxel versus sequential 
neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable 
breast cancer: second interim analysis. Clin Breast Cancer, 2002.3(4): p. 276-80.
44. Budzar, A.U., et al., Significantly higher pathological complete remission (PCR) rate 
following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline- 
containing chemotherapy (CT): initial results o f a randomized trial in operable breast 
cancer (BC) with HER/2 positive disease. Meeting Proceedings of American Society of 
Clinical Oncology, 2004. Vol. 23.
45. von Minckwitz, G., et al., In vivo chemosensitivity-adaptedpreoperative chemotherapy 
in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol, 
2005.16(1): p. 56-63.
46. Gusterson, B.A., et al., Prognostic importance o f c-erbB-2 expression in breast cancer. 
International (Ludwig) Breast Cancer Study Group. J Clin Oncol, 1992.10(7): p. 1049- 
56.
47. Paik, S., et al., erbB-2 and response to doxorubicin in patients with axillary lymph 
node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst, 1998. 
90(18): p. 1361-70.
48. Yamauchi, H., V. Stearns, and D.F. Hayes, When Is a Tumor Marker Ready for Prime 
Time? A Case Study o f c-erbB-2 as a Predictive Factor in Breast Cancer. J Clin Oncol, 
2001.19(8): p. 2334-2356.
49. Allred, D.C., et al., Prognostic and predictive factors in breast cancer by 
immunohistochemical analysis. Mod Pathol, 1998.11(2): p. 155-68.
50. Lippman, M.E. and J.C. Allegra, Quantitative estrogen receptor analyses: the response 
to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free 
interval. Cancer, 1980. 46(12 Suppl): p. 2829-34.
51. Bardou, V.J., et al., Progesterone receptor status significantly improves outcome 
prediction over estrogen receptor status alone for adjuvant endocrine therapy in two 
large breast cancer databases. J Clin Oncol, 2003. 21(10): p. 1973-9.
52. Mortimer, J., et al., Influence o f estrogen receptor status on response to combination 
chemotherapy for recurrent breast cancer. Cancer Treat Rep, 1981. 65(9-10): p. 763-6.
53. Lippman, M.E. and J.C. Allegra, Lack o f estrogen receptor associated with an 
increased response rate to cytotoxic chemotherapy in metastatic breast cancer? Recent 
Results Cancer Res, 1980. 71: p. 155-61.
54. Young, P.C., C.E. Ehrlich, and L.H. Einhom, Relationship between steroid receptors 
and response to endocrine therapy and cytotoxic chemotherapy in metastatic breast 
cancer. Cancer, 1980. 46(12 Suppl): p. 2961-3.
55. Kiang, D.T., et al., Estrogen receptors and responses to chemotherapy and hormonal 
therapy in advanced breast cancer. N Engl J Med, 1978. 299(24): p. 1330-4.
56. Makris, A., et al., Prediction o f response to neoadjuvant chemoendocrine therapy in 
primary breast carcinomas. Clin Cancer Res, 1997. 3(4): p. 593-600.
57. Chang, J., et al., Biologic markers as predictors o f clinical outcome from systemic 
therapy for primary operable breast cancer. J Clin Oncol, 1999.17(10): p. 3058-63.
58. Cleator, S.J., et al., Good clinical response o f breast cancers to neoadjuvant 
chemoendocrine therapy is associated with improved overall survival. Ann Oncol, 
2005.16(2): p. 267-72.
59. Penault-Llorca, F., et al., Induction chemotherapy for breast carcinoma: predictive 
markers and relation with outcome. Int J Oncol, 2003. 22(6): p. 1319-25.
60. Bottini, A., et al., Effect o f neoadjuvant chemotherapy on Ki67 labelling index, c-erbB- 
2 expression and steroid hormone receptor status in human breast tumours. Anticancer 
Res, 1996.16(5B): p. 3105-10.
61. Burcombe, R.J., et al., Evaluation o f ER, PgR, HER-2 and Ki-67 as predictors of 
response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J 
Cancer, 2005. 92(1): p. 147-55.
62. Colleoni, M., et al., Response to primary chemotherapy in breast cancer patients with 
tumors not expressing estrogen and progesterone receptors. Ann Oncol, 2000.11(8): p. 
1057-9.
63. Faneyte, I.F., et al., Breast cancer response to neoadjuvant chemotherapy: predictive 
markers and relation with outcome. Br J Cancer, 2003. 88(3): p. 406-12.
287
64. Assersohn, L., et al., Studies of the potential utility of Ki67 as a predictive molecular 
marker o f clinical response in primary breast cancer. Breast Cancer Res Treat, 2003. 
82(2): p. 113-23.
65. Bottini, A., et al., Relationship between tumour shrinkage and reduction in Ki67 
expression after primary chemotherapy in human breast cancer. Br J Cancer, 2001. 
85(8): p. 1106-12.
66. Vincent-Salomon, A., et al., Proliferation markers predictive o f the pathological 
response and disease outcome o f patients with breast carcinomas treated by 
anthracycline-based preoperative chemotherapy. Eur J Cancer, 2004. 40(10): p. 1502- 
8 .
67. Collecchi, P., et al., Primary chemotherapy in locally advanced breast cancer (LABC): 
effects on tumour proliferative activity, bcl-2 expression and the relationship between 
tumour regression and biological markers. Eur J Cancer, 1998. 34(11): p. 1701-4.
68. Steams, V., et al., A prospective randomized pilot study to evaluate predictors of 
response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel 
for patients with locally advanced breast cancer. Clin Cancer Res, 2003. 9(1): p. 124-
33.
69. Archer, C.D., et al., Early changes in apoptosis and proliferation following primary 
chemotherapy for breast cancer. Br J Cancer, 2003. 89(6): p. 1035-41.
70. Chang, J., et al., Apoptosis and proliferation as predictors of chemotherapy response in 
patients with breast carcinoma. Cancer, 2000. 89(11): p. 2145-52.
71. Kallab, A.M., et al., Immunohistochemical tumour markers do not predict response to 
neoadjuvant doxorubicin and doctaxel in breast cancer. Meeting Proceedings of 
American Society of Clinical Oncology, 2004. Vol. 23: p. Abstract 794.
72. Perou, C.M., et al., Molecular portraits o f human breast tumours. Nature, 2000. 
406(6797): p. 747-52.
73. Chang, J.C., et al., Gene expression profiling for the prediction o f therapeutic response 
to docetaxel in patients with breast cancer. Lancet, 2003.362(9381): p. 362-9.
74. Pierga, J.Y., et al., Prognostic factors for survival after neoadjuvant chemotherapy in 
operable breast cancer, the role o f clinical response. Eur J Cancer, 2003. 39(8): p. 
1089-96.
75. Bonadonna, G., et al., Primary chemotherapy in operable breast cancer: eight-year 
experience at the Milan Cancer Institute. J Clin Oncol, 1998.16(1): p. 93-100.
76. Gajdos, C., et al., Relationship of clinical and pathologic response to neoadjuvant 
chemotherapy and outcome o f locally advanced breast cancer. J Surg Oncol, 2002. 
80(1): p. 4-11.
77. Allen, S. A., et al., Pre-operative estimation o f primary breast cancer size: a 
comparison o f clinical assessment, mammography and ultrasound. Breast, 2001.10(4): 
p. 299-305.
78. Meden, H., et al., A clinical, mammographic, sonographic and histologic evaluation of 
breast cancer. Int J Gynaecol Obstet, 1995. 48(2): p. 193-9.
79. Forouhi, P., et al., Ultrasonography as a method o f measuring breast tumour size and 
monitoring response to primary systemic treatment. Br J Surg, 1994. 81(2): p. 223-5.
80. Pain, J.A., et al., Assessment o f breast cancer size: a comparison o f methods. Eur J Surg 
Oncol, 1992.18(1): p. 44-8.
81. Fomage, B.D., O. Toubas, and M. Morel, Clinical, mammographic, and sonographic 
determination o f preoperative breast cancer size. Cancer, 1987. 60(4): p. 765-71.
82. Herrada, J., et al., Relative value o f physical examination, mammography, and breast 
sonography in evaluating the size o f the primary tumor and regional lymph node 
metastases in women receiving neoadjuvant chemotherapy for locally advanced breast 
carcinoma. Clin Cancer Res, 1997.3(9): p. 1565-9.
83. Feldman, L.D., et al., Pathological assessment o f response to induction chemotherapy 
in breast cancer. Cancer Res, 1986. 46(5): p. 2578-81.
84. Smith, I.C., et al., Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose 
to predict the pathologic response o f breast cancer to primary chemotherapy. J Clin 
Oncol, 2000.18(8): p. 1676-88.
85. Delille, J.P., et al., Invasive ductal breast carcinoma response to neoadjuvant 
chemotherapy: nonirtvasive monitoring with functional MR imaging pilot study. 
Radiology, 2003. 228(1): p. 63-9.
288
86. Drew, P.J., et al., Evaluation o f response to neoadjuvant chemoradiotherapy for locally 
advanced breast cancer with dynamic contrast-enhanced MRI o f the breast. Eur J Surg 
Oncol, 2001. 27(7): p. 617-20.
87. Abraham, D.C., et al., Evaluation o f neoadjuvant chemotherapeutic response o f locally 
advanced breast cancer by magnetic resonance imaging. Cancer, 1996. 78(1): p. 91- 
100.
88. Rieber, A., et al., Breast MRIfor monitoring response of primary breast cancer to neo­
adjuvant chemotherapy. Eur Radiol, 2002.12(7): p. 1711-9.
89. Esserman, L., et al., Utility o f magnetic resonance imaging in the management of breast 
cancer: evidence for improved preoperative staging. J Clin Oncol, 1999.17(1): p. 110-
9.
90. Harms, S.E., et al., MR imaging o f the breast with rotating delivery o f excitation off 
resonance: clinical experience with pathologic correlation. Radiology, 1993.187(2): p. 
493-501.
91. Martincich, L., et al., Monitoring response to primary chemotherapy in breast cancer 
idsing dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res 
Treat, 2004. 83(1): p. 67-76.
92. Folkman, J., New perspectives in clinical oncology from angiogenesis research, in Eur 
J  Cancer. 1996. p. 2534-2539.
93. Folkman, J., The role o f angiogenesis in tumor growth. Semin Cancer Biol, 1992. 3(2): 
p. 65-71.
94. Senger, D.R., et al., Tumor cells secrete a vascular permeability factor that promotes 
accumulation o f ascites fluid. Science, 1983. 219(4587): p. 983-5.
95. Ferrara, N., Role o f vascular endothelial growth factor in physiologic and pathologic 
angiogenesis: therapeutic implications. Semin Oncol, 2002. 29(6 Suppl 16): p. 10-4.
96. Rak, J., et al., Oncogenes and tumor angiogenesis: differential modes o f vascular 
endothelial growth factor up-regulation in ras-transformed epithelial cells and 
fibroblasts. Cancer Res, 2000.60(2): p. 490-8.
97. Toi, M., T. Matsumoto, and H. Bando, Vascular endothelial growth factor: its 
prognostic, predictive, and therapeutic implications. Lancet Oncol, 2001. 2(11): p. 667-
73.
98. Jain, R.K., Molecular regulation o f vessel maturation. Nat Med, 2003. 9(6): p. 685-93.
99. Liu, W., et al., Antiangiogenic therapy targeting factors that enhance endothelial cell 
survival. Semin Oncol, 2002.29(3 Suppl 11): p. 96-103.
100. Gasparini, G., et al., Prognostic significance o f vascular endothelial growth factor 
protein in node-negative breast carcinoma. J Natl Cancer Inst, 1997. 89(2): p. 139-47.
101. Linderholm, B., et al., p53 and vascular-endothelial-growth-factor (VEGF) expression 
predicts outcome in 833 patients with primary breast carcinoma. Int J Cancer, 2000. 
89(1): p. 51-62.
102. Toi, M., et al., Tumor angiogenesis in breast cancer: its importance as a prognostic 
indicator and the association with vascular endothelial growth factor expression.
Breast Cancer Res Treat, 1995.36(2): p. 193-204.
103. Ragaz, J., Miller, K., Badve, S., Dayachko, Y., Dunn, S., Nielsen, T., Brodie, A., 
Huntsman, D., Bajdik, C., Sledge, G.„ Adverse association o f expression o f vascular 
endothelial growth factor(VEGF) with long-term outcome o f stage /-/// breast cancer, 
with co-expression data o f VEGF and HER2, Cox2, uPA and ER. Results from the 
British Columbia Tissue Microarray project. Proc Am Soc Clin Oncol, 2004. 22(14S): 
p. 8S (abstract 524).
104. Adams, J., et al., Vascular endothelial growth factor (VEGF) in breast cancer: 
comparison o f plasma, serum, and tissue VEGF and microvessel density and effects o f 
tamoxifen. Cancer Res, 2000. 60(11): p. 2898-905.
105. Lissoni, P., et al., Chemotherapy and angiogenesis in advanced cancer: vascular 
endothelial growth factor (VEGF) decline as predictor of disease control during taxol 
therapy in metastatic breast cancer. Int J Biol Markers, 2000.15(4): p. 308-11.
106. Lantzsch, T., et al., The correlation between immunohistochemically-detected markers 
of angiogenesis and serum vascular endothelial growth factor in patients with breast 
cancer. Anticancer Res, 2002.22(3): p. 1925-8.
107. Mulcahy, M.F. and A.B. Benson, 3rd, Bevacizumab in the treatment o f colorectal 
cancer. Expert Opin Biol Ther, 2005. 5(7): p. 997-1005.
289
108. Konner, J. and J. Dupont, Use o f soluble recombinant decoy receptor vascular 
endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth 
factor activity. Clin Colorectal Cancer, 2004.4 Suppl 2: p. S81-5.
109. Klement, G., et al., Continuous low-dose therapy with vinblastine and VEGF receptor-2 
antibody induces sustained tumor regression without overt toxicity. J Clin Invest, 2000. 
105(8): p. R15-24.
110. Ciardiello, F., et al., Antitumor effects ofZD6474, a small molecule vascular 
endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity 
against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res, 2003. 9(4): 
p. 1546-56.
111. Thomas, A.L., et al., Vascular endothelial growth factor receptor tyrosine kinase 
inhibitors: PTK787/ZK 222584. Semin Oncol, 2003. 30(3 Suppl 6): p. 32-8.
112. Miller, K.D., et al., Phase III trial o f capecitabine plus bevacizumab versus 
capecitabine alone in women with metastatic breast cancer previously treated with an 
anthracycline and a taxane. Breast Cancer Res Treat, 2002. 71(Supplement 1).
113. Vermeulen, P.B., et al., Quantification o f angiogenesis in solid human tumours: an 
international consensus on the methodology and criteria o f evaluation. Eur J Cancer, 
1996.32A(14): p. 2474-84.
114. Lee, A.H.S., Happerfield, L.C., Bobrow, L.G., Comparison o f four endothelial markers 
for asessing angiogenesis in carcinoma o f the breast. Journal of Cellular Pathology, 
1997. 2(2): p. 67-73.
115. Yamazaki, K., Eyden, B.P., Ultrastructural and immunohistochemical observations in
intralobular fibroblasts o f human breast, with pbservation on the CD34 antigen. J 
Submicrosc Cytol Pathol, 1995. 27: p. 309 - 323.
116. Martin, L., et al., Examining the technique o f angiogenesis assessment in invasive 
breast cancer. Br J Cancer, 1997. 76(8): p. 1046-54.
117. Weidner, N., et al., Tumor angiogenesis and metastasis—correlation in invasive breast 
carcinoma. N Engl J Med, 1991. 324(1): p. 1-8.
118. Weidner, N., et al., Tumor angiogenesis: a new significant and independent prognostic 
indicator in early-stage breast carcinoma. J Natl Cancer Inst, 1992. 84(24): p. 1875-87.
119. Folkman, J., Angiogenesis and breast cancer. J Clin Oncol, 1994.12(3): p. 441-3.
120. Fox, S.B., et al., Tumor angiogenesis in node-negative breast carcinomas—relationship 
with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer 
Res Treat, 1994.29(1): p. 109-16.
121. Hansen, S., et al., The prognostic value o f angiogenesis by Chalkley counting in a 
confirmatory study design on 836 breast cancer patients. Clin Cancer Res, 2000. 6(1): 
p. 139-46.
122. Fox, S.B., Tumour angiogenesis and prognosis. Histopathology, 1997. 30(3): p. 294- 
301.
123. Hasan, J., R. Byers, and G.C. Jayson, Intra-tumoural microvessel density in human 
solid tumours. Br J Cancer, 2002. 86(10): p. 1566-77.
124. Fitzgibbons, P.L., et al., Prognostic factors in breast cancer. College ofAmerican 
Pathologists Consensus Statement 1999. Arch Pathol Lab Med, 2000.124(7): p. 966-
78.
125. Vermeulen, P.B., et al., Second international consensus on the methodology and 
criteria o f evaluation o f angiogenesis quantification in solid human tumours. Eur J 
Cancer, 2002.38(12): p. 1564-79.
126. Colpaert, C., et al., lntratumoral hypoxia resulting in the presence o f a fibrotic focus is 
an independent predictor o f early distant relapse in lymph node-negative breast cancer 
patients. Histopathology, 2001.39(4): p. 416-25.
127. Guidi, A.J., et al., Association o f angiogenesis and disease outcome in node-positive 
breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and 
fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 
8541/8869. J Clin Oncol, 2002. 20(3): p. 732-42.
128. Makris, A., et al., Reduction in angiogenesis after neoadjuvant chemoendocrine therapy 
in patients with operable breast carcinoma. Cancer, 1999. 85(9): p. 1996-2000.
129. Bottini, A., et al., Changes in microvessel density as assessed by CD34 antibodies after 
primary chemotherapy in human breast cancer. Clin Cancer Res, 2002. 8(6): p. 1816- 
21 .
290
130. Tynninen, O., et al., Tumour microvessel density as predictor o f chemotherapy 
response in breast cancer patients. Br J Cancer, 2002. 86(12): p. 1905-8.
131. Marson, L.P., et al., The effect o f tamoxifen on breast tumour vascularity. Breast Cancer 
Res Treat, 2001.66(1): p. 9-15.
132. Hlatky, L., P. Hahnfeldt, and J. Folkman, Clinical application o f antiangiogenic 
therapy: microvessel density, what it does and doesn’t tell us. J Natl Cancer Inst, 2002. 
94(12): p. 883-93.
133. Eberhard, A., et al., Heterogeneity o f angiogenesis and blood vessel maturation in 
human tumors: implications for antiangiogenic tumor therapies. Cancer Res, 2000. 
60(5): p. 1388-93.
134. Beecken, W.D., et al., Effect o f antiangiogenic therapy on slowly growing, poorly 
vascularized tumors in mice. J Natl Cancer Inst, 2001. 93(5): p. 382-7.
135. Lindahl, P., et al., Pericyte loss and microaneurysm formation in PDGF-B-deficient 
mice. Science, 1997. 277(5323): p. 242-5.
136. Benjamin, L.E., et al., Selective ablation o f immature blood vessels in established 
human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest, 
1999.103(2): p. 159-65.
137. Gee, M.S., et al., Tumor vessel development and maturation impose limits on the 
effectiveness o f anti-vascular therapy. Am J Pathol, 2003.162(1): p. 183-93.
138. Kakolyris, S., et al., Relationship o f vascular maturation in breast cancer blood vessels 
to vascular density and metastasis, assessed by expression o f a novel basement 
membrane component, LH39. Br J Cancer, 2000. 82(4): p. 844-51.
139. Kakolyris, S., et al., Assessment o f vascular maturation in lung and breast carcinomas 
using a novel basement membrane component, LH39. Anticancer Res, 2001. 21(6B): p. 
4311-6.
140. Almeida, B.M., et al., A novel lamina lucida component o f epithelial and endothelial 
basement membranes detected by LH39 monoclonal antibody. J Pathol, 1992.166(3): p. 
243-53.
141. Almeida, B.M., et al., The distribution o f LH39 basement membrane epitope in the 
tumour stroma o f oral squamous cell carcinomas. J Pathol, 1992.166(4): p. 369-74.
142. Kumar, S., et al., Breast carcinoma: vascular density determined using CD105 
antibody correlates with tumor prognosis. Cancer Res, 1999. 59(4): p. 856-61.
143. Wang, J.M., et al., A monoclonal antibody detects heterogeneity in vascular 
endothelium o f tumours and normal tissues. Int J Cancer, 1993. 54(3): p. 363-70.
144. Kaiser, W.A. and E. Zeitler, MR imaging o f the breast: fast imaging sequences with and 
without Gd-DTPA. Preliminary observations. Radiology, 1989.170(3 Pt 1): p. 681-6.
145. Heywang, S.H., et al., MR imaging o f the breast with Gd-DTPA: use and limitations. 
Radiology, 1989.171(1): p. 95-103.
146. Fobben, E.S., et al., Breast MR imaging with commercially available techniques: 
radiologic-pathologic correlation. Radiology, 1995.196(1): p. 143-52.
147. Stomper, P.C., et al., Suspect breast lesions: findings at dynamic gadolinium-enhanced 
MR imaging correlated with mammographic and pathologic features. Radiology, 1995. 
197(2): p. 387-95.
148. Orel, S.G., et al., Suspicious breast lesions: MR imaging with radiologic-pathologic 
correlation. Radiology, 1994.190(2): p. 485-93.
149. Padhani, A.R. and A. Dzik-Jurasz, Perfusion MR imaging o f extracranial tumor 
angiogenesis. Top Magn Reson Imaging, 2004.15(1): p. 41-57.
150. Boetes, C., et al., MR characterization o f suspicious breast lesions with a gadolinium- 
enhanced TurboFLASH subtraction technique. Radiology, 1994.193(3): p. 777-81.
151. Flickinger, F. W., et al., Differentiation o f benign from malignant breast masses by time- 
intensity evaluation o f contrast enhanced MRI. Magn Reson Imaging, 1993.11(5): p. 
617-20.
152. Gilles, R., et al., Assessment o f breast cancer recurrence with contrast-enhanced 
subtraction MR imaging: preliminary results in 26patients. Radiology, 1993.188(2): p. 
473-8.
153. Roberts, T.P., Physiologic measurements by contrast-enhanced MR imaging: 
expectations and limitations. J Magn Reson Imaging, 1997. 7(1): p. 82-90.
154. Kuhl, C.K., et al., Dynamic breast MR imaging: are signal intensity time course data 
useful for differential diagnosis o f enhancing lesions? Radiology, 1999. 211(1): p. 101- 
10.
291
155. Liu, P.F., et al., Improved diagnostic accuracy in dynamic contrast enhanced MRI of 
the breast by combined quantitative and qualitative analysis. Br J Radiol, 1998. 
71(845): p. 501-9.
156. Denton, E.R., et al., Comparison and evaluation o f rigid, affine, and nonrigid 
registration o f breast MR images. J Comput Assist Tomogr, 1999. 23(5): p. 800-5.
157. Ikeda, D.M., et al., Development, standardization, and testing o f a lexicon for reporting 
contrast-enhanced breast magnetic resonance imaging studies. J Magn Reson Imaging, 
2001.13(6): p. 889-95.
158. Gribbestad, I.S., et al., Comparative signal intensity measurements in dynamic 
gadolinium-enhanced MR mammography. J Magn Reson Imaging, 1994. 4(3): p. 477-
80.
159. Evelhoch, J.L., Key factors in the acquisition o f contrast kinetic data for oncology. J 
Magn Reson Imaging, 1999.10(3): p. 254-9.
160. Parker, G.J., et al., Probing tumor microvascularity by measurement, analysis and 
display of contrast agent uptake kinetics. J Magn Reson Imaging, 1997. 7(3): p. 564-74.
161. Tofts, P.S. and A.G. Kermode, Measurement o f the blood-brain barrier permeability 
and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson 
Med, 1991.17(2): p. 357-67.
162. Tofts, P.S., et al., Estimating kinetic parameters from dynamic contrast-enhanced T(l)~ 
weighted MRI o f a diffusable tracer: standardized quantities and symbols. J Magn 
Reson Imaging, 1999.10(3): p. 223-32.
163. Tofts, P.S., Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson 
Imaging, 1997. 7(1): p. 91-101.
164. Tofts, P.S., B. Berkowitz, and M.D. Schnall, Quantitative analysis o f dynamic Gd- 
DTPA enhancement in breast tumors using a permeability model. Magn Reson Med, 
1995.33(4): p. 564-8.
165. den Boer, J.A., et al., Pharmacokinetic analysis o f Gd-DTPA enhancement in dynamic 
three-dimensional MRI o f breast lesions. J Magn Reson Imaging, 1997. 7(4): p. 702-15.
166. Knopp, M.V., et al., Pathophysiologic basis o f contrast enhancement in breast tumors, 
in J  Magn Reson Imaging. 1999. p. 260-6.
167. Buadu, L.D., et al., Breast lesions: correlation o f contrast medium enhancement 
patterns on MR images with histopathologic findings and tumor angiogenesis, in 
Radiology. 1996. p. 639-49.
168. Matsubayashi, R., et al., Breast masses with peripheral rim enhancement on dynamic 
contrast-enhanced MR images: correlation o f MR findings with histologic features and 
expression o f growth factors, in Radiology. 2000. p. 841-8.
169. Weidner, N., Tumoural vascularity as a prognostic factor in cancer patients: the 
evidence continues to grow, in J  Pathol. 1998. p. 119-22.
170. Stamper, P.C., et al., Angiogenesis and dynamic MR imaging gadolinium enhancement 
of malignant and benign breast lesions, in Breast Cancer Res Treat. 1997. p. 39-46.
171. Buckley, D.L., et al., Microvessel density o f invasive breast cancer assessed by dynamic 
Gd-DTPA enhanced MRI, in J  Magn Reson Imaging. 1997. p. 461-4.
172. Hulka, C. A., et al., Dynamic echo-planar imaging o f the breast: experience in 
diagnosing breast carcinoma and correlation with tumor angiogenesis, in Radiology. 
1997. p. 837-42.
173. Su, M. Y., et al., Correlation o f dynamic contrast enhancement MRI parameters with 
microvessel density and VEGF for assessment o f angiogenesis in breast cancer, in J  
Magn Reson Imaging. 2003. p. 467-77.
174. Su, M.Y., et al., Correlation o f dynamic contrast enhancement MRI parameters with 
microvessel density and VEGF for assessment o f angiogenesis in breast cancer. J Magn 
Reson Imaging, 2003.18(4): p. 467-77.
175. Hartmann, L.C., et al., Efficacy o f bilateral prophylactic mastectomy in women with a 
family history o f breast cancer. N Engl J Med, 1999. 340(2): p. 77-84.
176. Rebbeck, T.R., et al., Bilateral prophylactic mastectomy reduces breast cancer risk in 
BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol, 2004. 
22(6): p. 1055-62.
177. Rebbeck, T.R., et al., Breast cancer risk after bilateral prophylactic oophorectomy in 
BRCA1 mutation carriers. J Natl Cancer Inst, 1999. 91(17): p. 1475-9.
292
178. Fisher, B., et al., Tamoxifen for prevention o f breast cancer: report o f the National 
Surgical Adjuvant Breast and Bowel Project P-l Study. J Natl Cancer Inst, 1998.
90(18): p. 1371-88.
179. King, M.C., et al., Tamoxifen and breast cancer incidence among women with inherited 
mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel 
Project (NSABP-P1) Breast Cancer Prevention Trial. Jama, 2001. 286(18): p. 2251-6.
180. Thurfjell, E.L. and J.A. Lindgren, Breast cancer survival rates with mammographic 
screening: similar favorable survival rates for women younger and those older than 50 
years. Radiology, 1996. 201(2): p. 421-6.
181. Bjurstam, N., et al., The Gothenburg Breast Screening Trial. Cancer, 2003. 97(10): p. 
2387-96.
182. Brekelmans, C.T., et al., Effectiveness o f breast cancer surveillance in BRCA1/2 gene 
mutation carriers and women with high familial risk. J Clin Oncol, 2001.19(4): p. 924- 
30.
183. Deniz, K., et al., Breast cancer in women after treatment for Hodgkin's disease. Lancet 
Oncol, 2003. 4(4): p. 207-14.
184. Fourquet, A., A. De La Rochefordiere, and F. Campana, Occult primary cancer with 
axillary metastases, in Diseases o f the breast, L.M. Harris JR, Morrow M, Heilman S 
(Eds), Editor. 1996, Lippincott-Raven: Philadelphia, Pa. p. 892-896.
185. Rosen, P.P. and M. Kimmel, Occult breast carcinoma presenting with axillary lymph 
node metastases: a follow-up study o f 48 patients. Hum Pathol, 1990. 21(5): p. 518-23.
186. Fortunato, L., et al., Occult breast cancer. A case report and review o f the literature. N 
Y State J Med, 1992. 92(12): p. 555-7.
187. Ellerbroek, N., et al., Treatment ofpatients with isolated axillary nodal metastases from 
an occult primary carcinoma consistent with breast origin. Cancer, 1990. 66(7): p. 
1461-7.
188. Orel, S.G., et al., Breast MR imaging in patients with axillary node metastases and 
unknown primary malignancy. Radiology, 1999. 212(2): p. 543-9.
189. Olson, J.A., Jr., et al., Magnetic resonance imaging facilitates breast conservation for 
occult breast cancer. Ann Surg Oncol, 2000. 7(6): p. 411-5.
190. Tilanus-Linthorst, M.M., et al., MRI in patients with axillary metastases o f occult 
breast carcinoma. Breast Cancer Res Treat, 1997. 44(2): p. 179-82.
191. Schom, C., et al., MRI o f the breast in patients with metastatic disease o f unknown 
primary. Eur Radiol, 1999. 9(3): p. 470-3.
192. Knapper, W.H., Management o f occult breast cancer presenting as an axillary 
metastasis. Semin Surg Oncol, 1991. 7(5): p. 311-3.
193. T akehara, M., et al., Examination o f breast conserving therapy in lobular carcinoma. 
Breast Cancer, 2004.11(1): p. 69-72.
194. Diekmann, F., et al., [Preoperative MRT of the breast in invasive lobular carcinoma in 
comparison with invasive ductal carcinoma]. Rofo Fortschr Geb Rontgenstr Neuen 
Bildgeb Verfahr, 2004.176(4): p. 544-9.
195. Qayyum, A., et al., MR imaging features o f infiltrating lobular carcinoma of the breast: 
histopathologic correlation. AJR Am J Roentgenol, 2002.178(5): p. 1227-32.
196. Yeh, E.D., et al., Invasive lobular carcinoma: spectrum of enhancement and 
morphology on magnetic resonance imaging. Breast J, 2003. 9(1): p. 13-8.
197. Ringberg, A., B. Palmer, and F. Linell, The contralateral breast at reconstructive 
surgery after breast cancer operation--a histopathological study. Breast Cancer Res 
Treat, 1982.2(2): p. 151-61.
198. Rosen, P.P., et al., Noninvasive breast carcinoma: frequency of unsuspected invasion 
and implications for treatment. Ann Surg, 1979.189(3): p. 377-82.
199. Ciatto, S., et al., In situ ductal carcinoma of the breast—analysis o f clinical presentation 
and outcome in 156 consecutive cases. Eur J Surg Oncol, 1990.16(3): p. 220-4.
200. Holland, R., et al., Extent, distribution, and mammographic/histological correlations of 
breast ductal carcinoma in situ. Lancet, 1990. 335(8688): p. 519-22.
201. Neubauer, H., et al., High grade and non-high grade ductal carcinoma in situ on 
dynamic MR mammography: characteristic findings for signal increase and 
morphological pattern o f enhancement. Br J Radiol, 2003. 76(901): p. 3-12.
202. Gilles, R., et al., Ductal carcinoma in situ: MR imaging-histopathologic correlation. 
Radiology, 1995.196(2): p. 415-9.
293
203. Liberman, L., et al., Ductal enhancement on MR imaging o f the breast. AJR Am J 
Roentgenol, 2003.181(2): p. 519-25.
204. Snelling, J.D., et al., Measurement o f tumour size in case selection for breast cancer 
therapy by clinical assessment and ultrasound. Eur J Surg Oncol, 2004. 30(1): p. 5-9.
205. Pritt, B., et al., Influence o f breast cancer histology on the relationship between 
ultrasound and pathology tumor size measurements. Mod Pathol, 2004.
206. Davis, P.L., et al., Breast cancer measurements with magnetic resonance imaging, 
ultrasonography, and mammography. Breast Cancer Res Treat, 1996.37(1): p. 1-9.
207. Boetes, C., et al., Breast tumors: comparative accuracy of MR imaging relative to 
mammography and US for demonstrating extent. Radiology, 1995.197(3): p. 743-7.
208. Yang, W.T., et al., Sonographic, magnetic resonance imaging, and mammographic 
assessments o f preoperative size o f breast cancer. J Ultrasound Med, 1997.16(12): p. 
791-7.
209. Fischer, U., L. Kopka, and E. Grabbe, Breast carcinoma: effect o f preoperative 
contrast-enhanced MR imaging on the therapeutic approach. Radiology, 1999. 213(3):
p. 881-8.
210. Slanetz, P.J., et al., Occult contralateral breast carcinoma incidentally detected by 
breast magnetic resonance imaging. Breast J, 2002. 8(3): p. 145-8.
211. Lee, S.G., et al., MR imaging screening o f the contralateral breast in patients with 
newly diagnosed breast cancer: preliminary results. Radiology, 2003. 226(3): p. 773-8.
212. Liberman, L., et al., MR imaging findings in the contralateral breast o f women with 
recently diagnosed breast cancer. AJR Am J Roentgenol, 2003.180(2): p. 333-41.
213. Orel, S.G., et al., Staging o f suspected breast cancer: effect of MR imaging and MR- 
guided biopsy. Radiology, 1995.196(1): p. 115-22.
214. Drew, P J., et al., Dynamic contrast enhanced magnetic resonance imaging o f the 
breast is superior to triple assessment for the pre-operative detection o f multifocal 
breast cancer. Ann Surg Oncol, 1999. 6(6): p. 599-603.
215. Mumtaz, H., et al., Staging o f symptomatic primary breast cancer with MR imaging. 
AJR Am J Roentgenol, 1997.169(2): p. 417-24.
216. Liberman, L., et al., MR imaging o f the ipsilateral breast in women with percutaneously 
proven breast cancer. AJR Am J Roentgenol, 2003.180(4): p. 901-10.
217. Bedrosian, I., et al., Magnetic resonance imaging-guided biopsy o f mammographically 
and clinically occult breast lesions. Ann Surg Oncol, 2002. 9(5): p. 457-61.
218. Kramer, S., et al., Magnetic resonance imaging and its role in the diagnosis o f 
multicentric breast cancer. Anticancer Res, 1998.18(3C): p. 2163-4.
219. Esserman, L., et al., Utility o f magnetic resonance imaging in the management o f breast 
cancer: evidence for improved preoperative staging, in J  Clin Oncol. 1999. p. 110-9.
220. Drew, P.J., et al., eds. Dynamic contrast enhanced magnetic resonance imaging o f the 
breast is superior to triple assessment for the pre-operative detection o f multifocal 
breast cancer. Ann Surg Oncol. Vol. 6. 1999. 599-603.
221. Tan, J.E., et al., Role o f magnetic resonance imaging and magnetic resonance imaging- 
-guided surgery in the evaluation ofpatients with early-stage breast cancer for breast 
conservation treatment. Am J Clin Oncol, 1999. 22(4): p. 414-8.
222. Knopp, M.V., et al., MR mammography with pharmacokinetic mapping for monitoring 
of breast cancer treatment during neoadjuvant therapy, in Magn Reson Imaging Clin N  
Am. 1994. p. 633-58.
223. Hayes, C., A.R. Padhani, and M.O. Leach, Assessing changes in tumour vascular 
function using dynamic contrast-enhanced magnetic resonance imaging, in NMR 
Biomed. 2002. p. 154-63.
224. Esserman, L., et al., MRI phenotype is associated with response to doxorubicin and 
cyclophosphamide neoad/'uvant chemotherapy in stage III breast cancer, in Ann Surg 
Oncol. 2001. p. 549-59.
225. Fiorentino, C., et al., Accuracy o f mammography and echography versus clinical 
palpation in the assessment o f response to primary chemotherapy in breast cancer 
patients with operable disease, in Breast Cancer Res Treat. 2001. p. 143-51.
226. Feldman, L.D., et al., Pathological assessment o f response to induction chemotherapy 
in breast cancer, in Cancer Res. 1986. p. 2578-81.
227. Vinnicombe, S.J., et al., Primary breast cancer: mammographic changes after 
neoadjuvant chemotherapy, with pathologic correlation. Radiology, 1996.198(2): p. 
333-40.
294
228. Helvie, M.A., et al., Locally advanced breast carcinoma: accuracy o f mammography 
versus clinical examination in the prediction o f residual disease after chemotherapy, in 
Radiology. 1996. p. 327-32.
229. Herrada, J., et al., Relative value o f physical examination, mammography, and breast 
sonography in evaluating the size o f the primary tumor and regional lymph node 
metastases in women receiving neoadjuvant chemotherapy for locally advanced breast 
carcinoma, in Clin Cancer Res. 1997. p. 1565-9.
230. Sever, A.R., et al. Coil insertion prior to neoadjuvant chemotherapy in patients with 
breast cancer, in 26th Annual San Antonio Breast Cancer Symposium. 2004. San 
Antonio, Texas, U.S.A.: Kluwer Academic Publishers.
231. Delille, J.P., et al., Invasive ductal breast carcinoma response to neoadjuvant 
chemotherapy: noninvasive monitoring with functional MR imaging pilot study, in 
Radiology. 2003. p. 63-9.
232. Drew, P.J., et al., Evaluation o f response to neoadjuvant chemoradiotherapy for locally 
advanced breast cancer with dynamic contrast-enhanced MRI o f the breast, in Eur J  
Surg Oncol. 2001. p. 617-20.
233. Abraham, D.C., et al., Evaluation o f neoadjuvant chemotherapeutic response o f locally 
advanced breast cancer by magnetic resonance imaging, in Cancer. 1996. p. 91-100.
234. Rieber, A., et al., Breast MRI for monitoring response o f primary breast cancer to neo­
adjuvant chemotherapy, in Eur Radiol. 2002. p. 1711-9.
235. Gilles, R., et al., Locally advanced breast cancer: contrast-enhanced subtraction MR 
imaging of response to preoperative chemotherapy, in Radiology. 1994. p. 633-8.
236. Weatherall, P.T., et al., MRI vs. histologic measurement o f breast cancer following 
chemotherapy : comparison with x-ray mammography and palpation, m J Magn Reson 
Imaging. 2001. p. 868-75.
237. Esserman, L., et al., Utility o f magnetic resonance imaging in the management of breast 
cancer: evidence for improved preoperative staging, in J  Clin Oncol. 1999. p. 110-9.
238. Harms, S.E., et al., MR imaging o f the breast with rotating delivery o f excitation off 
resonance: clinical experience with pathologic correlation, in Radiology. 1993. p. 493- 
501.
239. Bonadonna, G., et al., Primary chemotherapy to avoid mastectomy in tumors with 
diameters o f three centimeters or more, in J  Natl Cancer Inst. 1990. p. 1539-45.
240. Pierce, W.B., et al., Three-dimensional gadolinium-enhanced MR imaging o f the 
breast: pulse sequence with fat suppression and magnetization transfer contrast. Work 
in progress, in Radiology. 1991. p. 757-63.
241. Davis, P.L., et al., Breast cancer measurements with magnetic resonance imaging, 
ultrasonography, and mammography, in Breast Cancer Res Treat. 1996. p. 1-9.
242. Veronesi, U., et al., Twenty-year follow-up o f a randomized study comparing breast- 
conserving surgery with radical mastectomy for early breast cancer. N Engl J Med, 
2002.347(16): p. 1227-32.
243. van Dongen, J.A., et al., Long-term results o f a randomized trial comparing breast- 
conserving therapy with mastectomy: European Organization for Research and 
Treatment o f Cancer 10801 trial. J Natl Cancer Inst, 2000. 92(14): p. 1143-50.
244. Kurtz, J.M., et al., Results o f salvage surgery for mammary recurrence following 
breast-conserving therapy. Ann Surg, 1988. 207(3): p. 347-51.
245. Osborne, M.P., et al., Salvage mastectomy for local and regional recurrence after 
breast-conserving operation and radiation therapy. Surg Gynecol Obstet, 1992.174(3): 
p. 189-94.
246. Boccardo, F., et al., Appropriateness o f the use o f clinical and radiologic examinations 
and laboratory tests in the follow-up o f surgically-treated breast cancer patients.
Results o f the Working Group on the Clinical Aspects of Follow-up. Ann Oncol, 1995. 6 
Suppl 2: p. 57-9.
247. RCR, The use o f imaging in the follow-up ofpatients with breast cancer. London:
Royal College of Radiologists, 1995.
248. Sickles, E.A. and K.A. Herzog, Mammography of the postsurgical breast. AJR Am J
Roentgenol, 1981.136(3): p. 585-8.
249. Paulus, D.D., Conservative treatment of breast cancer: mammography in patient 
selection andfollow-up. AJR Am J Roentgenol, 1984.143(3): p. 483-7.
250. Krishnamurthy, R., et al., Mammographic findings after breast conservation therapy. 
Radiographics, 1999.19 Spec No: p. S53-62; quiz S262-3.
295
251. Stomper, P.C., et al., Mammographic detection o f recurrent cancer in the irradiated 
breast. AJR Am J Roentgenol, 1987.148(1): p. 39-43.
252. Orel, S.G., et al., Breast cancer recurrence after lumpectomy and irradiation: role of 
mammography in detection. Radiology, 1992.183(1): p. 201-6.
253. Homer, M.J., Mammographic interpretation: a practical approach. New York, NY: 
McGraw-Hill 4-5., 1991.
254. Revel, D., et al., Gd-DTPA contrast enhancement and tissue differentiation in MR 
imaging o f experimental breast carcinoma. Radiology, 1986.158(2): p. 319-23.
255. Lewis-Jones, H.G., G.H. Whitehouse, and S.J. Leinster, The role o f magnetic resonance 
imaging in the assessment o f local recurrent breast carcinoma. Clin Radiol, 1991. 
43(3): p. 197-204.
256. Dao, T.H., et al., Tumor recurrence versus fibrosis in the irradiated breast: 
differentiation with dynamic gadolinium-enhanced MR imaging. Radiology, 1993. 
187(3): p. 751-5.
257. Kerslake, R.W., et al., Dynamic contrast-enhanced andfat suppressed magnetic 
resonance imaging in suspected recurrent carcinoma of the breast: preliminary 
experience. Br J Radiol, 1994. 67(804): p. 1158-68.
258. Whitehouse, G.H. and N.R. Moore, MR imaging o f the breast after surgery for breast 
cancer. Magn Reson Imaging Clin N Am, 1994. 2(4): p. 591-603.
259. Murray, A.D., et al., Dynamic magnetic resonance mammography o f both breasts 
following local excision and radiotherapy for breast carcinoma. Br J Radiol, 1996. 
69(823): p. 594-600.
260. Mussurakis, S., et al., Dynamic contrast-enhanced magnetic resonance imaging o f the 
breast combined with pharmacokinetic analysis o f gadolinium-DTPA uptake in the 
diagnosis o f local recurrence o f early stage breast carcinoma. Invest Radiol, 1995. 
30(11): p. 650-62.
261. Viehweg, P., et al., Retrospective analysis for evaluation of the value of contrast- 
enhanced MRI in patients treated with breast conservative therapy. Magma, 1998. 7(3): 
p. 141-52.
262. Heywang, S.H., et al., Gd-DTPA enhanced MR imaging o f the breast in patients with 
postoperative scarring and silicon implants. J Comput Assist Tomogr, 1990.14(3): p. 
348-56.
263. Heywang-Kobrunner, S.H., et al., Contrast-enhanced MRI of the breast after limited 
surgery and radiation therapy. J Comput Assist Tomogr, 1993.17(6): p. 891-900.
264. Muuller, R.D., et al., Assessment o f local recurrence after breast-conserving therapy 
with MRI. J Comput Assist Tomogr, 1998.22(3): p. 408-12.
265. Drew, P.J., et al., Routine screening for local recurrence following breast-conserving 
therapy for cancer with dynamic contrast-enhanced magnetic resonance imaging of the 
breast. Ann Surg Oncol, 1998. 5(3): p. 265-70.
266. Belli, P., et al., Magnetic resonance imaging in breast cancer recurrence. Breast 
Cancer Res Treat, 2002. 73(3): p. 223-35.
267. Mumtaz, H., et al., Comparison o f magnetic resonance imaging and conventional triple 
assessment in locally recurrent breast cancer. Br J Surg, 1997. 84(8): p. 1147-51.
268. Barbier, E.L., L. Lamalle, and M. Decorps, Methodology o f brain perfusion imaging, in 
J  Magn Reson Imaging. 2001. p. 496-520.
269. Sorensen, A.G., et al., Contrast agents in functional MR imaging, in J  Magn Reson 
Imaging. 1997. p. 47-55.
270. Dennie, J., et al., NMR imaging o f changes in vascular morphology due to tumor 
angiogenesis, in Magn Reson Med. 1998. p. 793-9.
271. Bruening, R., et al., Effects o f three different doses o f a bolus injection ofgadodiamide: 
assessment o f regional cerebral blood volume maps in a blinded reader study, in AJNR 
Am JNeuroradiol. 2000. p. 1603-10.
272. Rosen, B.R., et al., Contrast agents and cerebral hemodynamics, in Magn Reson Med. 
1991. p. 285-92.
273. Ostergaard, L., et al., High resolution measurement o f cerebral bloodflow using 
intravascular tracer bolus passages. Part II: Experimental comparison and preliminary 
results, in Magn Reson Med. 1996. p. 726-36.
274. Liu, Y.J., et al., A reinvestigation o f maximal signal drop in dynamic susceptibility 
contrast magnetic resonance imaging, in J  Neuroimaging. 2002. p. 330-8.
296
275. Taylor, N.J., et al., Pre- and post-chemotherapy comparisons o f calculated rBV and 
rBF with signal intensity drop on T2* dynamic contrast-enhanced MRI o f breast 
cancers. Proc. I.S.M.R.M., 2005.13th Annual Meeting: p. Abstract 91.
276. Kuhl, C.K., et al., Breast neoplasms: T2* susceptibility-contrast, first-pass perfusion 
MR imaging, in Radiology. 1997. p. 87-95.
277. Kvistad, K.A., et al., Differentiating benign and malignant breast lesions with T2*~ 
weighted first pass perfusion imaging, in Acta Radiol. 1999. p. 45-51.
278. Weind, K.L., et al., Invasive carcinomas andfibroadenomas o f the breast: comparison 
of microvessel distributions—implications for imaging modalities, in Radiology. 1998. 
p. 477-83.
279. Jitsuiki, Y., et al. Optimizing microvessel counts according to tumor zone in invasive 
ductal carcinoma of the breast, in Mod Pathol. 1999.
280. Howe, F.A., et al., Issues in flow and oxygenation dependent contrast (FLOOD) 
imaging o f tumours. NMR Biomed, 2001.14(7-8): p. 497-506.
281. T aylor, N.J., et al., BOLD MRI o f human tumor oxygenation during carbogen 
breathing. J Magn Reson Imaging, 2001.14(2): p. 156-63.
282. Warner, E., et al., Comparison o f breast magnetic resonance imaging, mammography, 
and ultrasoundfor surveillance o f women at high risk for hereditary breast cancer. J 
Clin Oncol, 2001.19(15): p. 3524-31.
283. Kuhl, C.K., et al., Breast MR imaging screening in 192 women proved or suspected to 
be carriers of a breast cancer susceptibility gene: preliminary results. Radiology, 2000. 
215(1): p. 267-79.
284. Podo, F., et al., The Italian multi-centre project on evaluation o f MRI and other 
imaging modalities in early detection o f breast cancer in subjects at high genetic risk J 
Exp Clin Cancer Res, 2002. 21(3 Suppl): p. 115-24.
285. Stoutjesdijk, M.J., et al., Magnetic resonance imaging and mammography in women 
with a hereditary risk o f breast cancer. J Natl Cancer Inst, 2001. 93(14): p. 1095-102.
286. Tilanus-Linthorst, M.M., et al., First experiences in screening women at high risk for 
breast cancer with MR imaging. Breast Cancer Res Treat, 2000. 63(1): p. 53-60.
287. Kriege, M., et al., Efficacy o f MRI and mammography for breast-cancer screening in 
women with a familial or genetic predisposition. N Engl J Med, 2004.351(5): p. 427- 
37.
288. Schnall, M.D. and D.M. Ikeda, Lesion Diagnosis Working Group report. J Magn Reson 
Imaging, 1999.10(6): p. 982-90.
289. Oken, M.M., et al., Toxicity and response criteria o f the Eastern Cooperative Oncology 
Group. Am J Clin Oncol, 1982. 5(6): p. 649-55.
290. Hayward, J.L., et al., Assessment o f response to therapy in advanced breast cancer. A 
project o f the programme on clinical oncology of the International Union against 
Cancer, Geneva, Switzerland. Eur J Cancer, 1978.14(11): p. 1291-2.
291. Miller, A.B., et al., Reporting results o f cancer treatment. Cancer, 1981. 47(1): p. 207- 
14.
292. Sharkey, F.E., et al., Effects o f preoperative chemotherapy on the morphology of 
resectable breast carcinoma. Mod Pathol, 1996. 9(9): p. 893-900.
293. Aktepe, F., N. Kapucuoglu, and I. Pak, The effects o f chemotherapy on breast cancer 
tissue in locally advanced breast cancer. Histopathology, 1996. 29(1): p. 63-7.
294. Ogston, K.N., et al., A new histological grading system to assess response o f breast 
cancers to primary chemotherapy: prognostic significance and survival. Breast, 2003. 
12(5): p. 320-7.
295. D'Arcy, J., et al., Magnetic Resonance Imaging Workbench (MRIW): Dynamic contrast 
enhanced MRI data analysis and visualisation. Radiographics - submitted, 2004.
296. Galbraith, S.M., et al., Reproducibility o f dynamic contrast-enhanced MRI in human 
muscle and tumours: comparison o f quantitative and semi-quantitative analysis. NMR 
Biomed, 2002.15(2): p. 132-42.
297. Bland, J.M. and D.G. Altman, Measurement error. Bmj, 1996. 312(7047): p. 1654.
298. Toi, M., J. Kashitani, and T. Tominaga, Tumor angiogenesis is an independent 
prognostic indicator in primary breast carcinoma. Int J Cancer, 1993. 55(3): p. 371-4.
299. Gerhardt, H. and C. Betsholtz, Endothelial-pericyte interactions in angiogenesis. Cell 
Tissue Res, 2003.314(1): p. 15-23.
297
300.
301.
302.
303.
304.
305.
306.
307.
308.
309.
310.
311.
312.
313.
314.
315.
316.
317.
318.
319.
320.
321.
322.
Kadambi, A., et al., Vascular endothelial growth factor (VEGF)-C differentially affects 
tumor vascular function and leukocyte recruitment: role ofVEGF-receptor 2 and host 
VEGF-A. Cancer Res, 2001. 61(6): p. 2404-8.
Willett, C.G., et al., Direct evidence that the VEGF-specific antibody bevacizumab has 
antivascular effects in human rectal cancer. Nat Med, 2004.10(2): p. 145-7.
Winkler, F., et al., Kinetics o f vascular normalization by VEGFR2 blockade governs 
brain tumor response to radiation: role o f oxygenation, angiopoietin-1, and matrix 
metalloproteinases. Cancer Cell, 2004. 6(6): p. 553-63.
Tong, R.T., et al., Vascular normalization by vascular endothelial growth factor 
receptor 2 blockade induces a pressure gradient across the vasculature and improves 
drug penetration in tumors. Cancer Res, 2004. 64(11): p. 3731-6.
Jain, R.K., Normalizing tumor vasculature with anti-angiogenic therapy: a new 
paradigm for combination therapy. Nat Med, 2001. 7(9): p. 987-9.
Buckley, D.L., et al., Microvessel density o f invasive breast cancer assessed by dynamic 
Gd-DTPA enhanced MR1. J Magn Reson Imaging, 1997. 7(3): p. 461-4.
Hulka, C.A., et al., Dynamic echo-planar imaging o f the breast: experience in 
diagnosing breast carcinoma and correlation with tumor angiogenesis. Radiology, 
1997.205(3): p. 837-42.
Stomper, P.C., et al., Angiogenesis and dynamic MR imaging gadolinium enhancement 
of malignant and benign breast lesions. Breast Cancer Res Treat, 1997. 45(1): p. 39-46. 
Knopp, M.V., et al., Pathophysiologic basis o f contrast enhancement in breast tumors.
J Magn Reson Imaging, 1999.10(3): p. 260-6.
Loncaster, J.A., et al., Carbonic anhydrase (CA IX) expression, a potential new 
intrinsic marker of hypoxia: correlations with tumor oxygen measurements and 
prognosis in locally advanced carcinoma o f the cervix. Cancer Res, 2001. 61(17): p. 
6394-9.
Taylor, N.J. in ISMRM. 2003.
Kostourou, V., et al., Overexpression o f dimethylarginine dimethylaminohydrolase 
enhances tumor hypoxia: an insight into the relationship of hypoxia and angiogenesis 
in vivo. Neoplasia, 2004. 6(4): p. 401-11.
Hawkins, R.A., et al., Prospective evaluation ofprognostic factors in operable breast 
cancer. Br J Cancer, 1996. 74(9): p. 1469-78.
Horita, K., et al., Prognostic factors affecting disease-free survival rate following 
surgical resection o f primary breast cancer. Eur J Histochem, 2001. 45(1): p. 73-84. 
Hayes, C., A.R. Padhani, and M.O. Leach, Assessing changes in tumour vascular 
function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed, 
2002.15(2): p. 154-63.
Leach, M.O., et al., The assessment of antiangiogenic and antivascular therapies in 
early-stage clinical trials using magnetic resonance imaging: issues and 
recommendations. Br J Cancer, 2005. 92(9): p. 1599-610.
Padhani, A.R., et al., Prediction o f clinicopathologic response of breast cancer to 
primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. 
Radiology, 2006. 239(2): p. 361-74.
Therasse, P., et al., New guidelines to evaluate the response to treatment in solid 
tumors. European Organization for Research and Treatment o f Cancer, National 
Cancer Institute o f the United States, National Cancer Institute of Canada. J Natl 
Cancer Inst, 2000. 92(3): p. 205-16.
Therasse, P., E.A. Eisenhauer, and J. Verweij, RECIST revisited: A review o f validation 
studies on tumour assessment. Eur J Cancer, 2006. 42(8): p. 1031-9.
Sataloff, D.M., et al., Pathologic response to induction chemotherapy in locally 
advanced carcinoma of the breast: a determinant o f outcome. J Am Coll Surg, 1995. 
180(3): p. 297-306.
Chevallier, B., et al., Inflammatory breast cancer. Pilot study of intensive induction 
chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol, 
1993.16(3): p. 223-8.
Jones, R.L., et al., Pathological complete response and residual DCIS following 
neoadjuvant chemotherapy for breast carcinoma. Br J Cancer, 2006. 94(3): p. 358-62. 
Port, R.E., et al., Multicompartment analysis o f gadolinium chelate kinetics: blood- 
tissue exchange in mammary tumors as monitored by dynamic MR imaging. J Magn 
Reson Imaging, 1999.10(3): p. 233-41.
298
323. Delille, J.P., et al., Hormone replacement therapy in postmenopausal women: breast 
tissue perfusion determined with MR imaging—initial observations. Radiology, 2005. 
235(1): p. 36-41.
324. Jain, R.K., Normalization o f tumor vasculature: an emerging concept in antiangiogenic 
therapy. Science, 2005.307(5706): p. 58-62.
325. Crowe, J.P., Jr., et al., Does ultrasound core breast biopsy predict histologic finding on 
excisional biopsy? Am J Surg, 2003.186(4): p. 397-9.
326. Monticciolo, D.L., Histologic grading at breast core needle biopsy: comparison with 
results from the excised breast specimen. Breast J, 2005.11(1): p. 9-14.
327. (UICC), I.U.A.C., TNM Classification o f Malignant Tumours. Sixth edition ed. 2002, 
New York: Wiley-Liss.
299
Appendices
300
Appendix 1: International Union Against Cancer (UICC)AYorld Health
Organisation (WHO) criteria for clinical response to therapy
Complete Response (cCR) Disappearance of all known disease
Partial Response (cPR) Decrease by at least 50% of the sum of the products 
of the largest perpendicular diameters of measurable 
lesions
Stable disease (cSD) Less than 50% decrease and less than 25% increase in 
the sum of the products of the largest perpendicular 
diameters of measurable lesions
Progressive disease (cPD) Increase of more than 25% in the size of a measurable 
lesion or appearance of a new lesion
301
Appendix 2: WHO performance status scale
Grade Performance scale
0 Able to carry out all normal activity without 
restriction
1 Restricted in physically strenuous activity but 
ambulatory and able to carry out light work.
2 Ambulatory and capable of all self-care but unable to 
carry out any work; up and about more than 50% of 
waking hours.
3 Capable of only limited self-care; confined to bed or 
chair more than 50% of waking hours
4 Completely disabled; cannot carry on any self-care; 
totally confined to bed or chair.
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Appendix 3: Exclusions for MRI scan
♦ Central nervous system aneurysm clips
♦ Implanted neural stimulator
♦ Implanted cardiac pacemaker of defibrillator
♦ Certain cardiac valve replacements
♦ Cochlear implant
♦ Ocular foreign body eg. metal fragments
♦ Metal shrapnel or bullet injuries
♦ Recent surgery requiring clips insertion
♦ Other implanted medical devices
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Appendix 4: International Union Against Cancer (UICC) TNM
classification of Primary Breast Cancer [327]
(i) Clinical
PRIMARY
TUMOUR
(T)
TX Primary tumour cannot be assessed
TO No evidence of primary tumour
Tis Carcinoma in situ
T1
Tumour 2.0cm or less in greatest dimension
Tlmic Microinvasion 0.1cm or less
T la More than 0.1cm but no more than 0.5cm
Tib More than 0.5cm but no more than 1.0cm
Tic More than 1.0cm but no more than 2.0cm
T2 Tumour more than 2.0cm but not more than 5.0cm in 
greatest dimension
T3 Tumour more than 5.0cm in greatest dimension
T4
Tumour of any size with direct extension to (a) chest 
wall or (b) skin, only as described below
T4a Extension to chest wall, not including 
pectoralis muscle
T4b Oedema (including peau d’orange) or 
ulceration of the skin of the breast, or satellite 
skin nodules confined to the same breast
T4c Both T4a and T4b
T4d Inflammatory carcinoma
REGIONAL
LYMPH
NODES
(N)
NX Regional lymph nodes (LN) cannot be assessed (e.g. 
previously removed)
NO No regional LN metastasis
N1 Metastasis to moveable ipsilateral axillary LN(s)
N2
Metastasis to ipsilateral axillary LN(s) fixed or matted, 
or in clinically apparent’1' ipsilateral internal mammary 
nodes in the absence of clinically evident LN metastasis
N2a Metastasis in ipsilateral axillary LNs fixed to 
one another (matted) or to other structures
N2b Metastasis only in clinically apparent1" 
ipsilateral internal mammary nodes and in the 
absence of clinically evident LN metastasis
N3
Metastasis in ipsilateral infraclavicular LN(s) with or 
without axillary LN involvement, or in clinically 
apparent3" ipsilateral internal mammary LN(s) and in the 
presence of clinically evident axillary LN metastasis; or 
metastasis in the ipsilateral supraclavicular LN(s) with or 
without axillary or internal mammary LN involvement
N3a Metastasis in ipsilateral infraclavicular LN(s)
N3b Metastasis in ipsilateral internal mammary 
LN(s) and axillary LN(s)
N3c Metastasis in ipsilateral supraclavicular LN(s)
DISTANT
METASTASIS
(M)
MX Presence of distant metastasis cannot be assessed
MO No distant metastasis
Ml Distant metastasis
’clinically apparent is defined as detected by imaging studies (excluding lymphoscintigraphy) or by clinical examination 
or grossly visible pathologically
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(ii) Pathological
PRIMARY
TUMOUR
(pT)
pT categories correspond to the T categories.
Requires the examination of primary carcinoma with no gross tumour at the margins 
of resection. Can be classifed pT if only microscopic tumour in a margin
pNX Regional LNs cannot be assessed
pNO No regional LN metastasis histologically, no additional examination 
for isolated tumour cells (ITC)
[Note; ITC are defined as single tumour cells or small cell clusters not 
greater than 0.2mm, usually detected only by immunohistochemistry 
(IHC) or molecular methods but which may be verifed on H&E stains. 
ITCs do not usually show evidence of malignant activity e.g. 
proliferation or stromal reaction]
pNO(I-) No regional LN metastasis histologically, negative IHC
pN0(I+) No regional LN metastasis histologically, positive IHC, no IHC cluster 
greater than 0.2mm
REGIONAL
pNO(mol-) No regional LN metastasis histologically, negative molecular findings 
(RT-PCR)”
LYMPH NODES 
(pN)*
pN0(mol+) No regional LN metastasis histologically, positive molecular findings 
(RT-PCR)”
Metastasis in 1 to 3 axillary LN(s), and/or in internal mammary nodes 
with microscopic disease detected by sentinel LN dissection but not 
clinically apparent*”
pNlmi Micrometastasis (greater than 0.2mm but not greater than 
2.0mm)
pNl pNla Metastasis in 1 to 3 axillary LN(s)
pNlb Metastasis in internal mammary nodes with microscopic 
disease detected by sentinel LN dissection but not 
clinically apparent**
pNlc Metastasis in 1 to 3 axillary LN(s), and in internal 
mammary nodes with microscopic disease detected by 
sentinel LN dissection but not clinically apparent**
Metastasis in 4 to 9 axillary LNs, or in clinically apparent*”  internal 
mammary LN(s) in the absence of axillary LN metastasis to ipsilateral 
axillary LN(s) fixed to each other or to other structures
pN2 pN2a Metastasis in 4 to 9 axillary LNs (at least one tumour 
deposit greater than 2.0mm)
pN2b Metastasis in clinically apparent*** internal mammary 
LN(s) in the absence of axillary LN metastasis
Metastasis in 10 or more axillary LNs, or in infraclavicular LNs, or in
clinically apparent*** ipsilateral internal mammary LN(s) in the 
presence of 1 or more positive axillary LN(s); or in more than 3 
axillary LNs with clinically negative microscopic metastasis in 
internal mammary LNs; or in ipsilateral supraclavicular LNs
pN3
pN3a Metastasis in 10 or more axillary LNs (at least one tumour 
deposit greater than 2.0mm), or metastasis to the 
infraclavicular LNs
pN3b Metastasis in clinically apparent*** ipsilateral internal 
mammary LN(s) in the presence of 1 or more positive 
axillary LN(s); or in more than 3 axillary LNs and in 
internal mammary LNs with microscopic disease detected 
by sentinel lymph node dissection but not clinically 
apparent
PN3c Metastasis in ipsilateral supraclavicular LNs
DISTANT
METASTASIS
pM categories correspond to the M categories.
(pM)
’ Classification based on axillary LN dissection(ALND) with or without sentinel LN dissection (SLND). Classification 
based solely on SLND without subsequent ALND is designated (sn) for “sentinel node”;
’ ’ RT-PCR: reverse transcriptase/polymerase chain reaction;
’ ’ ’ Clinically apparent is defined as detected by imaging studies (excluding lymphoscintigraphy) or by clinical 
examination.
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Appendix 5: Patient information sheet
PATIENT INFORMATION SHEET
Evaluation of MRI during neoadjuvant chemotherapy in primary breast cancer
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss 
it with friends, relatives and your GP if you wish. Ask us if there is anything that 
is not clear or if you would like more information. Take time to decide whether 
or not you wish to take part.
What is the purpose of this study?
This study is being done to evaluate the changes in blood flow, as measured by a 
special scanning method called Magnetic Resonance Imaging (MRI), during 
chemotherapy in patients with breast cancer. These changes help us to 
understand how cancers react to chemotherapy and additionally may help us in 
the future to identify those patients who will respond to treatment early in its 
course.
Why I have been chosen?
A total of 40 patients will be studied. You have been selected for this study 
because you are receiving chemotherapy prior to surgery.
Do I have to take part?
No. It is up to you to decide whether or not to take part. If you decide to take 
part you will be given this information sheet to keep and be asked to sign a 
consent form. You may still decide to withdraw at any time without having to 
give a reason.
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If you decide not to take part, or if you withdraw, this will not affect the 
standard of care you receive, nor will your legal rights be affected by agreeing or 
refusing to take part.
What will happen to me if I take part?
You will receive chemotherapy every three weeks. You will be asked to have an 
MRI scan prior to commencing chemotherapy and another prior to the third 
cycle of chemotherapy. A maximum of two extra visits may be required for the 
MRI scans.
At the same time you will be asked to give a blood sample, which will help us to 
measure substances in the blood which may be related to the blood flow which 
is measured by the MRI. In addition to the blood samples taken on the 
occasions you are having the MRI scans, we will ask you to have a repeat blood 
test with the last cycle of chemotherapy and another after your surgery. The 
amount of blood taken on each of these occasions will be 9mls (approximately 
two teaspoons). We will also ask for permission to review and perform special 
tests on part of the biopsy specimen and post-chemotherapy operation specimen 
that are taken as part of your treatment.
What are the risks of taking part?
MRI is considered to be a very safe technique as it does not use radiation. 
However, you will be exposed to a large magnetic field and radiowaves. 
International guidelines have been set up to prevent you receiving an excessive 
exposure. Because the scanner uses a magnetic field it may be unsafe for you to 
be scanned if you have a cardiac pacemaker, implanted metallic material such as 
surgical clips or possibly if you have had major surgery. You should also not be 
scanned if there is any possibility that you are pregnant. You will be asked to 
complete a safety questionnaire before the examination.
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What are the possible benefits of taking part?
Information from this study may help us to treat future patients with breast 
cancer. Additionally, the repeat scan may show evidence that your disease 
is not responding to the chemotherapy in which case alternative 
chemotherapy may be offered to you.
What if new information becomes available?
Sometimes during the course of a research project, new information becomes 
available about the treatment/drug that is being studied. If this happens, your 
research doctor will tell you about it and discuss with you whether you want to 
continue in this study. If you decide to withdraw, your research doctor will 
make arrangements for your care to continue. If you decide to continue in the 
study, you will be asked to sign an updated consent form. Also on receiving 
new information, your research doctor might consider it to be in your best 
interests to withdraw you from the study. He/she will explain the reasons, and 
arrange for your care to continue.
Will my taking part in this study be kept confidential?
All information which is collected about you, during the course of this research, 
will be kept strictly confidential. Any information about you which leaves the 
hospital/surgery will have your name and address removed so that you cannot be 
recognised from it. Your GP will be informed that you have agreed to take part 
in this study.
What will happen to the results of the research study?
At the end of the research study, the results will be analysed and presented at 
scientific meetings as well as being published in a medical journal.
Who is organising and funding the research?
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This research study is being conducted by clinicians at Mount Vernon Hospital 
and the scans are funded by the Paul Strickland Scanner Centre.
How can I make a complaint if something goes wrong?
There are no special compensation arrangements for taking part in this study but 
the normal NHS complaints mechanism is available to you if you wish to 
complain about any aspect of the way you are approached or treated. Formal 
complaints should be addressed to the Quality Assurance Office, Administration 
Block, Watford General Hospital, Watford, WD1 2AA (Tel: 01923 245285). 
Should you require independent advice, you may wish to contact the South West 
Herts Community Health Council, Abbey House (3rd Floor), 26 The Parade, 
High Street, Watford, WD1 2AA (Tel: 01923 245285).
Who can I contact if I want any more information about this study?
If you have any further questions please contact Linda Culver or James Stirling 
at the Scanner Centre on 01923 844353.
This study has been reviewed by the Local Research Ethics Committee for 
Mount Vernon and Watford Hospitals.
A copy of the information sheet can be kept by the patient.
We very much appreciate your taking time to read this information sheet.
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Appendix 6: MRI study patient consent form 
Patient Identification Number for this trial:
CONSENT FORM
Title of Project: Evaluation of MRI during neoadjuvant chemotherapy in primary breast cancer 
Name of Researchers: Dr. A Makris, Dr. A Padhani, Dr. M Ah-See 
I (name) ______________________________________________________________
of (address) __________________________________________________________
Please initial box
1. I confirm that I have read and understand the patient information sheet dated__________
for the above study and have had the opportunity to ask questions. □
2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected.
3. I understand that sections of any of my medical notes may be looked at by responsible 
individuals or from regulatory authorities where it is relevant to my taking part in research.
4. I give permission for these individuals to have access to my records.
5. I grant permission for samples from pathological specimens taken during my treatment 
(diagnostic or operation specimens) to be collected, stored and then analysed as part of a 
research study.
6. I agree to take part in the above study.
Name of Patient Signature Date
Name of Person taking consent Signature Date
(if different from researcher)
Researcher Signature Date
1 for patient; 1 for researcher; 1 to be kept with hospital notes
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□ □ 
□□
